U.S. patent application number 12/882052 was filed with the patent office on 2011-04-07 for vaccines directed to langerhans cells.
This patent application is currently assigned to BAYLOR RESEARCH INSTITUTE. Invention is credited to Jacques F. Banchereau, Eynav Klechevsky, SangKon Oh, Gerard Zurawski, Sandra Zurawski.
Application Number | 20110081343 12/882052 |
Document ID | / |
Family ID | 43733140 |
Filed Date | 2011-04-07 |
United States Patent
Application |
20110081343 |
Kind Code |
A1 |
Banchereau; Jacques F. ; et
al. |
April 7, 2011 |
VACCINES DIRECTED TO LANGERHANS CELLS
Abstract
The present invention includes isolated anti-Langerin vaccines,
methods for making and using an isolated anti-Langerin antibody or
binding fragment thereof and one or more antigenic peptides at the
carboxy-terminus of the isolated anti-Langerin antibody, wherein
when two or more antigenic peptides are present, the peptides are
separated by the one or more linker peptides that comprise at least
one glycosylation site. The present invention also includes
isolated vectors for the expression of the anti-Langerin antigen
delivery vectors and their manufactures and use.
Inventors: |
Banchereau; Jacques F.;
(Dallas, TX) ; Zurawski; Gerard; (Midlothian,
TX) ; Zurawski; Sandra; (Midlothian, TX) ;
Klechevsky; Eynav; (Haifa, IL) ; Oh; SangKon;
(Baltimore, MD) |
Assignee: |
BAYLOR RESEARCH INSTITUTE
Dallas
TX
|
Family ID: |
43733140 |
Appl. No.: |
12/882052 |
Filed: |
September 14, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61242283 |
Sep 14, 2009 |
|
|
|
Current U.S.
Class: |
424/134.1 ;
435/189; 435/193; 435/29; 435/320.1; 435/325; 435/69.3; 530/387.1;
530/387.3; 536/23.53 |
Current CPC
Class: |
A61K 2039/505 20130101;
C07K 14/4748 20130101; C12N 2760/16134 20130101; A61P 31/12
20180101; A61K 39/145 20130101; A61K 2039/6056 20130101; C12N 7/00
20130101; A61K 2039/55561 20130101; A61P 37/04 20180101; C07K
14/005 20130101; A61P 35/00 20180101; A61P 31/18 20180101; C07K
16/2896 20130101; C07K 2319/00 20130101; A61K 39/0011 20130101;
A61P 31/04 20180101; A61P 35/02 20180101; A61K 39/12 20130101; A61P
25/00 20180101; C07K 2319/33 20130101; A61K 39/001129 20180801;
C07K 16/2851 20130101; C12N 2740/16034 20130101; A61K 39/21
20130101; A61P 31/16 20180101; A61K 2039/5154 20130101 |
Class at
Publication: |
424/134.1 ;
435/320.1; 435/69.3; 435/189; 435/193; 435/29; 435/325; 530/387.1;
530/387.3; 536/23.53 |
International
Class: |
A61K 39/395 20060101
A61K039/395; C12N 15/63 20060101 C12N015/63; C12P 21/00 20060101
C12P021/00; C12N 9/02 20060101 C12N009/02; C12N 9/10 20060101
C12N009/10; C12P 21/02 20060101 C12P021/02; C12Q 1/02 20060101
C12Q001/02; C12N 5/0783 20100101 C12N005/0783; C12N 5/0781 20100101
C12N005/0781; C07K 16/18 20060101 C07K016/18; C07H 21/00 20060101
C07H021/00; C07K 19/00 20060101 C07K019/00; A61P 35/00 20060101
A61P035/00; A61P 37/04 20060101 A61P037/04; A61P 35/02 20060101
A61P035/02 |
Goverment Interests
STATEMENT OF FEDERALLY FUNDED RESEARCH
[0002] This invention was made with U.S. Government support under
Contract No. 1U19AI057234-0100003 awarded by the NIH. The
government has certain rights in this invention.
Claims
1. A vaccine comprising an isolated anti-Langerin antibody or
binding fragment thereof and one or more antigenic peptides at the
carboxy-terminus of the anti-Langerin antibody, wherein when two or
more antigens are present, they are separated by one or more linker
peptides that comprise at least one glycosylation site.
2. The vaccine of claim 1, wherein the antibody binding fragment is
selected from an Fv, Fab, Fab', F(ab').sub.2, Fc, or a ScFv
fragment.
3. The vaccine of claim 1, wherein the antibody comprises one or
more complementarity determining regions selected from:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45);
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46);
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47);
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); or a direct equivalent
thereof.
4. The vaccine of claim 1, wherein the antigenic peptide is a
cancer antigen selected from:
MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHP QWV (SEQ
ID NO.: 9);
LTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSH D (SEQ
ID NO.: 10);
LMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVI S (SEQ
ID NO.: 11);
NDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALP ERP (SEQ
ID NO.: 12); SLYTKVVHYRKWIKDTIVANP (SEQ ID NO.: 13); IMDQVPFSV (SEQ
ID NO.: 14); ITDQVPFSV (SEQ ID NO.: 15); YLEPGPVTV (SEQ ID NO.:
16); YLEPGPVTA (SEQ ID NO.: 17); KTWGQYWQV (SEQ ID NO.: 18);
APLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILL
GRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTD
AVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKV
TKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYR
KWIKDTIVANP (SEQ ID NO.: 19);
DTTEPATPTTPVTTPTTTKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRG
GQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVY
PQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAML
GTHTMEVTVYHRRGSQSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQ (SEQ ID
NO.: 20);
PLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRAXVVTHTYLEPGPVTAQVVLQA
AIPLTSCGSSPVPAS (SEQ ID NO.: 21);
GTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQM
PTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAA (SEQ ID NO.:
22); QVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVL
YRYGSFSVTLDIVQ (SEQ ID NO.: 23);
GIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQ
LVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIVPGILLTGQEAGLGQ (SEQ ID NO.: 24);
MEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDY (SEQ ID NO.:
25); DWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKK (SEQ ID NO.: 26);
MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCV (SEQ ID NO.: 27);
QKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATC
MFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELL (SEQ ID NO.: 28);
LVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSM V (SEQ
ID NO.: 29); or
AAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQA
QQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI (SEQ ID NO.: 30), or binding
fragments thereof.
5. The vaccine of claim 1, wherein the antigenic peptide is a viral
antigen selected from: TABLE-US-00032 (SEQ ID NO.: 31)
VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL; (SEQ ID NO.: 32)
HTQGYFPDWQNYTPGPGVRYPLTFGWLYKL; (SEQ ID NO.: 33)
EKIRLRPGGKKKYKLKHIV; (SEQ ID NO.: 34)
NPPIPVGEIYKRWIILGLNKIVRMYSPTSILD; (SEQ ID NO.: 35)
AIFQSSMTKILEPFRKQNPDIVIYQYMDDLY; (SEQ ID NO.: 36)
DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIA
PLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFI
DYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFY
RNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQ
NENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTII
FEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSS
LPYQNIHPVTIGECPKYVRSAKLRMV; (SEQ ID NO.: 37)
DQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKKHNGKLCDLDGVK
PLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPVNDLCYPGDFN
DYEELKHLLSRINHFEKIQIIPKSSWSSHEASLGVSSACPYQGKSSFF
RNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTKLYQ
NPTTYISVGTSTLNQRLVPRIATRSKVNGQSGRMEFFWTILKPNDAIN
FESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNTKCQTPMGAINSS
MPFHNIHPLTIGECPKYVKSNRLVLA; or (SE0 ID NO.: 38)
PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGAT
PQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQM
REPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRM
YSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQ
NANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL.
6. The vaccine of claim 1, wherein the one or more peptide linkers
are selected from: TABLE-US-00033 SSVSPTTSVHPTPTSVPPTPTKSSP; (SEQ
ID NO.: 39) PTSTPADSSTITPTATPTATPTIKG; (SEQ ID NO.: 40)
TVTPTATATPSAIVTTITPTATTKP; (SEQ ID NO.: 41) or
TNGSITVAATAPTVTPTVNATPSAA. (SEQ ID NO.: 42)
7. The vaccine of claim 1, wherein the anti-Langerin antibody is
selected from the following pairs of amino acid sequences SEQ ID
NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58; and 78 and 80 or
binding fragments thereof.
8. The vaccine of claim 1, wherein the anti-Langerin antibody is
the expression product of the following pairs of nucleic acid
sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and
77 and 79.
9. The vaccine of claim 1, wherein the anti-Langerin antibody or
binding fragment thereof is at least one of 15B10 having ATCC
Accession No. PTA-9852, 2G3 having ATCC Accession No. PTA-9853,
91E7, 37C1, or 4C7 and humanized derivatives thereof.
10. The vaccine of claim 1, wherein the anti-Langerin antibody or
binding fragment thereof and the antigenic peptide are a fusion
protein.
11. An isolated nucleic acid vector that expresses an anti-Langerin
antibody or binding fragment thereof and two or more antigenic
peptides at the carboxy-terminus of the light chain, the heavy
chain or both the light and heavy chains of the anti-Langerin
antibody, wherein when two or more antigenic peptides are present,
the antigenic peptides are separated by the one or more peptide
linkers that comprise at least one glycosylation site.
12. The vector of claim 11, wherein the antigenic peptides are
cancer peptides selected from tumor associated antigens selected
from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE,
MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and
GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen),
MARCO-MART, cyclin B1, cyclin D, Pmel 17(gp100), GnT-V intron V
sequence (N-acetylglucoaminyltransferase V intron V sequence),
Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma
antigen), .beta.-catenin, MUM-1-B (melanoma ubiquitous mutated gene
product), GAGE (melanoma antigen)1, BAGE (melanoma antigen) 2-10,
c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6,
gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance
protein (LRP), Bcl-2, and Ki-67.
13. The vector of claim 11, wherein the antigenic peptides are
cancer peptides are selected from tumor associated antigens
comprising antigens from leukemias and lymphomas, neurological
tumors such as astrocytomas or glioblastomas, melanoma, breast
cancer, lung cancer, head and neck cancer, gastrointestinal tumors,
gastric cancer, colon cancer, liver cancer, pancreatic cancer,
genitourinary tumors such cervix, uterus, ovarian cancer, vaginal
cancer, testicular cancer, prostate cancer or penile cancer, bone
tumors, vascular tumors, or cancers of the lip, nasopharynx,
pharynx and oral cavity, esophagus, rectum, gall bladder, biliary
tree, larynx, lung and bronchus, bladder, kidney, brain and other
parts of the nervous system, thyroid, Hodgkin's disease,
non-Hodgkin's lymphoma, multiple myeloma and leukemia.
14. The vector of claim 11, wherein the antigenic peptides are
selected from Influenza A Hemagglutinin HA-1 from a H1N1 Flu
strain, HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer, Avian
Flu (HA5-1), dockerin domain from C. thermocellum (doc), HIV gag
p24 (gag), or a string of HIV peptides (Lipo5), PSA
(KLQCVDLHV)-tetramer, or an HIVgag-derived p24-PLA.
15. The vector of claim 11, wherein the anti-Langerin antibody is
selected from the following pairs of amino acid sequences SEQ ID
NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58; and 78 and 80 or
binding fragments thereof.
16. The vector of claim 11, wherein the anti-Langerin antibody is
the expression product of the following pairs of nucleic acid
sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and
77 and 79.
17. The vector of claim 11, wherein the anti-Langerin antibody or
binding fragment thereof is at least one of 15B10 having ATCC
Accession No. PTA-9852, 2G3 having ATCC Accession No. PTA-9853,
91E7, 37C1, or 4C7 and humanized derivatives thereof.
18. The vector of claim 11, wherein the anti-Langerin antibody or
binding fragment thereof and the antigenic peptide are a fusion
protein.
19. A method of enhancing T and B cell responses comprising:
immunizing a subject in need of vaccination with an effective
amount of a vaccine comprising an isolated fusion protein
comprising an anti-Langerin antibody or binding portion thereof and
one or more antigenic peptides linked to the carboxy-terminus of
the anti-Langerin antibody.
20. The method of claim 19, wherein the antigenic peptides are
cancer peptides selected from tumor associated antigens selected
from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE,
MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and
GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen),
MARCO-MART, cyclin B1, cyclin D, Pmel 17(gp100), GnT-V intron V
sequence (N-acetylglucoaminyltransferase V intron V sequence),
Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma
antigen), .beta.-catenin, MUM-1-B (melanoma ubiquitous mutated gene
product), GAGE (melanoma antigen)1, BAGE (melanoma antigen) 2-10,
c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6,
gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance
protein (LRP), Bcl-2, and Ki-67.
21. The method of claim 19, wherein the antigenic peptides are
cancer peptides selected from tumor associated antigens comprising
antigens from leukemias, lymphomas, neurological tumors such as
astrocytomas or glioblastomas, melanoma, breast cancer, lung
cancer, head and neck cancer, gastrointestinal tumors, gastric
cancer, colon cancer, liver cancer, pancreatic cancer,
genitourinary tumors such cervix, uterus, ovarian cancer, vaginal
cancer, testicular cancer, prostate cancer or penile cancer, bone
tumors, vascular tumors, or cancers of the lip, nasopharynx,
pharynx and oral cavity, esophagus, rectum, gall bladder, biliary
tree, larynx, lung and bronchus, bladder, kidney, brain and other
parts of the nervous system, thyroid, Hodgkin's disease,
non-Hodgkin's lymphoma, multiple myeloma and leukemia.
22. The method of claim 19, wherein the antigenic peptides are
selected from Influenza A Hemagglutinin HA-1 from a H1N1 Flu
strain, HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer, Avian
Flu (HA5-1), Influenza A Hemagglutinin HA-1 from a H1N1 Flu strain
(HA1-1), dockerin domain from C. thermocellum (doc), HIV gag p24
(gag), or a string of HIV peptides (Hipo5), PSA
(KLQCVDLHV)-tetramer, or an HIVgag-derived p24-PLA.
23. A method of making an anti-Langerin-antigen fusion protein
comprising: expressing an isolated fusion protein comprising an
anti-Langerin antibody or binding fragment thereof in a host cell,
the fusion protein comprising one or more antigenic peptides at the
carboxy-terminus of the anti-Langerin antibody or binding fragment
thereof, wherein when two or more cancer peptides are present, the
cancer peptides are separated by one or more linkers, at least one
linker comprising a glycosylation site; and isolating the fusion
protein.
24. The method of claim 23, wherein the fusion protein expressed in
the host is further purified.
25. The method of claim 23, wherein the host is a eukaryotic
cell.
26. The method of claim 23, wherein the antigenic peptides are
cancer peptides selected from tumor associated antigens selected
from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE,
MAGE 1-4, 6 and 12, MUC-related protein (Mucin) (MUC-1, MUC-2,
etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART
(melanoma antigen), MARCO-MART, cyclin B1, cyclin D, Pmel
17(gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase
V intron V sequence), Prostate Ca psm, prostate serum antigen
(PSA), PRAME (melanoma antigen), .beta.-catenin, MUM-1-B (melanoma
ubiquitous mutated gene product), GAGE (melanoma antigen).sub.1,
BAGE (melanoma antigen) 2-10, c-ERB2 (Her2/neu), EBNA (Epstein-Barr
Virus nuclear antigen) 1-6, gp75, human papilloma virus (HPV) E6
and E7, p53, lung resistance protein (LRP), Bcl-2, and Ki-67.
27. The method of claim 23, wherein the antigenic peptides are
cancer peptides selected from tumor associated antigens comprising
antigens from leukemias and lymphomas, neurological tumors such as
astrocytomas or glioblastomas, melanoma, breast cancer, lung
cancer, head and neck cancer, gastrointestinal tumors, gastric
cancer, colon cancer, liver cancer, pancreatic cancer,
genitourinary tumors such cervix, uterus, ovarian cancer, vaginal
cancer, testicular cancer, prostate cancer or penile cancer, bone
tumors, vascular tumors, or cancers of the lip, nasopharynx,
pharynx and oral cavity, esophagus, rectum, gall bladder, biliary
tree, larynx, lung and bronchus, bladder, kidney, brain and other
parts of the nervous system, thyroid, Hodgkin's disease,
non-Hodgkin's lymphoma, multiple myeloma and leukemia.
28. The method of claim 23, wherein the cancer peptides are
selected from at least one of:
MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHP QWV (SEQ
ID NO.: 9);
LTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSH D (SEQ
ID NO.: 10);
LMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVI S (SEQ
ID NO.: 11);
NDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALP ERP (SEQ
ID NO.: 12); SLYTKVVHYRKWIKDTIVANP (SEQ ID NO.: 13); IMDQVPFSV (SEQ
ID NO.: 14); ITDQVPFSV (SEQ ID NO.: 15); YLEPGPVTV (SEQ ID NO.:
16); YLEPGPVTA (SEQ ID NO.: 17); KTWGQYWQV (SEQ ID NO.: 18);
APLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILL
GRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTD
AVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKV
TKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYR
KWIKDTIVANP (SEQ ID NO.: 19);
DTTEPATPTTPVTTPTTTKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRG
GQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVY
PQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAML
GTHTMEVTVYHRRGSQSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQ (SEQ ID
NO.: 20);
PLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRAXVVTHTYLEPGPVTAQVVLQA
AIPLTSCGSSPVPAS (SEQ ID NO.: 21);
GTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQM
PTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAA (SEQ ID NO.:
22); QVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVL
YRYGSFSVTLDIVQ (SEQ ID NO.: 23);
GIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQ
LVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIVPGILLTGQEAGLGQ (SEQ ID NO.: 24);
MEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDY (SEQ ID NO.:
25); DWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKK (SEQ ID NO.: 26);
MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCV (SEQ ID NO.: 27);
QKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATC
MFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELL (SEQ ID NO.: 28);
LVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSM V (SEQ
ID NO.: 29); or
AAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQA
QQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI (SEQ ID NO.: 30), or immunogenic
fragments thereof.
29. A method of expanding antigen-specific T cells or B cells in
vitro comprising: isolating peripheral blood mononuclear cells
(PBMCs) from a cancer patient; incubating the isolated PBMCs with
an immunogenic amount of an isolated anti-Langerin-(PL-Ag)x or
anti-Langerin-(Ag-PL)x vaccine, wherein Ag is a tumor associated
antigen and x is an integer 1 to 20; expanding the PBMCs in the
presence of an effective amount of IL-2; harvesting the cells; and
assessing the cytokine production by the cells to determine the
presence of anti-cancer specific T cells or B cells.
30. A tumor associated antigen-specific T cell or B cell made by
the method comprising: isolating peripheral blood mononuclear cells
(PBMCs) from a cancer patient; incubating the isolated PBMCs with
an immunogenic amount of an anti-Langerin-(PL-Ag)x or
anti-Langerin-(Ag-PL)x vaccine, wherein Ag is a tumor associated
antigen and x is an integer 1 to 20; expanding the PBMCs in the
presence of an effective amount of IL-2; harvesting the cells; and
assessing the cytokine production by the cells to determine the
presence of tumor associated antigen-specific T cells or B
cells.
31. A therapeutic vaccine comprising an isolated fusion protein
comprising the formula: Ab-(PL-Ag)x; Ab-(Ag-PL)x; Ab-(PL-Ag-PL)x;
Ab-(Ag-PL-Ag)x; Ab-(PL-Ag)x-PL; or Ab-(Ag-PL)x-Ag; wherein Ab is an
anti-Langerin monoclonal antibody or binding fragment thereof; PL
is at least one peptide linker comprising at least one
glycosylation site; Ag is at least one infectious disease antigen;
and x is an integer from 1 to 20.
32. A method of expanding antigen-specific T cells or B cells in
vitro comprising: isolating peripheral blood mononuclear cells
(PBMCs) from a patient suspected of having an infection; incubating
the isolated PBMCs with an immunogenic amount of an isolated
anti-Langerin-(PL-Ag)x or .alpha.Langerin-(Ag-PL)x vaccine, wherein
Ag is an antigen of the infectious agent and x is an integer 1 to
20; expanding the PBMCs in the presence of an effective amount of
one or more cytokines; harvesting the cells; and assessing the
cytokine production by the cells to determine the presence of
anti-infections agent specific T cells or B cells.
33. A viral associated antigen-specific T cell or B cell made by
the method comprising: isolating peripheral blood mononuclear cells
(PBMCs) from a patient suspected of having a viral infection;
incubating the isolated PBMCs with an immunogenic amount of an
isolated anti-Langerin-(PL-Ag)x or anti-Langerin-(Ag-PL)x vaccine,
wherein Ag is a viral associated antigen and x is an integer 1 to
20; expanding the PBMCs in the presence of an effective amount of
one or more cytokines; harvesting the cells; and assessing the
cytokine production by the cells to determine the presence of viral
associated antigen-specific T cells or B cells.
34. A therapeutic vaccine comprising an isolated fusion protein
comprising the formula: Ab-(PL-Ag)x; Ab-(Ag-PL)x; Ab-(PL-Ag-PL)x;
Ab-(Ag-PL-Ag)x; Ab-(PL-Ag)x-PL; or Ab-(Ag-PL)x-Ag; wherein Ab is an
anti-Langerin monoclonal antibody or binding fragment thereof; PL
is at least one peptide linker comprising at least one
glycosylation site; Ag is at least one viral antigen; and x is an
integer from 1 to 20.
35. An isolated antibody comprising one or more of complementarity
determining regions selected from:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45);
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46);
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47);
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); or a direct equivalent
thereof.
36. The antibody of claim 27, wherein the antibody is
humanized.
37. The antibody of claim 27, wherein the antibody is 15B10 having
ATCC Accession No. PTA-9852, 2G3 having ATCC Accession No.
PTA-9853, 91E7, 37C1, or 4C7, and humanized derivatives
thereof.
38. An isolated nucleic acid that encodes a 15B10, 2G3, 91E7, 37C1,
or 4C7 antibody, antibody binding fragment or a humanized
derivative thereof.
39. The nucleic acid of claim 38, wherein the anti-Langerin
antibody is selected from the following pairs of amino acid
sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58; and
78 and 80; or binding fragments thereof.
40. The nucleic acid of claim 38, wherein the anti-Langerin
antibody is the expression product from the following pairs of
nucleic acid sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55
and 57; and 77 and 79; or binding fragments thereof.
41. A pharmaceutical composition comprising an isolated
anti-Langerin antibody or binding fragment thereof and one or more
antigenic peptides attached to the anti-Langerin antibody, wherein
when two or more antigens are present, they are separated by one or
more linker peptides that comprise at least one glycosylation
site.
42. The composition of claim 41, wherein the antibody binding
fragment is selected from an Fv, Fab, Fab', F(ab').sub.2, Fc, or a
ScFv fragment.
43. The composition of claim 41, wherein the anti-Langerin antibody
is selected from the following pairs of amino acid sequences SEQ ID
NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58; and 78 and 80 or
binding fragments thereof.
44. The composition of claim 41, wherein the anti-Langerin antibody
is the expression product of the following pairs of nucleic acid
sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and
77 and 79.
45. The composition of claim 41, wherein the anti-Langerin antibody
or binding fragment thereof is at least one of 15B10 having ATCC
Accession No. PTA-9852, 2G3 having ATCC Accession No. PTA-9853,
91E7, 37C1, or 4C7 and humanized derivatives thereof.
46. The composition of claim 41, wherein the anti-Langerin antibody
or binding fragment thereof and the antigenic peptide are a fusion
protein.
47. The composition of claim 41, wherein the composition further
comprises an adjuvant.
48. The composition of claim 41, wherein the composition further
comprises one or more pharmaceutical excipients.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application Ser. No. 61/242,283, filed Sep. 14, 2009, the entire
contents of which are incorporated herein by reference.
TECHNICAL FIELD OF THE INVENTION
[0003] The present invention relates in general to the field of
vaccines, and more particularly, to compositions and methods for
targeting and delivering antigens to Langerhans cells for antigen
presentation using high affinity anti-Langerin monoclonal
antibodies and fusion proteins therewith.
INCORPORATION-BY-REFERENCE OF MATERIALS FILED ON COMPACT DISC
[0004] None.
BACKGROUND OF THE INVENTION
[0005] Without limiting the scope of the invention, its background
is described in connection with antigen presentation.
[0006] Dendritic Cells (DCs) are professional antigen-presenting
cells (APCs) that induce and sustain immune responses and are
fundamental in establishing both tolerance and immunity. DCs
capture and present antigens to CD4.sup.+ T cells, which then
determine the quantity and quality of antigen-specific CD8.sup.+ T
cells. There are subsets of DCs.sup.1,2, including both myeloid and
plasmacytoid DCs (mDCs and pDCs, respectively).
[0007] Prior Langerin related agents include those taught in U.S.
Pat. No. 6,878,528, issued to Duvert-Frances, et al., which include
polynucleotides encoding a mammalian Langerhans cell antigen,
including purified mammalian DC cell surface protein, designated
Langerin, nucleic acids encoding Langerin, and antibodies which
specifically bind Langerin.
[0008] Other anti-DC related agents are taught in, e.g., United
States Patent Application Publication No. 20060257412, filed by
Bowdish, et al., which includes a method of treating autoimmune
disease by inducing antigen presentation by tolerance inducing
antigen presenting cells. Briefly, this application teaches that
antibodies to antigen presenting cells may be utilized to interfere
with the interaction of the antigen presenting cell and immune
cells, including T cells. Peptides may be linked to the antibodies
thereby generating an immune response to such peptides, e.g., those
peptides associated with autoimmunity.
SUMMARY OF THE INVENTION
[0009] In one embodiment, the present invention includes
compositions and methods for activating T and B cell responses by
targeting antigens to antigen presenting cells along with the
proper activation of the APC to activate T cell and B cells
responses. One embodiment is a vaccine comprising an isolated
anti-Langerin antibody or binding fragment thereof and one or more
antigenic peptides at the carboxy-terminus of the anti-Langerin
antibody, wherein when two or more antigens are present, they are
separated by one or more linker peptides that comprise at least one
glycosylation site. In one aspect, the antibody binding fragment is
selected from an Fv, Fab, Fab', F(ab').sub.2, Fc, or a ScFv
fragment. In another aspect, the antibody comprises one or more
complementarity determining regions selected from:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45);
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46);
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47);
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAYYC (SEQ ID NO.: 48); or a direct equivalent
thereof. In another aspect, the antigenic peptide is a cancer
antigen selected from:
MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHP QWV (SEQ
ID NO.: 9);
LTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSH D (SEQ
ID NO.: 10);
LMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVI S (SEQ
ID NO.: 11);
NDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALP ERP (SEQ
ID NO.: 12); SLYTKVVHYRKWIKDTIVANP (SEQ ID NO.: 13); IMDQVPFSV (SEQ
ID NO.: 14); ITDQVPFSV (SEQ ID NO.: 15); YLEPGPVTV (SEQ ID NO.:
16); YLEPGPVTA (SEQ ID NO.: 17); KTWGQYWQV (SEQ ID NO.: 18);
APLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILL
GRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTD
AVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKV
TKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYR
KWIKDTIVANP (SEQ ID NO.: 19);
DTTEPATPTTPVTTPTTTKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRG
GQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVY
PQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAML
GTHTMEVTVYHRRGSQSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQ (SEQ ID
NO.: 20);
PLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRAXVVTHTYLEPGPVTAQVVLQA
AIPLTSCGSSPVPAS (SEQ ID NO.: 21);
GTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQM
PTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAA (SEQ ID NO. 22);
QVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVL
YRYGSFSVTLDIVQ (SEQ ID NO.: 23);
GIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQ
LVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIVPGILLTGQEAGLGQ (SEQ ID NO.: 24);
MEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDY (SEQ ID NO.:
25); DWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKK (SEQ ID NO.: 26);
MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCV (SEQ ID NO.: 27);
QKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATC
MFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELL (SEQ ID NO.: 28);
LVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSM V (SEQ
ID NO.: 29); or
AAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQA
QQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI (SEQ ID NO.: 30), or binding
fragments thereof. In another aspect, the antigenic peptide is a
viral antigen selected from: VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL (SEQ
ID NO.: 31); HTQGYFPDWQNYTPGPGVRYPLTFGWLYKL (SEQ ID NO.: 32);
EKIRLRPGGKKKYKLKHIV (SEQ ID NO.: 33);
NPPIPVGEIYKRWIILGLNKIVRMYSPTSILD (SEQ ID NO.: 34);
AIFQSSMTKILEPFRKQNPDIVIYQYMDDLY (SEQ ID NO.: 35);
DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAG
WLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKES
SWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGI
HHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKP
GDTIIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHP
VTIGECPKYVRSAKLRMV (SEQ ID NO.: 36);
DQICIGYHANNSTEQVDTIMEKNTVTHAQDILEKKHNGKLCDLDGVKPLILRDCSVA
GWLLGNPMCDEFINVPEWSYIVEKANPVNDLCYPGDFNDYEELKHLLSRINHFEKIQIIP
KSSWSSHEASLGVSSACPYQGKSSFFRNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLW
GIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPRIATRSKVNGQSGRMEFFWTILKP
NDAINFESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNTKCQTPMGAINSSMPFHNIH
PLTIGECPKYVKSNRLVLA (SEQ ID NO.: 37); or
PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTV
GGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIG
WMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQ
ASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL (SEQ ID
NO.: 38). In another aspect, when two or more antigens are present,
the antigens are separated by one or more peptide linkers are
selected from: SSVSPTTSVHPTPTSVPPTPTKSSP (SEQ ID NO.: 39);
PTSTPADSSTITPTATPTATPTIKG (SEQ ID NO.: 40);
TVTPTATATPSAIVTTITPTATTKP (SEQ ID NO.: 41); or
TNGSITVAATAPTVTPTVNATPSAA (SEQ ID NO.: 42). In another aspect, the
anti-Langerin antibody is selected from the following pairs of
amino acid sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56
and 58; and 78 and 80 or binding fragments thereof. In another
aspect, the anti-Langerin antibody is the expression product of the
following pairs of nucleic acid sequences SEQ ID NOS.: 1 and 3; 5
and 6; 51 and 53; 55 and 57; and 77 and 79. In another aspect, the
anti-Langerin antibody or binding fragment thereof is at least one
of 15B10 having ATCC Accession No. PTA-9852, 2G3 having ATCC
Accession No. PTA-9853, 91E7, 37C1, or 4C7 and humanized
derivatives thereof. In another aspect, the anti-Langerin antibody
or binding fragment thereof and the antigenic peptide are a fusion
protein.
[0010] Another embodiment of the present invention includes an
isolated nucleic acid vector that expresses an anti-Langerin
antibody or binding fragment thereof and two or more antigenic
peptides at the carboxy-terminus of the light chain, the heavy
chain or both the light and heavy chains of the anti-Langerin
antibody, wherein when two or more antigenic peptides are present,
the antigenic peptides are separated by the one or more peptide
linkers that comprise at least one glycosylation site. In one
aspect, the antigenic peptides are cancer peptides selected from
tumor associated antigens selected from CEA, prostate specific
antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC
(Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and GD2 gangliosides, ras,
myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin B1,
cyclin D, Pmel 17(gp100), GnT-V intron V sequence
(N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca
psm, prostate serum antigen (PSA), PRAME (melanoma antigen),
O-catenin, MUM-1-B (melanoma ubiquitous mutated gene product), GAGE
(melanoma antigen) 1, BAGE (melanoma antigen) 2-10, c-ERB2
(Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6, gp75,
human papilloma virus (HPV) E6 and E7, p53, lung resistance protein
(LRP), Bcl-2, and Ki-67. In another aspect, the antigenic peptides
are cancer peptides are selected from tumor associated antigens
comprising antigens from leukemias and lymphomas, neurological
tumors such as astrocytomas or glioblastomas, melanoma, breast
cancer, lung cancer, head and neck cancer, gastrointestinal tumors,
gastric cancer, colon cancer, liver cancer, pancreatic cancer,
genitourinary tumors such cervix, uterus, ovarian cancer, vaginal
cancer, testicular cancer, prostate cancer or penile cancer, bone
tumors, vascular tumors, or cancers of the lip, nasopharynx,
pharynx and oral cavity, esophagus, rectum, gall bladder, biliary
tree, larynx, lung and bronchus, bladder, kidney, brain and other
parts of the nervous system, thyroid, Hodgkin's disease,
non-Hodgkin's lymphoma, multiple myeloma and leukemia. In another
aspect, the antigenic peptides are selected from Influenza A
Hemagglutinin HA-1 from a H1N1 Flu strain, HLA-A201-FluMP (58-66)
peptide (GILGFVFTL) tetramer, Avian Flu (HA5-1), dockerin domain
from C. thermocellum (doc), HIV gag p24 (gag), or a string of HIV
peptides (Lipo5), PSA (KLQCVDLHV)-tetramer, or an HIVgag-derived
p24-PLA. In another aspect, the anti-Langerin antibody is selected
from the following pairs of amino acid sequences SEQ ID NOS.: 2 and
4; 6 and 7; 52 and 54; 56 and 58; and 78 and 80 or binding
fragments thereof. In another aspect, the anti-Langerin antibody is
the expression product of the following pairs of nucleic acid
sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and
77 and 79. In another aspect, the anti-Langerin antibody or binding
fragment thereof is at least one of 15B10 having ATCC Accession No.
PTA-9852, 2G3 having ATCC Accession No. PTA-9853, 91E7, 37C1, or
4C7 and humanized derivatives thereof. In another aspect, the
anti-Langerin antibody or binding fragment thereof and the
antigenic peptide are a fusion protein.
[0011] Yet another embodiment of the present invention includes a
method of enhancing T and B cell responses comprising: immunizing a
subject in need of vaccination with an effective amount of a
vaccine comprising an isolated fusion protein comprising an
anti-Langerin antibody or binding portion thereof and one or more
antigenic peptides linked to the carboxy-terminus of the
anti-Langerin antibody. In one aspect, the antigenic peptides are
cancer peptides selected from tumor associated antigens selected
from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE,
MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and
GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen),
MARCO-MART, cyclin B1, cyclin D, Pmel 17(gp100), GnT-V intron V
sequence (N-acetylglucoaminyltransferase V intron V sequence),
Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma
antigen), .beta.-catenin, MUM-1-B (melanoma ubiquitous mutated gene
product), GAGE (melanoma antigen)1, BAGE (melanoma antigen) 2-10,
c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6,
gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance
protein (LRP), Bcl-2, and Ki-67. In another aspect, the antigenic
peptides are cancer peptides selected from tumor associated
antigens comprising antigens from leukemias, lymphomas,
neurological tumors such as astrocytomas or glioblastomas,
melanoma, breast cancer, lung cancer, head and neck cancer,
gastrointestinal tumors, gastric cancer, colon cancer, liver
cancer, pancreatic cancer, genitourinary tumors such cervix,
uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate
cancer or penile cancer, bone tumors, vascular tumors, or cancers
of the lip, nasopharynx, pharynx and oral cavity, esophagus,
rectum, gall bladder, biliary tree, larynx, lung and bronchus,
bladder, kidney, brain and other parts of the nervous system,
thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple
myeloma and leukemia. In another aspect, the antigenic peptides are
selected from Influenza A Hemagglutinin HA-1 from a H1N1 Flu
strain, HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer, Avian
Flu (HA5-1), Influenza A Hemagglutinin HA-1 from a H1N1 Flu strain
(HA1-1), dockerin domain from C. thermocellum (doc), HIV gag p24
(gag), or a string of HIV peptides (Hipo5), PSA
(KLQCVDLHV)-tetramer, or an HIVgag-derived p24-PLA.
[0012] Yet another embodiment is a method of making an
anti-Langerin-antigen fusion protein comprising: expressing an
isolated fusion protein comprising an anti-Langerin antibody or
binding fragment thereof in a host cell, the fusion protein
comprising one or more antigenic peptides at the carboxy-terminus
of the anti-Langerin antibody or binding fragment thereof, wherein
when two or more cancer peptides are present, the cancer peptides
are separated by one or more linkers, at least one linker
comprising a glycosylation site; and isolating the fusion protein.
In one aspect, fusion protein expressed in the host is further
isolated and purified. In another aspect, the host is a eukaryotic
cell. In another aspect, the antigenic peptides are cancer peptides
selected from tumor associated antigens selected from CEA, prostate
specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12,
MUC-related protein (Mucin) (MUC-1, MUC-2, etc.), GM2 and GD2
gangliosides, ras, myc, tyrosinase, MART (melanoma antigen),
MARCO-MART, cyclin B1, cyclin D, Pmel 17(gp100), GnT-V intron V
sequence (N-acetylglucoaminyltransferase V intron V sequence),
Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma
antigen), .beta.-catenin, MUM-1-B (melanoma ubiquitous mutated gene
product), GAGE (melanoma antigen).sub.1, BAGE (melanoma antigen)
2-10, c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen)
1-6, gp75, human papilloma virus (HPV) E6 and E7, p53, lung
resistance protein (LRP), Bcl-2, and Ki-67. In another aspect, the
antigenic peptides are cancer peptides selected from tumor
associated antigens comprising antigens from leukemias and
lymphomas, neurological tumors such as astrocytomas or
glioblastomas, melanoma, breast cancer, lung cancer, head and neck
cancer, gastrointestinal tumors, gastric cancer, colon cancer,
liver cancer, pancreatic cancer, genitourinary tumors such cervix,
uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate
cancer or penile cancer, bone tumors, vascular tumors, or cancers
of the lip, nasopharynx, pharynx and oral cavity, esophagus,
rectum, gall bladder, biliary tree, larynx, lung and bronchus,
bladder, kidney, brain and other parts of the nervous system,
thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple
myeloma and leukemia. In another aspect, the cancer peptides are
selected from at least one of:
MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHP QWV (SEQ
ID NO.: 9);
LTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSH D (SEQ
ID NO.: 10);
LMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVI S (SEQ
ID NO.: 11);
NDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALP ERP (SEQ
ID NO.: 12); SLYTKVVHYRKWIKDTIVANP (SEQ ID NO.: 13); IMDQVPFSV (SEQ
ID NO.: 14); ITDQVPFSV (SEQ ID NO.: 15); YLEPGPVTV (SEQ ID NO.:
16); YLEPGPVTA (SEQ ID NO.: 17); KTWGQYWQV (SEQ ID NO.: 18);
APLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILL
GRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTD
AVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKV
TKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYR
KWIKDTIVANP (SEQ ID NO.: 19);
DTTEPATPTTPVTTPTTTKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRG
GQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVY
PQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAML
GTHTMEVTVYHRRGSQSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQ (SEQ ID
NO.: 20);
PLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRAXVVTHTYLEPGPVTAQVVLQA
AIPLTSCGSSPVPAS (SEQ ID NO.: 21);
GTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQM
PTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAA (SEQ ID NO.:
22); QVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVL
YRYGSFSVTLDIVQ (SEQ ID NO.: 23);
GIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQ
LVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIVPGILLTGQEAGLGQ (SEQ ID NO.: 24);
MEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDY (SEQ ID NO.:
25); DWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKK (SEQ ID NO.: 26);
MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCV (SEQ ID NO.: 27);
QKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATC
MFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELL (SEQ ID NO.: 28);
LVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSM V (SEQ
ID NO.: 29); or
AAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQA
QQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI (SEQ ID NO.: 30), or immunogenic
fragments thereof.
[0013] In another embodiment, the invention includes a method of
expanding antigen-specific T cells or B cells in vitro comprising:
isolating peripheral blood mononuclear cells (PBMCs) from a cancer
patient; incubating the isolated PBMCs with an immunogenic amount
of an isolated anti-Langerin-(PL-Ag)x or anti-Langerin-(Ag-PL)x
vaccine, wherein Ag is a tumor associated antigen and x is an
integer 1 to 20; expanding the PBMCs in the presence of an
effective amount of IL-2; harvesting the cells; and assessing the
cytokine production by the cells to determine the presence of
anti-cancer specific T cells or B cells.
[0014] In yet another embodiment, the invention includes a tumor
associated antigen-specific T cell or B cell made by the method
comprising: isolating peripheral blood mononuclear cells (PBMCs)
from a cancer patient; incubating the isolated PBMCs with an
immunogenic amount of an anti-Langerin-(PL-Ag)x or
anti-Langerin-(Ag-PL)x vaccine, wherein Ag is a tumor associated
antigen and x is an integer 1 to 20; expanding the PBMCs in the
presence of an effective amount of IL-2; harvesting the cells; and
assessing the cytokine production by the cells to determine the
presence of tumor associated antigen-specific T cells or B
cells.
[0015] Another embodiment of the invention includes a therapeutic
vaccine comprising an isolated fusion protein comprising the
formula: Ab-(PL-Ag)x; Ab-(Ag-PL)x; Ab-(PL-Ag-PL)x; Ab-(Ag-PL-Ag)x;
Ab-(PL-Ag)x-PL; or Ab-(Ag-PL)x-Ag; wherein Ab is an anti-Langerin
monoclonal antibody or binding fragment thereof; PL is at least one
peptide linker comprising at least one glycosylation site; Ag is at
least one infectious disease antigen; and x is an integer from 1 to
20.
[0016] Yet another embodiment includes a method of expanding
antigen-specific T cells or B cells in vitro comprising: isolating
peripheral blood mononuclear cells (PBMCs) from a patient suspected
of having an infection; incubating the isolated PBMCs with an
immunogenic amount of an isolated anti-Langerin-(PL-Ag)x or
.alpha.Langerin-(Ag-PL)x vaccine, wherein Ag is an antigen of the
infectious agent and x is an integer 1 to 20; expanding the PBMCs
in the presence of an effective amount of one or more cytokines;
harvesting the cells; and assessing the cytokine production by the
cells to determine the presence of anti-infections agent specific T
cells or B cells. Another embodiment is a viral associated
antigen-specific T cell or B cell made by the method comprising:
isolating peripheral blood mononuclear cells (PBMCs) from a patient
suspected of having a viral infection; incubating the isolated
PBMCs with an immunogenic amount of an isolated
anti-Langerin-(PL-Ag)x or anti-Langerin-(Ag-PL)x vaccine, wherein
Ag is a viral associated antigen and x is an integer 1 to 20;
expanding the PBMCs in the presence of an effective amount of one
or more cytokines; harvesting the cells; and assessing the cytokine
production by the cells to determine the presence of viral
associated antigen-specific T cells or B cells.
[0017] Another embodiment is a therapeutic vaccine comprising an
isolated fusion protein comprising the formula: Ab-(PL-Ag)x;
Ab-(Ag-PL)x; Ab-(PL-Ag-PL)x; Ab-(Ag-PL-Ag)x; Ab-(PL-Ag)x-PL; or
Ab-(Ag-PL)x-Ag; wherein Ab is an anti-Langerin monoclonal antibody
or binding fragment thereof; PL is at least one peptide linker
comprising at least one glycosylation site; Ag is at least one
viral antigen; and x is an integer from 1 to 20. In one example,
the isolated antibody comprising one or more of complementarity
determining regions selected from:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45);
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46);
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47);
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); or a direct equivalent
thereof. In one aspect, the antibody is humanized. In another
aspect, the antibody is 15B10 having ATCC Accession No. PTA-9852
and humanized derivatives thereof. In another aspect, the antibody
is 2G3 having ATCC Accession No. PTA-9853, 91E7, 37C1, or 4C7, and
humanized derivatives thereof.
[0018] Yet another embodiment is an isolated isolated nucleic acid
that encodes a 15B10, 2G3, 91E7, 37C1, or 4C7 antibody, antibody
binding fragment or a humanized derivative thereof. In one aspect,
the anti-Langerin antibody is selected from the following pairs of
amino acid sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56
and 58; and 78 and 80; or binding fragments thereof respectively.
In another aspect, the anti-Langerin antibody is the expression
product from the following pairs of nucleic acid sequences SEQ ID
NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and 77 and 79; or
binding fragments thereof, which are the 15B10, 2G3, 91E7, 37C1, or
4C7 antibodies, respectively.
[0019] Yet another embodiment of the present invention is a
pharmaceutical composition comprising an isolated anti-Langerin
antibody or binding fragment thereof and one or more antigenic
peptides attached to the anti-Langerin antibody, wherein when two
or more antigens are present, they are separated by one or more
linker peptides that comprise at least one glycosylation site. In
one aspect, the antibody binding fragment is selected from an Fv,
Fab, Fab', F(ab').sub.2, Fc, or a ScFv fragment. In another aspect,
the anti-Langerin antibody is selected from the following pairs of
amino acid sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56
and 58; and 78 and 80 or binding fragments thereof. In another
aspect, the anti-Langerin antibody is the expression product of the
following pairs of nucleic acid sequences SEQ ID NOS.: 1 and 3; 5
and 6; 51 and 53; 55 and 57; and 77 and 79. In another aspect, the
anti-Langerin antibody or binding fragment thereof is at least one
of 15B10 having ATCC Accession No. PTA-9852, 2G3 having ATCC
Accession No. PTA-9853, 91E7, 37C1, or 4C7 and humanized
derivatives thereof. In another aspect, the anti-Langerin antibody
or binding fragment thereof and the antigenic peptide are a fusion
protein. In another aspect, the composition further comprises an
adjuvant. In another aspect, the composition further comprises one
or more pharmaceutical excipients.
[0020] Yet another embodiment of the present invention is a
therapeutic vaccine comprising a fusion protein comprising the
formula: Ab-(PL-Ag)x; Ab-(Ag-PL)x; Ab-(PL-Ag-PL)x; Ab-(Ag-PL-Ag)x;
Ab-(PL-Ag)x-PL; or Ab-(Ag-PL)x-Ag; wherein Ab is an anti-Langerin
monoclonal antibody or binding fragment thereof; PL is at least one
peptide linker comprising at least one glycosylation site; Ag is at
least one viral antigen; and x is an integer from 1 to 20.
[0021] The invention provides a Langerin binding antibody (15B10)
that comprises at least one immunoglobulin light chain variable
domain (VL) which comprises the amino acid and nucleic acid
sequence encoding:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45); or and direct equivalent
thereof.
[0022] Accordingly the invention provides a Langerin binding
antibody (15B10) that comprises an antigen binding site comprising
at least one immunoglobulin heavy chain variable domain (VH) which
comprises the amino acid and nucleic acid sequence encoding:
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46); and direct equivalents
thereof.
[0023] The invention provides a Langerin binding antibody (2G3)
that comprises at least one immunoglobulin light chain variable
domain (VL) which comprises the amino acid and nucleic acid
sequence encoding:
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47); or and direct equivalent
thereof.
[0024] Accordingly the invention provides a Langerin binding
antibody (2G3) that comprises an antigen binding site comprising at
least one immunoglobulin heavy chain variable domain (VH) which
comprises the amino acid and nucleic acid sequence encoding:
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); and direct equivalents
thereof.
[0025] In one aspect the invention provides a single domain
Langerin antibody comprising an isolated immunoglobulin light chain
comprising a heavy chain variable domain (VL) as defined above. In
another aspect the invention provides a single domain Langrin
binding molecule comprising an isolated immunoglobulin heavy chain
comprising a heavy chain variable domain (VH) as defined above.
[0026] In another aspect the invention also provides a Langerin
binding antibody comprising a light chain (VL) variable domains in
which the Langerin binding antibody comprises at least one antigen
binding site comprising: an antibody light chain variable domain
(VL) which comprises in sequence hypervariable regions obtained
from the amino acid and nucleic acid sequences encoding:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45); or
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47); and direct equivalents
thereof.
[0027] In another aspect the invention also provides a Langerin
binding antibody comprising, the amino acid and nucleic acid
sequences of heavy chain variable domain (VH) which comprises in
sequence hypervariable regions obtained from:
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46); or
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); and direct equivalents
thereof.
[0028] mAnti-Langerin15B10K--Nucleotide and mature protein amino
acid sequence of the light chain of the mouse anti-Langerin 15B10
antibody cDNA, respectively. The variable region residues are
underlined.
TABLE-US-00001 (SEQ ID NO. 49)
ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTG
CTTCCAGCAGTGATGTTGTGATGACCCAAACTCCACTCTCCCTGCC
TGTCCGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAG
AGCCTTGTACACAGTAATGGAAACACCTATTTACATTGGTACCTGC
AGAAGCCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAA
CCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGG
ACAAATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGG
GACTTTATTTCTGCTCTCAAAGTACACATGTTCCGTACACGTTCGG
AGGGGGGACCAAGCTGGAAATAAAACGGGCTGATGCTGCACCAACT
GTATCCATCTTCCCACCATCCAGTGAGCAGTTAACATCTGGAGGTG
CCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAA
TGTCAAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTG
AACAGTTGGACTGATCAGGACAGCAAAGACAGCACCTACAGCATGA
ACAGCACCCTCACGTTGACCAAGGACGAGTATGAACGACATAACAG
CTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATCGTC
AAGAGCTTCAACAGGAATGAGTGTTAG (SEQ ID NO. 50)
DVVMTQTPLSLPVRLGDQASISCRSSQSLVHSNGNTYLHWYLQKPG
QSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTLKISRVEAEDLGLYF
CSQSTHVPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVV
CFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMNSTL
TLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
[0029] mAnti-Langerin15B10H-LV-hIgG4H-C--Nucleotide and mature
protein amino acid sequence of the heavy chain variable region of
the mouse anti-Langerin 15B10 antibody fused to human IgG4,
respectively. The variable region residues are underlined.
TABLE-US-00002 (SEQ ID NO. 51)
ATGGAATGGAGGATCTTTCTCTTCATCCTGTCAGGAACTGCAGGTG
TCCACTCCCAGGTTCAGCTGCGGCAGTCTGGACCTGAGCTGGTGAA
GCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACA
TTTACTGACTATGTTATAAGTTGGGTGAAGCAGAGAACTGGACAGG
GCCTTGAGTGGATTGGAGATATTTATCCTGGAAGTGGTTATTCTTT
CTACAATGAGAACTTCAAGGGCAAGGCCACACTGACTGCAGACAAA
TCCTCCACCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGG
ACTCTGCGGTCTATTTCTGTGCAACCTACTATAACTACCCTTTTGC
TTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACA
ACGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCT
CCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCC
CGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC
GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCC
TCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGAC
CTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGAC
AAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAA
ACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGC
GTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACT
GGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCG
GGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACC
GTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGG
TCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAA
AGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCA
TCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAA
TGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGAC
TCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGA
GCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGA
GGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTG GGTAAAGCTAGCTGA (SEQ
ID NO. 52) QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLE
WIGDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSA
VYFCATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPE
FEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYV
DGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRW
QEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
[0030] mAnti-Langerin2G3L--Nucleotide and mature protein amino acid
sequence of the light chain of the mouse anti-Langerin 2G3 antibody
cDNA, respectively. The variable region residues are
underlined.
TABLE-US-00003 (SEQ ID NO. 53)
ATGGCCTGGATTTCACTTATACTCTCTCTCCTGGCTCTCAGCTCAGGG
GCCATTTCCCAGGCTGTTGTGACTCAGGAATCTGCACTCACCACATCA
CCTGGTGAAACAGTCACACTCACTTGTCGCTCAAGTACTGGGGCTGTT
ACAACTAGTAACTATGCCAACTGGGTCCAAGAAAAACCAGATCATTTA
TTCACTGGTCTAATAGGTGGTACCAACAACCGAGTTTCAGGTGTTCCT
GCCAGATTCTCAGGCTCCCTGATTGGAGACAAGGCTGCCCTCACCATC
ACAGGGGCACAGACTGAGGATGAGGCAATATATTTCTGTGCTCTATGG
TACAGCAACCATTGGGTGTTCGGTGGAGGAACCAAACTGACTGTCCTA
GGCCAGCCCAAGTCTTCGCCATCAGTCACCCTGTTTCCACCTTCCTCT
GAAGAGCTCGAGACTAACAAGGCCACACTGGTGTGTACGATCACTGAT
TTCTACCCAGGTGTGGTGACAGTGGACTGGAAGGTAGATGGTACCCCT
GTCACTCAGGGTATGGAGACAACCCAGCCTTCCAAACAGAGCAACAAC
AAGTACATGGCTAGCAGCTACCTGACCCTGACAGCAAGAGCATGGGAA
AGGCATAGCAGTTACAGCTGCCAGGTCACTCATGAAGGTCACACTGTG
GAGAAGAGTTTGTCCCGTGCTGACTGTTCCTAG (SEQ ID NO. 54)
QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTG
LIGGTNNRVSGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSN
HWVFGGGTKLTVLGQPKSSPSVTLFPPSSEELETNKATLVCTITDFYP GVVTVDWKVDGT
PVTQGMETTQPSKQSNNKYMASSYLTLTARAWERHSSYSCQVTHEGHT VEKSLSRADCS
[0031] mAnti-Langerin2G3H--Nucleotide and mature protein amino acid
sequence of the heavy chain of the mouse anti-Langerin 2G3 antibody
cDNA, respectively. The variable region residues are
underlined.
TABLE-US-00004 (SEQ ID NO. 55)
ATGACATTGAACATGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTT
TTTTATCAAGGTGTGCATTGTGAGGTGCAGCTTGTTGAGTCTGGTGGA
GGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCT
GGATTAACCTTCAATATCTACGCCATGAACTGGGTCCGCCAGGCTCCA
GGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAAT
TATGCAACATATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCC
AGAGATGATTCACAAAGCTTGCTCTATCTGCAAATGAACAACTTGAAA
ACTGAGGACACAGCCATGTATTACTGTGTGGGACGGGACTGGTTTGAT
TACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGACA
CCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAAC
TCCATGGTGACCCTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCA
GTGACAGTGACCTGGAACTCTGGATCCCTGTCCAGCGGTGTGCACACC
TTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTG
ACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTT
GCCCACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGG
GATTGTGGTTGTAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCT
GTCTTCATCTTCCCCCCAAAGCCCAAGGATGTGCTCACCATTACTCTG
ACTCCTAAGGTCACGTGTGTTGTGGTAGACATCAGCAAGGATGATCCC
GAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGTGCACACAGCT
CAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCTCAGTC
AGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTC
AAATGCAGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACC
ATCTCCAAAACCAAAGGCAGACCGAAGGCTCCACAGGTGTACACCATT
CCACCTCCCAAGGAGCAGATGGCCAAGGATAAAGTCAGTCTGACCTGC
ATGATAACAGACTTCTTCCCTGAAGACATTACTGTGGAGTGGCAGTGG
AATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCCCATCATGGAC
ACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGAAGAGC
AACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGC
CTGCACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAA GCTAGCTGA (SEQ ID
NO. 56) EVQLVESGGGLVQPKGSLKLSCAASGLTFNIYAMNWVRQAPGKGLEWV
ARIRNKSNNYATYYADSVKDRFTISRDDSQSLLYLQMNNLKTEDTAMY
YCVGRDWFDYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGC
LVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTW
PSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPK
PKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREE
QFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGR
PKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAEN
YKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTE KSLSHSPGKAS
[0032] In another embodiment the invention includes an antibody
comprising one or more of the complementarity determining regions
selected from:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45);
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46);
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47);
[0033] SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); or a direct equivalent
thereof. In one aspect, the antibody is humanized. In another
aspect, the antibody is 15B10, 2G3 or humanized derivatives
thereof. In another aspect, the invention includes nucleic acids
that encode the 15B10, the 2G3 antibody or humanized derivatives
thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] For a more complete understanding of the features and
advantages of the present invention, reference is now made to the
detailed description of the invention along with the accompanying
figures and in which:
[0035] FIG. 1 shows that two main DC differentiation pathways
exist. A myeloid pathway generates two subsets: Langerhans cells
(LCs) found in stratified epithelia such as the skin, and
interstitial DCs (intDCs) found in all other tissues.
[0036] FIG. 2 shows that recombinant anti-Langerin antibodies fused
to antigens retain their ability to bind to cell surface
Langerin.
[0037] FIG. 3 is a demonstration of the ability of recombinant
anti-Langerin antibody fused to the human prostate specific cancer
antigen to elicit the expansion of antigen-specific CD4+T cells
from a health donor.
[0038] FIG. 4 is a demonstration of the ability of recombinant
anti-Langerin antibody fused to the human prostate specific cancer
antigen to elicit the expansion of antigen-specific CD8+T cells
from a prostate cancer patient.
[0039] FIG. 5 shows that anti-Langerin preferentially targets
epidermal LCs.
[0040] FIG. 6 shows the differential expression of Langerin by
human skin DCs.
[0041] FIG. 7 shows that the anti-Langerin antibody (15B10)
specifically stains human Langerhans cells.
[0042] FIG. 8 shows the binding results of the anti-Langerin
antibodies against a non-human primate target.
[0043] FIG. 9 shows the ability of recombinant anti-Langerin 15B10
antibody fused to Influenza A Hemagglutinin HA-1 from a H1N1 Flu
strain to evoke potent antigen-specific antibody production in
NHP.
[0044] FIG. 10 shows that recombinant fusion proteins of anti-human
DC receptors and antigens induce antigen-specific immune responses
in NHP.
[0045] FIG. 11 shows that the Anti-Langerin G3 antibody
specifically stains NHP Langerhans cells.
[0046] FIG. 12 shows the antibody titers for anti-HIV-gag
antibodies in NHP vaccination with a gag-microparticle, an
anti-hIGG4-gag antibody, an anti-DCIR-gag vaccine and an
anti-Langerin-gag-p24 vaccine, all with or without poly I:C as an
adjuvant.
[0047] FIG. 13 shows FACS analysis on Langerin clones: 293F cells
were transiently transfected with vectors directing the expression
of full-length (cell surface) Langerin from human, Rhesus macaque,
and mouse.
[0048] FIG. 14 show the results of ELISA binding analysis in two
formats--direct (antigen bound to plate directly and bound antibody
detected with an anti-mouse IgG-HRP conjugate) and capture
(antibody bound to plate.
DETAILED DESCRIPTION OF THE INVENTION
[0049] While the making and using of various embodiments of the
present invention are discussed in detail below, it should be
appreciated that the present invention provides many applicable
inventive concepts that can be embodied in a wide variety of
specific contexts. The specific embodiments discussed herein are
merely illustrative of specific ways to make and use the invention
and do not delimit the scope of the invention.
[0050] To facilitate the understanding of this invention, a number
of terms are defined below. Terms defined herein have meanings as
commonly understood by a person of ordinary skill in the areas
relevant to the present invention. Terms such as "a", "an" and
"the" are not intended to refer to only a singular entity, but
include the general class of which a specific example may be used
for illustration. The terminology herein is used to describe
specific embodiments of the invention, but their usage does not
delimit the invention, except as outlined in the claims.
[0051] Subsets of Dendritic Cells (DCs). The present inventors have
discovered that two main DC differentiation pathways exist. A
myeloid pathway generates two subsets: Langerhans cells (LCs) found
in stratified epithelia such as the skin, and interstitial DCs
(intDCs) found in all other tissues. A plasmacytoid pathway
generates plasmacytoid DCs (pDCs), which secrete large amounts of
IFN.alpha..beta. after viral infection.sup.3 and efficiently
present viral antigens in a novel mechanism.sup.4 (FIG. 1). DCs and
their precursors show remarkable functional plasticity. For
example, pDCs form a first barrier to the expansion of intruding
viruses, thereby acting, through the release of interferon, as part
of the innate immune response.sup.5,6. Monocytes can differentiate
into either macrophages, which act as scavengers, or DCs that
induce specific immune responses.sup.7,8. Different cytokines skew
the in vitro differentiation of monocytes into DCs with different
phenotypes and functions. Thus, when activated (e.g., by GM-CSF)
monocytes encounter IL-4, they yield IL-4DCs.sup.9-11. By contrast,
after encountering IFN.alpha., TNF.alpha., or IL-15, activated
monocytes will differentiate into IFNDCs.sup.12-15, TNFDCs.sup.8,
or IL-15DCs.sup.16. Each of these DC subsets has common as well as
unique biological functions, determined by a unique combination of
cell-surface molecules and cytokines For example, whereas IL-4DCs
are a homologous population of immature cells devoid of LCs, large
portions of IFNDCs express CD1a and Langerin.sup.8.
[0052] The invention includes also variants and other modification
of an antibody (or "Ab") of fragments thereof, e.g., anti-Langerin
fusion protein (antibody is used interchangeably with the term
"immunoglobulin"). As used herein, the term "antibodies or binding
fragments thereof," includes whole antibodies or binding fragments
of an antibody, e.g., Fv, Fab, Fab', F(ab').sub.2, Fc, and single
chain Fv fragments (ScFv) or any biologically effective fragments
of an immunoglobulins that binds specifically to, e.g., Langerin.
Antibodies from human origin or humanized antibodies have lowered
or no immunogenicity in humans and have a lower number or no
immunogenic epitopes compared to non-human antibodies. Antibodies
and their fragments will generally be selected to have a reduced
level or no antigenicity in humans.
[0053] As used herein, the terms "Ag" or "antigen" refer to a
substance capable of either binding to an antigen binding region of
an immunoglobulin molecule or of eliciting an immune response,
e.g., a T cell-mediated immune response by the presentation of the
antigen on Major Histocompatibility Antigen (MHC) cellular
proteins. As used herein, "antigen" includes, but is not limited
to, antigenic determinants, haptens, and immunogens, which may be
peptides, small molecules, carbohydrates, lipids, nucleic acids or
combinations thereof. The skilled immunologist will recognize that
when discussing antigens that are processed for presentation to T
cells, the term "antigen" refers to those portions of the antigen
(e.g., a peptide fragment) that is a T cell epitope presented by
MHC to the T cell receptor. When used in the context of a B cell
mediated immune response in the form of an antibody that is
specific for an "antigen", the portion of the antigen that binds to
the complementarity determining regions of the variable domains of
the antibody (light and heavy) the bound portion may be a linear or
three-dimensional epitope. In the context of the present invention,
the term antigen is used on both contexts, that is, the antibody is
specific for a protein antigen (Langerin), but also carries one or
more peptide epitopes for presentation by MHC to T cells. In
certain cases, the antigens delivered by the vaccine or fusion
protein of the present invention are internalized and processed by
antigen presenting cells prior to presentation, e.g., by cleavage
of one or more portions of the antibody or fusion protein.
[0054] As used herein, the term "antigenic peptide" refers to that
portion of a polypeptide antigen that is specifically recognized by
either B-cells or T-cells. B-cells respond to foreign antigenic
determinants via antibody production, whereas T-lymphocytes are the
mediate cellular immunity. Thus, antigenic peptides are those parts
of an antigen that are recognized by antibodies, or in the context
of an MHC, by T-cell receptors.
[0055] As used herein, the term "epitope" refers to any protein
determinant capable of specific binding to an immunoglobulin or of
being presented by a Major Histocompatibility Complex (MHC) protein
(e.g., Class I or Class II) to a T-cell receptor. Epitopic
determinants are generally short peptides 5-30 amino acids long
that fit within the groove of the MHC molecule that presents
certain amino acid side groups toward the T cell receptor and has
certain other residues in the groove, e.g., due to specific charge
characteristics of the groove, the peptide side groups and the T
cell receptor. Generally, an antibody specifically binds to an
antigen when the dissociation constant is 1 mM, 100 nM or even 10
nM.
[0056] As used herein, the term "vector" is used in two different
contexts. When using the term "vector" with reference to a vaccine,
a vector is used to describe a non-antigenic portion that is used
to direct or deliver the antigenic portion of the vaccine. For
example, an antibody or binding fragments thereof may be bound to
or form a fusion protein with the antigen that elicits the immune
response. For cellular vaccines, the vector for delivery and/or
presentation of the antigen is the antigen presenting cell, which
is delivered by the cell that is loaded with antigen. In certain
cases, the cellular vector itself may also process and present the
antigen(s) to T cells and activate an antigen-specific immune
response. When used in the context of nucleic acids, a "vector"
refers a construct that is capable of delivering, and preferably
expressing, one or more genes or polynucleotide sequences of
interest in a host cell. Examples of vectors include, but are not
limited to, viral vectors, naked DNA or RNA expression vectors, DNA
or RNA expression vectors associated with cationic condensing
agents, DNA or RNA expression vectors encapsulated in liposomes,
and certain eukaryotic cells, such as producer cells.
[0057] The compositions and methods of the present invention can be
used with a wide variety of peptides and/or protein in which the
antibody or binding fragment thereof and the peptide linker or "PL"
create a protein that is stable and/or soluble.
[0058] As used herein, the compositions and methods use an
anti-Langerin antigen delivery vector comprising the formula:
Ab-(PL-Ag)x or Ab-(Ag-PL)x;
wherein Ab is an anti-Langerin antibody or binding fragment
thereof; PL is at least one Peptide Linker comprising at least one
glycosylation site; Ag is at least one antigen; and x is an integer
from 1 to 20.
[0059] As used herein, the terms "stable" and "unstable" when
referring to proteins is used to describe a peptide or protein that
maintains its three-dimensional structure and/or activity (stable)
or that loses immediately or over time its three-dimensional
structure and/or activity (unstable). As used herein, the term
"insoluble" refers to those proteins that when produced in a cell
(e.g., a recombinant protein expressed in a eukaryotic or
prokaryotic cell or in vitro) are not soluble in solution absent
the use of denaturing conditions or agents (e.g., heat or chemical
denaturants, respectively). The antibody or binding fragment
thereof and the linkers taught herein have been found to convert
antibody fusion proteins with the peptides from insoluble and/or
unstable into proteins that are stable and/or soluble. Another
example of stability versus instability is when the domain of the
protein with a stable conformation has a higher melting temperature
(T.sub.m) than the unstable domain of the protein when measured in
the same solution. A domain is stable compared to another domain
when the difference in the T.sub.m is at least about 2.degree. C.,
more preferably about 4.degree. C., still more preferably about
7.degree. C., yet more preferably about 10.degree. C., even more
preferably about 15.degree. C., still more preferably about
20.degree. C., even still more preferably about 25.degree. C., and
most preferably about 30.degree. C., when measured in the same
solution.
[0060] As used herein, "polynucleotide" or "nucleic acid" refers to
a strand of deoxyribonucleotides or ribonucleotides in either a
single- or a double-stranded form (including known analogs of
natural nucleotides). A double-stranded nucleic acid sequence will
include the complementary sequence. The polynucleotide sequence may
encode variable and/or constant region domains of immunoglobulin
that are formed into a fusion protein with one or more linkers. For
use with the present invention, multiple cloning sites (MCS) may be
engineered into the locations at the carboxy-terminal end of the
heavy and/or light chains of the antibodies to allow for in-frame
insertion of peptide for expression between the linkers. As used
herein, the term "isolated polynucleotide" refers to a
polynucleotide of genomic, cDNA, or synthetic origin or some
combination thereof. By virtue of its origin the "isolated
polynucleotide" (1) is not associated with all or a portion of a
polynucleotide in which the "isolated polynucleotides" are found in
nature, (2) is operably linked to a polynucleotide which it is not
linked to in nature, or (3) does not occur in nature as part of a
larger sequence. The skilled artisan will recognize that to design
and implement a vector having the formula Ab-(PL-Ag)x or
Ab-(Ag-PL)x, can be manipulated at the nucleic acid level by using
techniques known in the art, such as those taught in Current
Protocols in Molecular Biology, 2007 by John Wiley and Sons,
relevant portions incorporated herein by reference. Briefly, the
Ab, Ag and PL encoding nucleic acid sequences can be inserted using
polymerase chain reaction, enzymatic insertion of oligonucleotides
or polymerase chain reaction fragments in a vector, which may be an
expression vector. To facilitate the insertion of (PL-Ag)x or
(Ag-PL)x at the carboxy terminus of the antibody light chain, the
heavy chain, or both, a multiple cloning site (MCS) may be
engineered in sequence with the antibody sequences.
[0061] As used herein, the term "polypeptide" refers to a polymer
of amino acids and does not refer to a specific length of the
product; thus, peptides, oligopeptides, and proteins are included
within the definition of polypeptide. This term also does not refer
to or exclude post expression modifications of the polypeptide, for
example, glycosylations, acetylations, phosphorylations and the
like. Included within the definition are, for example, polypeptides
containing one or more analogs of an amino acid (including, for
example, unnatural amino acids, etc.), polypeptides with
substituted linkages, as well as other modifications known in the
art, both naturally occurring and non-naturally occurring. The term
"domain," or "polypeptide domain" refers to that sequence of a
polypeptide that folds into a single globular region in its native
conformation, and that may exhibit discrete binding or functional
properties. As used herein, the term "fusion protein" refers to a
hybrid protein expressed by a nucleic acid molecule comprising
nucleotide sequences of at least two genes into a protein. For
example, a fusion protein can comprise at least part of
anti-Langerin antibody or binding fragment thereof fused with one
or more antigen and/or one or more linkers if more than one antigen
is fused with the antibody or fragment thereof.
[0062] A polypeptide or amino acid sequence "derived from" a
designated nucleic acid sequence refers to a polypeptide having an
amino acid sequence identical to that of a polypeptide encoded in
the sequence, or a portion thereof wherein the portion consists of
at least 3-5 amino acids, preferably at least 4-7 amino acids, more
preferably at least 8-10 amino acids, and even more preferably at
least 11-15 amino acids, or which is immunologically identifiable
with a polypeptide encoded in the sequence. This terminology also
includes a polypeptide expressed from a designated nucleic acid
sequence.
[0063] As used herein, "pharmaceutically acceptable carrier" refers
to any material that when combined with an immunoglobulin (Ig)
fusion protein of the present invention allows the Ig to retain
biological activity and is generally non-reactive with the
subject's immune system. Examples include, but are not limited to,
standard pharmaceutical carriers such as a phosphate buffered
saline solution, water, emulsions such as an oil/water emulsion,
and various types of wetting agents. Certain diluents may be used
with the present invention, e.g., for aerosol or parenteral
administration, that may be phosphate buffered saline or normal
(0.85%) saline.
[0064] The invention provides a Langerin binding antibody (15B10)
that comprises at least one immunoglobulin light chain variable
domain (VL) which comprises the amino acid and nucleic acid
sequence encoding:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45); or and direct equivalent
thereof.
[0065] Accordingly the invention provides a Langerin binding
antibody (15B10) that comprises an antigen binding site comprising
at least one immunoglobulin heavy chain variable domain (VH) which
comprises the amino acid and nucleic acid sequence encoding:
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46); and direct equivalents
thereof.
[0066] The invention provides a Langerin binding antibody (2G3)
that comprises at least one immunoglobulin light chain variable
domain (VL) which comprises the amino acid and nucleic acid
sequence encoding:
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47); or and direct equivalent
thereof.
[0067] Accordingly the invention provides a Langerin binding
antibody (2G3) that comprises an antigen binding site comprising at
least one immunoglobulin heavy chain variable domain (VH) which
comprises the amino acid and nucleic acid sequence encoding:
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); and direct equivalents
thereof.
[0068] In one aspect the invention provides a single domain
Langerin antibody comprising an isolated immunoglobulin light chain
comprising a heavy chain variable domain (VL) as defined above. In
another aspect the invention provides a single domain Langerin
binding molecule comprising an isolated immunoglobulin heavy chain
comprising a heavy chain variable domain (VH) as defined above.
[0069] In another aspect the invention also provides a Langerin
binding antibody comprising a light chain (VL) variable domains in
which the Langerin binding antibody comprises at least one antigen
binding site comprising: an antibody light chain variable domain
(VL) which comprises in sequence hypervariable regions obtained
from the amino acid and nucleic acid sequences encoding:
ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL
KISRVEAEDLGLYFCS (SEQ ID NO.: 45); or
VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT
ITGAQTEDEAIYFCA (SEQ ID NO.: 47); and direct equivalents
thereof.
[0070] In another aspect the invention also provides a Langerin
binding antibody comprising, the amino acid and nucleic acid
sequences of heavy chain variable domain (VH) which comprises in
sequence hypervariable regions obtained from:
SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK
SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46); or
SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR
DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); and direct equivalents
thereof.
[0071] Unless otherwise indicated, any polypeptide chain is herein
described as having an amino acid sequence starting at the
N-terminal end and ending at the C-terminal end. When the antigen
binding site comprises both the VH and VL domains, these may be
located on the same polypeptide molecule or, preferably, each
domain may be on a different chain, the VH domain being part of an
immunoglobulin heavy chain or binding fragment thereof and the VL
being part of an immunoglobulin light chain or binding fragment
thereof.
[0072] As used herein, the term "Langerin binding molecule" or
"Langerin binding antibody" refer to any molecule capable of
binding to the Langerin antigen either alone or associated with
other molecules having one or more the VL and VH CDRs taught
herein, in some cases 2, 3, 4, 5, or all 6 CDRs. The binding
reaction may be shown by standard methods (qualitative assays)
including, for example, a bioassay for determining by blocking the
binding of other molecules to Langerin or any kind of binding or
activity assays (e.g., activation, reduction or modulation of an
immune response), with reference to a negative control test in
which an antibody of unrelated specificity but of the same isotype,
e.g., an anti-CD25 or anti-CD80 antibody, is used.
[0073] The present invention may also be made into a single chain
antibody having the variable domains of the heavy and light chains
of an antibody covalently bound by a peptide linker usually
including from 10 to 30 amino acids, preferably from 15 to 25 amino
acids. Therefore, such a structure does not include the constant
part of the heavy and light chains and it is believed that the
small peptide spacer should be less antigenic than a whole constant
part.
[0074] As used herein, the term "chimeric antibody" refers to an
antibody in which the constant regions of heavy or light chains or
both are of human origin while the variable domains of both heavy
and light chains are of non-human (e.g., mouse, hamster or rat)
origin or of human origin but derived from a different human
antibody.
[0075] As used herein, the term "CDR-grafted antibody" refers to an
antibody in which the hypervariable complementarity determining
regions (CDRs) are derived from a donor antibody, such as a
non-human (e.g., mouse) antibody or a different human antibody,
while all or substantially all the other parts of the
immunoglobulin (e.g., the conserved regions of the variable
domains, i.e., framework regions), are derived from an acceptor
antibody (in the case of a humanized antibody--an antibody of human
origin). A CDR-grafted antibody may include a few amino acids of
the donor sequence in the framework regions, for instance in the
parts of the framework regions adjacent to the hypervariable
regions.
[0076] As used herein, the term "human antibody" refers to an
antibody in which the constant and variable regions of both the
heavy and light chains are all of human origin, or substantially
identical to sequences of human origin, not necessarily from the
same antibody and includes antibodies produced by mice in which the
mouse, hamster or rat immunoglobulin variable and constant part
genes have been replaced by their human counterparts, e.g. as
described in general terms in EP 0546073 B1, U.S. Pat. No.
5,545,806, U.S. Pat. No. 5,569,825, U.S. Pat. No. 5,625,126, U.S.
Pat. No. 5,633,425, U.S. Pat. No. 5,661,016, U.S. Pat. No.
5,770,429, EP Patent No. 0 438-474 B1 and EP Patent No. 0 463151
B1, relevant portions incorporated herein by reference.
[0077] The Langerin binding antibodies of the invention include
humanized antibodies that comprise the CDRs obtained from the
anti-Langerin 15B10 or 2G3 antibody. One example of a chimeric
antibody includes the variable domains of both heavy and light
chains are of human origin, for instance those of the anti-Langerin
15B10 or 2G3 antibody. The constant region domains preferably also
comprise suitable human constant region domains, for instance as
described in "Sequences of Proteins of Immunological Interest",
Kabat E. A. et al, US Department of Health and Human Services,
Public Health Service, National Institute of Health.
[0078] Hypervariable regions may be associated with any kind of
framework regions, e.g., of human origin. Suitable framework
regions were described Kabat E. A. One heavy chain framework is a
heavy chain framework, for instance those of the anti-Langerin
15B10 or 2G3 antibody, includes sequences for the light chain
framework regions: FR1L, FR2L, FR3L and
[0079] FR4L regions. In a similar manner, the anti-Langerin 15B10
or 2G3 heavy chain framework that includes the sequence of FR1H,
FR2H, FR3H and FR4H regions. The CDRs may be added to a human
antibody framework, such as those described in 7,456,260, issued to
Rybak, et al., which teach new human variable chain framework
regions and humanized antibodies comprising the framework regions,
relevant portions and framework sequences incorporated herein by
reference. To accomplish the engraftment at a genetic level, the
present invention also includes the underlying nucleic acid
sequences for the VL AND VH regions as well as the complete
antibodies and the humanized versions thereof. The nucleic acid
sequences of the present invention include the anti-Langerin
antibody light and the heavy chains, respectively, as well as those
nucleic acid sequences that include variable codon usage for the
same amino acid sequences and conservative variations thereof
having 85, 90, 95 or 100% sequence identity at the nucleic or amino
acid level. Likewise, the CDRs may have 85, 90, 95 or 100% sequence
identity at the nucleic or amino acid level, individually, in
groups or 2, 3, 4 or 5 or all together.
[0080] Monoclonal antibodies raised against a protein naturally
found in all humans are typically developed in a non-human system
e.g. in mice, and as such are typically non-human proteins. As a
direct consequence of this, a xenogenic antibody as produced by a
hybridoma, when administered to humans, elicits an undesirable
immune response that is predominantly mediated by the constant part
of the xenogenic immunoglobulin. Xenogeneic antibodies tend to
elicit a host immune response, thereby limiting the use of such
antibodies as they cannot be administered over a prolonged period
of time. Therefore, it is particularly useful to use single chain,
single domain, chimeric, CDR-grafted, or especially human
antibodies that are not likely to elicit a substantial allogenic
response when administered to humans. The present invention
includes antibodies with minor changes in an amino acid sequence
such as deletion, addition or substitution of one, a few or even
several amino acids which are merely allelic forms of the original
protein having substantially identical properties.
[0081] The inhibition of the binding of Langerin to its receptor
may be conveniently tested in various assays including such assays
are described hereinafter in the text. By the term "to the same
extent" is meant that the reference and the equivalent molecules
exhibit, on a statistical basis, essentially identical Langerin
binding inhibition curves in one of the assays referred to above.
For example, the assay used may be an assay of competitive
inhibition of binding of Langerin by the binding molecules of the
invention.
[0082] Generally, the human anti-Langerin antibody comprises at
least: (a) one light chain which comprises a variable domain having
an amino acid sequence substantially identical to the 15B10 or 2G3
antibody starting with the amino acid at position 1 and ending with
the amino acid at position 107 and the constant part of a human
light chain; and (b) one heavy chain which comprises a variable
domain having an amino acid sequence substantially identical to the
15B10 or 2G3 antibody and the constant part of a human heavy chain.
The constant part of a human heavy chain may be of the .gamma.1,
.gamma.2, .gamma.3, .gamma.4, .mu., .beta.2, or .delta. or
.epsilon. type, preferably of the .gamma.-type, whereas the
constant part of a human light chain may be of the .kappa. or
.lamda. type (which includes the .lamda.1, .lamda.2 and .lamda.3
subtypes) but is preferably of the .kappa. type. The amino acid
sequences of the general locations of the variable and constant
domains are well known in the art and generally follow the Kabat
nomenclature.
[0083] A Langerin binding molecule of the invention may be produced
by recombinant DNA techniques. In view of this, one or more DNA
molecules encoding the binding molecule must be constructed, placed
under appropriate control sequences and transferred into a suitable
host organism for expression.
[0084] In a very general manner, there are accordingly provided:
(i) DNA molecules encoding a single domain Langerin binding
molecule of the invention, a single chain Langerin binding molecule
of the invention, a heavy or light chain or binding fragments
thereof of a Langerin binding molecule of the invention; and (ii)
the use of the DNA molecules of the invention for the production of
a Langerin binding molecule of the invention by recombinant
methods.
[0085] The present state of the art is such that the skilled worker
in the art can synthesize the DNA molecules of the invention given
the information provided herein, i.e., the amino acid sequences of
the hypervariable regions and the DNA sequences coding for them. A
method for constructing a variable domain gene is for example
described in EPA 239 400, relevant portions incorporated herein by
reference. Briefly, a gene encoding a variable domain of a MAb is
cloned. The DNA segments encoding the framework and hypervariable
regions are determined and the DNA segments encoding the
hypervariable regions are removed so that the DNA segments encoding
the framework regions are fused together with suitable restriction
sites at the junctions. The restriction sites may be generated at
the appropriate positions by mutagenesis of the DNA molecule by
standard procedures. Double stranded synthetic CDR cassettes are
prepared by DNA synthesis according to the sequences given in for
15B10 or 2G3 (amino acid and nucleic acid sequences, respectively).
These cassettes are often provided with sticky ends so that they
can be ligated at the junctions of the framework.
[0086] It is not necessary to have access to the mRNA from a
producing hybridoma cell line in order to obtain a DNA construct
coding for the Langerin binding molecules of the invention. For
example, PCT application WO 90/07861 gives full instructions for
the production of an antibody by recombinant DNA techniques given
only written information as to the nucleotide sequence of the gene,
relevant portions incorporated herein by reference. Briefly, the
method comprises the synthesis of a number of oligonucleotides,
their amplification by the PCR method, and their splicing to give
the desired DNA sequence.
[0087] Expression vectors comprising a suitable promoter or genes
encoding heavy and light chain constant parts are publicly
available. Thus, once a DNA molecule of the invention is prepared
it may be conveniently transferred in an appropriate expression
vector. DNA molecules encoding single chain antibodies may also be
prepared by standard methods, for example, as described in WO
88/1649. In view of the foregoing, no hybridoma or cell line
deposit is necessary to comply with the criteria of sufficiency of
description.
[0088] For example, first and second DNA constructs are made that
bind specifically to Langerin. Briefly, a first DNA construct
encodes a light chain of an antibody, CDRs or binding fragments
thereof and comprises a) a first part which encodes a variable
domain comprising alternatively framework and hypervariable
regions, the hypervariable regions being in sequence CDR1L, CDR2L
and CDR3L the amino acid sequences of which are found in SEQ ID
NOs. 45-48; this first part starting with a codon encoding the
first amino acid of the variable domain and ending with a codon
encoding the last amino acid of the variable domain, and b) a
second part encoding a light chain constant part or binding
fragment thereof which starts with a codon encoding the first amino
acid of the constant part of the heavy chain and ends with a codon
encoding the last amino acid of the constant part or binding
fragment thereof, followed by a stop codon.
[0089] The first part encodes a variable domain having an amino
acid sequence substantially identical to the amino acid sequences
of 15B10 or 2G3. A second part encodes the constant part of a human
heavy chain, more preferably the constant part of the human yl
chain. This second part may be a DNA fragment of genomic origin
(comprising introns) or a cDNA fragment (without introns).
[0090] The second DNA construct encodes a heavy chain or binding
fragment thereof and comprises a) a first part which encodes a
variable domain comprising alternatively framework and
hypervariable regions; the hypervariable regions being CDR1H and
optionally CDR2H and CDR3H, the amino acid sequences of 15B10 or
2G3; this first part starting with a codon encoding the first amino
acid of the variable domain and ending with a codon encoding the
last amino acid of the variable domain, and b) a second part
encoding a heavy chain constant part or binding fragment thereof
which starts with a codon encoding the first amino acid of the
constant part of the light chain and ends with a codon encoding the
last amino acid of the constant part or binding fragment thereof
followed by a stop codon.
[0091] The first part encodes a variable domain having an amino
acid sequence substantially identical to the amino acid sequence of
15B10 or 2G3. The first part has the nucleotide sequence of the
15B10 or 2G3 antibodies starting with the nucleotide at position 1
and ending with the nucleotide at position 321. Also preferably the
second part encodes the constant part of a human light chain, more
preferably the constant part of the human .kappa. chain.
[0092] The invention also includes Langerin binding molecules in
which one or more of the residues of CDR1L, CDR2L, CDR3L, CDR1H,
CDR2H or CDR3H or the frameworks, typically only a few (e.g. FR1-4L
or H), are changed from the residues of the 15B10 or 2G3
antibodies; by, e.g., site directed mutagenesis of the
corresponding DNA sequences. The invention includes the DNA
sequences coding for such changed Langerin binding molecules. In
particular the invention includes a Langerin binding molecules in
which one or more residues of CDR1L, CDR2L and/or CDR3L have been
changed from the residues of the 15B10 or 2G3 antibodies and one or
more residues of CDR1H, CDR2H and/or CDR3H have been changed from
the residues of the 15B10 or 2G3 antibodies.
[0093] Each of the DNA constructs are placed under the control of
suitable control sequences, in particular under the control of a
suitable promoter. Any kind of promoter may be used, provided that
it is adapted to the host organism in which the DNA constructs will
be transferred for expression. However, if expression is to take
place in a mammalian cell, an immunoglobulin gene promoter may be
used in B cells. The first and second parts may be separated by an
intron, and, an enhancer may be conveniently located in the intron
between the first and second parts. The presence of such an
enhancer that is transcribed but not translated, may assist in
efficient transcription. In particular embodiments the first and
second DNA constructs comprise the enhancer of, e.g., a heavy chain
human gene.
[0094] The antibody or binding fragments thereof can be isolated,
purified, and stored using any method known in the art. The binding
fragments retain the specific binding activity of the intact
antibody, and can be used for any application that employs the
intact antibody (e.g., therapeutics, diagnostic assays, competitive
binding assays, etc.).
[0095] In another aspect, the invention provides an antibody or
binding fragment generated by the above-described method, and may
further include a half-life extending vehicle, such as those known
to those skilled in the art. Such vehicles include, but are not
limited to, linear polymers (e.g., polyethylene glycol (PEG),
polylysine, dextran, etc.); branched-chain polymers (See, e.g.,
U.S. Pat. No. 4,289,872; U.S. Pat. No. 5,229,490; WO 93/21259); a
lipid; a cholesterol group (such as a steroid); a carbohydrate or
polysaccharide; or any natural or synthetic protein, polypeptide or
peptide. Additionally, it will be appreciated that one or more Fc
regions, can also be employed with the invention to increase
half-life. It will be appreciated that the vehicle can be linked to
the antibody or binding fragment by way of various techniques known
in the art including, for example, covalent linkage.
[0096] The desired antibody may be produced in an animal as an
ascites, in cell culture or in a transgenic animal. A suitable
transgenic animal may be obtained according to standard methods
that include micro injecting into eggs the first and second DNA
constructs placed under suitable control sequences transferring the
so prepared eggs into appropriate pseudo-pregnant females and
selecting a descendant expressing the desired antibody.
[0097] The invention also provides an expression vector able to
replicate in a prokaryotic or eukaryotic cell line, which comprises
at least one of the DNA constructs above described. Each expression
vector containing a DNA construct is then transferred into a
suitable host organism. When the DNA constructs are separately
inserted on two expression vectors, they may be transferred
separately, i.e. one type of vector per cell, or co-transferred,
this latter possibility being preferred. A suitable host organism
may be a bacterium, a yeast or a mammalian cell line, this latter
being preferred. More preferably, the mammalian cell line is of
lymphoid origin, e.g., a myeloma, hybridoma or a normal
immortalized B-cell, which conveniently does not express any
endogenous antibody heavy or light chain.
[0098] When the antibody chains are produced in a cell culture, the
DNA constructs must first be inserted into either a single
expression vector or into two separate but compatible expression
vectors, the latter possibility being preferred. For expression in
mammalian cells it is preferred that the coding sequence of the
Langerin binding molecule is integrated into the host cell DNA
within a locus which permits or favors high level expression of the
Langerin binding molecule.
[0099] In a further aspect of the invention there is provided a
process for the product of a Langerin binding molecule that
comprises: (i) culturing an organism which is transformed with an
expression vector as defined above; and (ii) recovering the
Langerin binding molecule from the culture.
[0100] In accordance with the present invention it has been found
that the anti-Langerin antibodies 15B10, 2G3, 91E7, 37C1, or 4C7
and humanized derivatives thereof, appear to have binding
specificity for the antigenic epitope of human Langerin. It is
therefore most surprising that antibodies to this epitope, e.g. the
anti-Langerin 15B10, 2G3, 91E7, 37C1, or 4C7 and humanized
derivatives thereof, are capable of delivering antigen efficiently
into dendritic cells (DCs). Antibodies, in particular chimeric and
CDR-grafted antibodies and especially human antibodies, which have
binding specificity for the antigenic epitope of mature human
Langerin; and use of such antibodies for DC antigen loading are
novel and are included within the scope of the present
invention.
[0101] To use the anti-Langerin antibody of the present invention
for treatment indications, the appropriate dosage will, of course,
vary depending upon, for example, the antibody disclosed herein to
be employed, the host, the mode of administration and the nature
and severity of the condition being treated. However, in
prophylactic use, satisfactory results are generally found at
dosages from about 0.05 mg to about 10 mg per kilogram body weight
more usually from about 0.1 mg to about 5 mg per kilogram body
weight. The frequency of dosing for prophylactic uses will normally
be in the range from about once per week up to about once every 3
months, more usually in the range from about once every 2 weeks up
to about once every 10 weeks, e.g., once every 4 to 8 weeks. The
anti-Langerin antibody of the present can be administered
parenterally, intravenously, e.g., into the antecubital or other
peripheral vein, intramuscularly, or subcutaneously.
[0102] Pharmaceutical compositions of the invention may be
manufactured in conventional manner, e.g., in a lyophilized form.
For immediate administration it is dissolved in a suitable aqueous
carrier, for example sterile water for injection or sterile
buffered physiological saline. If it is considered desirable to
make up a solution of larger volume for administration by infusion
rather as a bolus injection, it is advantageous to incorporate
human serum albumin or the patient's own heparinized blood into the
saline at the time of formulation. The presence of an excess of
such physiologically inert protein prevents loss of antibody by
adsorption onto the walls of the container and tubing used with the
infusion solution. If albumin is used, a suitable concentration is
from 0.5 to 4.5% by weight of the saline solution.
[0103] One embodiment of the present invention provides an
immunoconjugate comprising a humanized antibody of the invention,
e.g., a humanized anti-Langerin antibody, linked to one or more
effector molecules, antigen(s) and/or a detectable label(s).
Preferably, the effector molecule is a therapeutic molecule such
as, for example, one or more peptides that comprise one or more T
cell epitopes, a toxin, a small molecule, a cytokine or a
chemokine, an enzyme, or a radiolabel.
[0104] Exemplary toxins include, but are not limited to,
Pseudomonas exotoxin or diphtheria toxin. Examples of small
molecules include, but are not limited to, chemotherapeutic
compounds such as taxol, doxorubicin, etoposide, and bleiomycin.
Exemplary cytokines include, but are not limited to, IL-1, IL-2,
IL-4, IL-5, IL-6, and IL-12, IL-17, and IL-25. Exemplary enzymes
include, but are not limited to, RNAses, DNAses, proteases,
kinases, and caspases. Exemplary radioisotopes include, but are not
limited to, 32P and 125I.
[0105] As used herein, the term "epitope" refers to a molecule or
substance capable of stimulating an immune response. In one
example, epitopes include but are not limited to a polypeptide and
a nucleic acid encoding a polypeptide, wherein expression of the
nucleic acid into a polypeptide is capable of stimulating an immune
response when the polypeptide is processed and presented on a Major
Histocompatibility Complex (MHC) molecule. Generally, epitopes
include peptides presented on the surface of cells non-covalently
bound to the binding groove of Class I or Class II MHC, such that
they can interact with T cell receptors and the respective T cell
accessory molecules.
[0106] Proteolytic Processing of Antigens. Epitopes that are
displayed by MHC on antigen presenting cells are cleavage peptides
or products of larger peptide or protein antigen precursors. For
MHC I epitopes, protein antigens are often digested by proteasomes
resident in the cell. Intracellular proteasomal digestion produces
peptide fragments of about 3 to 23 amino acids in length that are
then loaded onto the MHC protein. Additional proteolytic activities
within the cell, or in the extracellular milieu, can trim and
process these fragments further. Processing of MHC Class II
epitopes generally occurs via intracellular proteases from the
lysosomal/endosomal compartment. The present invention includes, in
one embodiment, pre-processed peptides that are attached to the
anti-Langerin antibody (or binding fragment thereof) that directs
the peptides against which an enhanced immune response is sought
directly to antigen presenting cells.
[0107] To identify epitopes potentially effective as immunogenic
compounds, predictions of MHC binding alone are useful but often
insufficient. The present invention includes methods for
specifically identifying the epitopes within antigens most likely
to lead to the immune response sought for the specific sources of
antigen presenting cells and responder T cells.
[0108] The present invention allows for a rapid and easy assay for
the identification of those epitopes that are most likely to
produce the desired immune response using the patient's own antigen
presenting cells and T cell repertoire. The compositions and
methods of the present invention are applicable to any protein
sequence, allowing the user to identify the epitopes that are
capable of binding to MHC and are properly presented to T cells
that will respond to the antigen. Accordingly, the invention is not
limited to any particular target or medical condition, but instead
encompasses and MHC epitope(s) from any useful source.
[0109] As used herein, the term "veneered" refers to a humanized
antibody framework onto which antigen-binding sites or CDRs
obtained from non-human antibodies (e.g., mouse, rat or hamster),
are placed into human heavy and light chain conserved structural
framework regions (FRs), for example, in a light chain or heavy
chain polynucleotide to "graft" the specificity of the non-human
antibody into a human framework from, e.g., SEQ ID NOS: 45-48 or
the nucleic acids that encode those sequences, as will be readily
apparent to the skilled artisan. The polynucleotide expression
vector or vectors that express the veneered antibodies can be
transfected mammalian cells for the expression of recombinant human
antibodies which exhibit the antigen specificity of the non-human
antibody and will undergo posttranslational modifications that will
enhance their expression, stability, solubility, or combinations
thereof.
[0110] Antigens.
[0111] Examples of viral antigens for use with the present
invention include, but are not limited to, e.g., HIV, HCV, CMV,
adenoviruses, retroviruses, picornaviruses, etc. Non-limiting
example of retroviral antigens such as retroviral antigens from the
human immunodeficiency virus (HIV) antigens such as gene products
of the gag, pol, and env genes, the Nef protein, reverse
transcriptase, and other HIV components; hepatitis viral antigens
such as the S, M, and L proteins of hepatitis B virus, the pre-S
antigen of hepatitis B virus, and other hepatitis, e.g., hepatitis
A, B, and C, viral components such as hepatitis C viral RNA;
influenza viral antigens such as hemagglutinin and neuraminidase
and other influenza viral components; measles viral antigens such
as the measles virus fusion protein and other measles virus
components; rubella viral antigens such as proteins E1 and E2 and
other rubella virus components; rotaviral antigens such as VP7sc
and other rotaviral components; cytomegaloviral antigens such as
envelope glycoprotein B and other cytomegaloviral antigen
components; respiratory syncytial viral antigens such as the RSV
fusion protein, the M2 protein and other respiratory syncytial
viral antigen components; herpes simplex viral antigens such as
immediate early proteins, glycoprotein D, and other herpes simplex
viral antigen components; varicella zoster viral antigens such as
gpI, gpII, and other varicella zoster viral antigen components;
Japanese encephalitis viral antigens such as proteins E, M-E,
M-E-NS1, NS1, NS1-NS2A, 80% E, and other Japanese encephalitis
viral antigen components; rabies viral antigens such as rabies
glycoprotein, rabies nucleoprotein and other rabies viral antigen
components. See Fundamental Virology, Second Edition, eds. Fields,
B. N. and Knipe, D. M. (Raven Press, New York, 1991) for additional
examples of viral antigens. The at least one viral antigen may be
peptides from an adenovirus, retrovirus, picornavirus, herpesvirus,
rotaviruses, hantaviruses, coronavirus, togavirus, flavirvirus,
rhabdovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenavirus,
reovirus, papilomavirus, parvovirus, poxvirus, hepadnavirus, or
spongiform virus. In certain specific, non-limiting examples, the
at least one viral antigen are peptides obtained from at least one
of HIV, CMV, hepatitis A, B, and C, influenza, measles, polio,
smallpox, rubella; respiratory syncytial, herpes simplex, varicella
zoster, Epstein-Barr, Japanese encephalitis, rabies, flu, and/or
cold viruses.
[0112] In one aspect, the one or more of the antigenic peptides are
selected from at least one of: Nef (66-97):
VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL (SEQ ID NO.: 31); Nef (116-145):
HTQGYFPDWQNYTPGPGVRYPLTFGWLYKL (SEQ ID NO.: 32); Gag p17 (17-35):
EKIRLRPGGKKKYKLKHIV (SEQ ID NO.: 33); Gag p17-p24 (253-284):
NPPIPVGEIYKRWIILGLNKIVRMYSPTSILD (SEQ ID NO.: 34); or Pol 325-355
(R.sub.T 158-188) is: AIFQSSMTKILEPFRKQNPDIVIYQYMDDLY (SEQ ID NO.:
35). In one aspect, the fusion protein peptides are separated by
one or more linkers selected from:
TABLE-US-00005 SSVSPTTSVHPTPTSVPPTPTKSSP; (SEQ ID NO.: 39)
PTSTPADSSTITPTATPTATPTIKG; (SEQ ID NO.: 40)
TVTPTATATPSAIVTTITPTATTKP; (SEQ ID NO.: 41) or
TNGSITVAATAPTVTPTVNATPSAA. (SEQ ID NO.: 42)
[0113] Antigenic targets that may be delivered using the
anti-Langerin-antigen vaccines of the present invention include
genes encoding antigens such as viral antigens, bacterial antigens,
fungal antigens or parasitic antigens. Pathogens include
trypanosomes, tapeworms, roundworms, helminthes, malaria. Tumor
markers, such as fetal antigen or prostate specific antigen, may be
targeted in this manner. Other examples include: HIV env proteins
and hepatitis B surface antigen. Administration of a vector
according to the present invention for vaccination purposes would
require that the vector-associated antigens be sufficiently
non-immunogenic to enable long-term expression of the transgene,
for which a strong immune response would be desired. In some cases,
vaccination of an individual may only be required infrequently,
such as yearly or biennially, and provide long-term immunologic
protection against the infectious agent. Specific examples of
organisms, allergens and nucleic and amino sequences for use in
vectors and ultimately as antigens with the present invention may
be found in U.S. Pat. No. 6,541,011, relevant portions incorporated
herein by reference, in particular, the tables that match organisms
and specific sequences that may be used with the present
invention.
[0114] Bacterial antigens for use with the anti-Langerin-antigen
vaccines disclosed herein include, but are not limited to, e.g.,
bacterial antigens such as pertussis toxin, filamentous
hemagglutinin, pertactin, FIM2, FIM3, adenylate cyclase and other
pertussis bacterial antigen components; diptheria bacterial
antigens such as diptheria toxin or toxoid and other diptheria
bacterial antigen components; tetanus bacterial antigens such as
tetanus toxin or toxoid and other tetanus bacterial antigen
components; streptococcal bacterial antigens such as M proteins and
other streptococcal bacterial antigen components; gram-negative
bacilli bacterial antigens such as lipopolysaccharides and other
gram-negative bacterial antigen components, Mycobacterium
tuberculosis bacterial antigens such as mycolic acid, heat shock
protein 65 (HSP65), the 30 kDa major secreted protein, antigen 85A
and other mycobacterial antigen components; Helicobacter pylori
bacterial antigen components; pneumococcal bacterial antigens such
as pneumolysin, pneumococcal capsular polysaccharides and other
pneumococcal bacterial antigen components; haemophilus influenza
bacterial antigens such as capsular polysaccharides and other
haemophilus influenza bacterial antigen components; anthrax
bacterial antigens such as anthrax protective antigen and other
anthrax bacterial antigen components; rickettsiae bacterial
antigens such as rompA and other rickettsiae bacterial antigen
component. Also included with the bacterial antigens described
herein are any other bacterial, mycobacterial, mycoplasmal,
rickettsial, or chlamydial antigens. Partial or whole pathogens may
also be: haemophilus influenza; Plasmodium falciparum; neisseria
meningitidis; streptococcus pneumoniae; neisseria gonorrhoeae;
salmonella serotype typhi; shigella; vibrio cholerae; Dengue Fever;
Encephalitides; Japanese Encephalitis; lyme disease; Yersinia
pestis; west nile virus; yellow fever; tularemia; hepatitis (viral;
bacterial); RSV (respiratory syncytial virus); HPIV 1 and HPIV 3;
adenovirus; small pox; allergies and cancers.
[0115] Fungal antigens for use with compositions and methods of the
invention include, but are not limited to, e.g., candida fungal
antigen components; histoplasma fungal antigens such as heat shock
protein 60 (HSP60) and other histoplasma fungal antigen components;
cryptococcal fungal antigens such as capsular polysaccharides and
other cryptococcal fungal antigen components; coccidiodes fungal
antigens such as spherule antigens and other coccidiodes fungal
antigen components; and tinea fungal antigens such as trichophytin
and other coccidiodes fungal antigen components.
[0116] Examples of protozoal and other parasitic antigens include,
but are not limited to, e.g., plasmodium falciparum antigens such
as merozoite surface antigens, sporozoite surface antigens,
circumsporozoite antigens, gametocyte/gamete surface antigens,
blood-stage antigen pf 155/RESA and other plasmodial antigen
components; toxoplasma antigens such as SAG-1, p30 and other
toxoplasmal antigen components; schistosomae antigens such as
glutathione-S-transferase, paramyosin, and other schistosomal
antigen components; leishmania major and other leishmaniae antigens
such as gp63, lipophosphoglycan and its associated protein and
other leishmanial antigen components; and trypanosoma cruzi
antigens such as the 75-77 kDa antigen, the 56 kDa antigen and
other trypanosomal antigen components.
[0117] Antigen that can be targeted using the anti-Langerin-antigen
vaccines of the present invention will generally be selected based
on a number of factors, including: likelihood of internalization,
level of immune cell specificity, type of immune cell targeted,
level of immune cell maturity and/or activation and the like. In
this embodiment, the antibodies may be mono- or bi-specific
antibodies that include one anti-Langerin binding domain and one
binding domain against a second antigen, e.g., cell surface markers
for dendritic cells such as, MHC class I, MHC Class II, B7-2, CD18,
CD29, CD31, CD43, CD44, CD45, CD54, CD58, CD83, CD86, CMRF-44,
CMRF-56, DCIR and/or Dectin-1 and the like; while in some cases
also having the absence of CD2, CD3, CD4, CD8, CD14, CD15, CD16, CD
19, CD20, CD56, and/or CD57. Examples of cell surface markers for
antigen presenting cells include, but are not limited to, MHC class
I, MHC Class II, CD45, B7-1, B7-2, IFN-.gamma. receptor and IL-2
receptor, ICAM-1 and/or Fc.gamma. receptor. Examples of cell
surface markers for T cells include, but are not limited to, CD3,
CD4, CD8, CD 14, CD20, CD11b, CD16, CD45 and HLA-DR.
[0118] Target antigens on cell surfaces for delivery include those
characteristic of tumor antigens typically will be derived from the
cell surface, cytoplasm, nucleus, organelles and the like of cells
of tumor tissue. Examples of tumor targets for the antibody portion
of the present invention include, without limitation, hematological
cancers such as leukemias and lymphomas, neurological tumors such
as astrocytomas or glioblastomas, melanoma, breast cancer, lung
cancer, head and neck cancer, gastrointestinal tumors such as
gastric or colon cancer, liver cancer, pancreatic cancer,
genitourinary tumors such cervix, uterus, ovarian cancer, vaginal
cancer, testicular cancer, prostate cancer or penile cancer, bone
tumors, vascular tumors, or cancers of the lip, nasopharynx,
pharynx and oral cavity, esophagus, rectum, gall bladder, biliary
tree, larynx, lung and bronchus, bladder, kidney, brain and other
parts of the nervous system, thyroid, Hodgkin's disease,
non-Hodgkin's lymphoma, multiple myeloma and leukemia.
[0119] Examples of antigens that may be delivered alone or in
combination to immune cells for antigen presentation using the
present invention includes tumor proteins, e.g., mutated oncogenes;
viral proteins associated with tumors; and tumor mucins and
glycolipids. The antigens may be viral proteins associated with
tumors would be those from the classes of viruses noted above.
Certain antigens may be characteristic of tumors (one subset being
proteins not usually expressed by a tumor precursor cell), or may
be a protein that is normally expressed in a tumor precursor cell,
but having a mutation characteristic of a tumor. Other antigens
include mutant variant(s) of the normal protein having an altered
activity or subcellular distribution, e.g., mutations of genes
giving rise to tumor antigens.
[0120] Specific non-limiting examples of tumor antigens for use in
an anti-Langerin-fusion protein vaccine include, e.g., CEA,
prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6
and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and GD2
gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), Pmel
17(gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase
V intron V sequence), Prostate Ca psm, PRAME (melanoma antigen),
.beta.-catenin, MUM-1-B (melanoma ubiquitous mutated gene product),
GAGE (melanoma antigen)1, MAGE, BAGE (melanoma antigen) 2-10,
c-ERB2 (Her2/neu), DAGE, EBNA (Epstein-Barr Virus nuclear antigen)
1-6, gp75, human papilloma virus (HPV) E6 and E7, p53, lung
resistance protein (LRP), Bcl-2, Ki-67, Cyclin B1, gp100, Survivin,
and NYESO-1.
[0121] In addition, the immunogenic molecule can be an autoantigen
involved in the initiation and/or propagation of an autoimmune
disease, the pathology of which is largely due to the activity of
antibodies specific for a molecule expressed by the relevant target
organ, tissue, or cells, e.g., SLE or MG. In such diseases, it can
be desirable to direct an ongoing antibody-mediated (i.e., a
Th2-type) immune response to the relevant autoantigen towards a
cellular (i.e., a Th1-type) immune response. Alternatively, it can
be desirable to prevent onset of or decrease the level of a Th2
response to the autoantigen in a subject not having, but who is
suspected of being susceptible to, the relevant autoimmune disease
by prophylactically inducing a Th1 response to the appropriate
autoantigen. Autoantigens of interest include, without limitation:
(a) with respect to SLE, the Smith protein, RNP ribonucleoprotein,
and the SS-A and SS-B proteins; and (b) with respect to MG, the
acetylcholine receptor. Examples of other miscellaneous antigens
involved in one or more types of autoimmune response include, e.g.,
endogenous hormones such as luteinizing hormone, follicular
stimulating hormone, testosterone, growth hormone, prolactin, and
other hormones.
[0122] Antigens involved in autoimmune diseases, allergy, and graft
rejection can be used in the compositions and methods of the
invention. For example, an antigen involved in any one or more of
the following autoimmune diseases or disorders can be used in the
present invention: diabetes, diabetes mellitus, arthritis
(including rheumatoid arthritis, juvenile rheumatoid arthritis,
osteoarthritis, psoriatic arthritis), multiple sclerosis,
myasthenia gravis, systemic lupus erythematosis, autoimmune
thyroiditis, dermatitis (including atopic dermatitis and eczematous
dermatitis), psoriasis, Sjogren's Syndrome, including
keratoconjunctivitis sicca secondary to Sjogren's Syndrome,
alopecia greata, allergic responses due to arthropod bite
reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis,
keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma,
cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis,
drug eruptions, leprosy reversal reactions, erythema nodosum
leprosum, autoimmune uveitis, allergic encephalomyelitis, acute
necrotizing hemorrhagic encephalopathy, idiopathic bilateral
progressive sensorineural hearing loss, aplastic anemia, pure red
cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's
granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome,
idiopathic sprue, lichen planus, Crohn's disease, Graves
ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis
posterior, and interstitial lung fibrosis. Examples of antigens
involved in autoimmune disease include glutamic acid decarboxylase
65 (GAD 65), native DNA, myelin basic protein, myelin proteolipid
protein, acetylcholine receptor components, thyroglobulin, and the
thyroid stimulating hormone (TSH) receptor.
[0123] Examples of antigens involved in allergy include pollen
antigens such as Japanese cedar pollen antigens, ragweed pollen
antigens, rye grass pollen antigens, animal derived antigens such
as dust mite antigens and feline antigens, histocompatiblity
antigens, and penicillin and other therapeutic drugs. Examples of
antigens involved in graft rejection include antigenic components
of the graft to be transplanted into the graft recipient such as
heart, lung, liver, pancreas, kidney, and neural graft components.
The antigen may be an altered peptide ligand useful in treating an
autoimmune disease.
[0124] It will be appreciated by those of skill in the art that the
sequence of any protein effector molecule may be altered in a
manner that does not substantially affect the functional advantages
of the effector protein. For example, glycine and alanine are
typically considered to be interchangeable as are aspartic acid and
glutamic acid and asparagine and glutamine. One of skill in the art
will recognize that many different variations of effector sequences
will encode effectors with roughly the same activity as the native
effector. The effector molecule and the antibody may be conjugated
by chemical or by recombinant means as described above. Chemical
modifications include, for example, derivitization for the purpose
of linking the effector molecule and the antibody to each other,
either directly or through a linking compound, by methods that are
well known in the art of protein chemistry. Both covalent and
noncovalent attachment methods may be used with the humanized
antibodies of the present invention.
[0125] The procedure for attaching an effector molecule to an
antibody will vary according to the chemical structure of the
moiety to be attached to the antibody. Polypeptides typically
contain a variety of functional groups; e.g., carboxylic acid
(COOH), free amine (--NH.sub.2) or sulfhydryl (--SH) groups, which
are available for reaction with a suitable functional group on an
antibody to result in the binding of the effector molecule.
Alternatively, the antibody can be derivatized to expose or to
attach additional reactive functional groups, e.g., by attachment
of any of a number of linker molecules such as those available from
Pierce Chemical Company, Rockford Ill.
[0126] The linker is capable of forming covalent bonds to both the
antibody and to the effector molecule. Suitable linkers are well
known to those of skill in the art and include, but are not limited
to, straight or branched-chain carbon linkers, heterocyclic carbon
linkers, or peptide linkers. Where the antibody and the effector
molecule are polypeptides, the linkers may be joined to the
constituent amino acids through their side groups (e.g., through a
disulfide linkage to cysteine). However, in a preferred embodiment,
the linkers will be joined to the alpha carbon amino and carboxyl
groups of the terminal amino acids.
[0127] In some circumstances, it is desirable to free the effector
molecule from the antibody when the immunoconjugate has reached its
target site. Therefore, in these circumstances, immunoconjugates
will comprise linkages that are cleavable in the vicinity of the
target site. Cleavage of the linker to release the effector
molecule from the antibody may be prompted by enzymatic activity or
conditions to which the immunoconjugate is subjected either inside
the target cell or in the vicinity of the target site. When the
target site is a tumor, a linker that is cleavable under conditions
present at the tumor site (e.g. when exposed to tumor-associated
enzymes or acidic pH) may be used.
[0128] Exemplary chemical modifications of the effector molecule
and the antibody of the present invention also include
derivitization with polyethylene glycol (PEG) to extend time of
residence in the circulatory system and reduce immunogenicity,
according to well known methods (See for example, Lisi, et al.,
Applied Biochem. 4:19 (1982); Beauchamp, et al., Anal Biochem.
131:25 (1982); and Goodson, et al., Bio/Technology 8:343
(1990)).
[0129] The present invention contemplates vaccines for use in both
active and passive immunization embodiments. Immunogenic
compositions, proposed to be suitable for use as a vaccine, may be
prepared most readily directly from immunogenic T-cell stimulating
peptides prepared in a manner disclosed herein. The final
vaccination material is dialyzed extensively to remove undesired
small molecular weight molecules and/or lyophilized for more ready
formulation into a desired vehicle. In certain embodiment of the
present invention, the compositions and methods of the present
invention are used to manufacture a cellular vaccine, e.g., the
antigen-delivering anti-Langerin binding portion of the antibody is
used to direct the antigen(s) to an antigen presenting cell, which
then "loads" the antigen onto MHC proteins for presentation. The
cellular vaccine is, therefore, the antigen presenting cell that
has been loaded using the compositions of the present invention to
generate antigen-loaded antigen presenting cells.
[0130] When the vaccine is the anti-Langerin binding protein
itself, e.g., a complete antibody or binding fragments thereof,
then these "active ingredients" can be made into vaccines using
methods understood in the art, e.g., U.S. Pat. Nos. 4,608,251;
4,601,903; 4,599,231; 4,599,230; and 4,578,770, relevant portions
incorporated herein by reference. Typically, such vaccines are
prepared as injectables, e.g., as liquid solutions or suspensions
or solid forms suitable for re-suspension in liquid prior to
injection. The preparation may also be emulsified. The active
immunogenic ingredient is often mixed with excipients which are
pharmaceutically acceptable and compatible with the active
ingredient. Suitable excipients are, for example, water, saline,
dextrose, glycerol, ethanol, or the like and combinations thereof.
In addition, if desired, the vaccine may contain minor amounts of
auxiliary substances such as wetting or emulsifying agents, pH
buffering agents, or adjuvants that enhance the effectiveness of
the vaccines.
[0131] The vaccines are administered in a manner compatible with
the dosage formulation, and in such amount as will be
therapeutically effective and immunogenic. The quantity to be
administered depends on the subject to be treated, including, e.g.,
the capacity of the individual's immune system to generate an
immune response. Precise amounts of cells or active ingredient
required to be administered depend on the judgment of the
practitioner. However, suitable dosage ranges are of the order of a
few thousand cells (to millions of cells) for cellular vaccines.
For standard epitope or epitope delivery vaccines then the vaccine
may be several hundred micrograms active ingredient per
vaccination. Suitable regimes for initial administration and
booster shots are also variable, but are typified by an initial
administration followed by subsequent inoculations or other
administrations.
[0132] The manner of application may vary widely, however, certain
embodiments herein will most likely be delivered intravenously or
at the site of a tumor or infection directly. Regardless, any of
the conventional methods for administration of a vaccine are
applicable. The dosage of the vaccine will depend on the route of
administration and will vary according to the size of the host.
[0133] In many instances, it will be desirable to have multiple
administrations of the vaccine, e.g., four to six vaccinations
provided weekly or every other week. A normal vaccination regimen
will often occur in two to twelve week intervals or from three to
six week intervals. Periodic boosters at intervals of 1-5 years,
usually three years, may be desirable to maintain protective levels
of the immune response or upon a likelihood of a remission or
re-infection. The course of the immunization may be followed by
assays for, e.g., T cell activation, cytokine secretion or even
antibody production, most commonly conducted in vitro. These immune
response assays are well known and may be found in a wide variety
of patents and as taught herein.
[0134] The vaccine of the present invention may be provided in one
or more "unit doses" depending on whether the nucleic acid vectors
are used, the final purified proteins, or the final vaccine form is
used. Unit dose is defined as containing a predetermined-quantity
of the therapeutic composition calculated to produce the desired
responses in association with its administration, i.e., the
appropriate route and treatment regimen. The quantity to be
administered, and the particular route and formulation, are within
the skill of those in the clinical arts. The subject to be treated
may also be evaluated, in particular, the state of the subject's
immune system and the protection desired. A unit dose need not be
administered as a single injection but may include continuous
infusion over a set period of time. Unit dose of the present
invention may conveniently be described in terms of DNA/kg (or
protein/Kg) body weight, with ranges between about 0.05, 0.10,
0.15, 0.20, 0.25, 0.5, 1, 10, 50, 100, 1,000 or more mg/DNA or
protein/kg body weight are administered.
[0135] Likewise, the amount of anti-Langerin-antigen vaccine
delivered can vary from about 0.2 to about 8.0 mg/kg body weight.
Thus, in particular embodiments, 0.4 mg, 0.5 mg, 0.8 mg, 1.0 mg,
1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5
mg, 7.0 mg and 7.5 mg of the vaccine may be delivered to an
individual in vivo. The dosage of vaccine to be administered
depends to a great extent on the weight and physical condition of
the subject being treated as well as the route of administration
and the frequency of treatment. A pharmaceutical composition that
includes a naked polynucleotide prebound to a liposomal or viral
delivery vector may be administered in amounts ranging from 1 .mu.g
to 1 mg polynucleotide to 1 .mu.g to 100 mg protein. Thus,
particular compositions may include between about 1 .mu.g, 5 .mu.g,
10 .mu.g, 20 .mu.g, 30 .mu.g, 40 .mu.g, 50 .mu.g, 60 .mu.g, 70
.mu.g, 80 .mu.g, 100 .mu.g, 150 .mu.g, 200 .mu.g, 250 .mu.g, 500
.mu.g, 600 .mu.g, 700 .mu.g, 800 .mu.g, 900 .mu.g or 1,000 .mu.g
polynucleotide or protein that is bound independently to 1 .mu.g, 5
.mu.g, 10 .mu.g, 20 .mu.g, 3.0 .mu.g, 40 .mu.g 50 .mu.g, 60 .mu.g,
70 .mu.g, 80 .mu.g, 100 .mu.g, 150 .mu.g, 200 .mu.g, 250 .mu.g, 500
.mu.g, 600 .mu.g, 700 .mu.g, 800 .mu.g, 900 .mu.g, 1 mg, 1.5 mg, 5
mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg
or 100 mg vector.
[0136] Antibodies of the present invention may optionally be
covalently or non-covalently linked to a detectable label.
Detectable labels suitable for such use include any composition
detectable by spectroscopic, photochemical, biochemical,
immunochemical, electrical, optical or chemical methods. Useful
labels in the present invention include magnetic beads (e.g.
DYNABEADS.TM.), fluorescent dyes (e.g., fluorescein isothiocyanate,
Texas red, rhodamine, green fluorescent protein, and the like),
radiolabels (e.g., .sup.3H, .sup.125I, .sup.35S, .sup.14C, or
.sup.32P), enzymes (e.g., horse radish peroxidase, alkaline
phosphatase and others commonly used in an ELISA), and colorimetric
labels such as colloidal gold or colored glass or plastic (e.g.
polystyrene, polypropylene, latex, etc.) beads.
[0137] Methods of detecting such labels are well known to those of
skill in the art. Thus, for example, radiolabels may be detected
using photographic film or scintillation counters, fluorescent
markers may be detected using a photodetector to detect emitted
illumination. Enzymatic labels are typically detected by providing
the enzyme with a substrate and detecting the reaction product
produced by the action of the enzyme on the substrate, and
colorimetric labels are detected by simply visualizing the colored
label.
[0138] The antibody and/or immunoconjugate compositions of this
invention are particularly useful for parenteral administration,
such as intravenous administration or administration into a body
cavity. The compositions for administration will commonly comprise
a solution of the antibody and/or immunoconjugate dissolved in a
pharmaceutically acceptable carrier, preferably an aqueous carrier.
A variety of aqueous carriers can be used, e.g., buffered saline
and the like. These solutions are sterile and generally free of
undesirable matter. These compositions may be sterilized by
conventional, well-known sterilization techniques. The compositions
may contain pharmaceutically acceptable auxiliary substances as
required to approximate physiological conditions such as pH
adjusting and buffering agents, toxicity adjusting agents and the
like, for example, sodium acetate, sodium chloride, potassium
chloride, calcium chloride, sodium lactate and the like. The
concentration of fusion protein in these formulations can vary
widely, and will be selected primarily based on fluid volumes,
viscosities, body weight and the like in accordance with the
particular mode of administration selected and the patient's
needs.
[0139] Thus, a typical pharmaceutical immunoconjugate composition
of the present invention for intravenous administration would be
about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to
about 100 mg per patient per day may be used. Actual methods for
preparing administrable compositions will be known or apparent to
those skilled in the art and are described in more detail in such
publications as REMINGTON'S PHARMACEUTICAL SCIENCE, 19TH ED., Mack
Publishing Company, Easton, Pa. (1995).
[0140] The compositions of the present invention can be
administered for therapeutic treatments. In therapeutic
applications, compositions are administered to a patient suffering
from a disease, in an amount sufficient to cure or at least
partially arrest the disease and its complications. An amount
adequate to accomplish this is defined as a "therapeutically
effective dose." Amounts effective for this use will depend upon
the severity of the disease and the general state of the patient's
health. An effective amount of the compound is that which provides
either subjective relief of a symptom(s) or an objectively
identifiable improvement as noted by the clinician or other
qualified observer.
[0141] Single or multiple administrations of the compositions are
administered depending on the dosage and frequency as required and
tolerated by the patient. In any event, the composition should
provide a sufficient quantity of the proteins of this invention to
effectively treat the patient. Preferably, the dosage is
administered once but may be applied periodically until either a
therapeutic result is achieved or until side effects warrant
discontinuation of therapy. Generally, the dose is sufficient to
treat or ameliorate symptoms or signs of disease without producing
unacceptable toxicity to the patient.
[0142] Controlled release parenteral formulations of the
immunoconjugate compositions of the present invention can be made
as implants, oily injections, or as particulate systems. For a
broad overview of protein delivery systems see, Banga, A. J.,
THERAPEUTIC PEPTIDES AND PROTEINS: FORMULATION, PROCESSING, AND
DELIVERY SYSTEMS, Technomic Publishing Company, Inc., Lancaster,
Pa., (1995) incorporated herein by reference. Particulate systems
include microspheres, microparticles, microcapsules, nanocapsules,
nanospheres, and nanoparticles. Microcapsules contain the
therapeutic protein as a central core. In microspheres the
therapeutic is dispersed throughout the particle. Particles,
microspheres, and microcapsules smaller than about 1 .mu.m are
generally referred to as nanoparticles, nanospheres, and
nanocapsules, respectively. Capillaries have a diameter of
approximately 5 .mu.m so that only nanoparticles are administered
intravenously. Microparticles are typically around 100 .mu.m in
diameter and are administered subcutaneously or
intramuscularly.
[0143] Polymers can be used for ion-controlled release of
immunoconjugate compositions of the present invention. Various
degradable and non-degradable polymeric matrices for use in
controlled drug delivery are known in the art (Langer, R., Accounts
Chem. Res. 26:537-542 (1993)). For example, the block copolymer,
poloxamer 407.RTM. exists as a viscous yet mobile liquid at low
temperatures but forms a semisolid gel at body temperature,
hydroxyapatite has been used as a microcarrier for controlled
release of proteins, and/or liposomes may be used for controlled
release as well as drug targeting of the lipid-capsulated drug.
Numerous additional systems for controlled delivery of therapeutic
proteins are known. See, e.g., U.S. Pat. Nos. 5,055,303, 5,188,837,
4,235,871, 4,501,728, 4,837,028 4,957,735 and 5,019,369, 5,055,303;
5,514,670; 5,413,797; 5,268,164; 5,004,697; 4,902,505; 5,506,206,
5,271,961; 5,254,342 and 5,534,496, relevant portions of each of
which are incorporated herein by reference.
[0144] Among various uses of the immunoconjugates of the invention
are included a variety of disease conditions caused by specific
human cells that may be eliminated by the toxic action of the
fusion protein. For example, for the humanized Anti-Langerin
antibodies, e.g., 15B10 having ATCC Accession No. PTA-9852, 2G3
having ATCC Accession No. PTA-9853, 91E7, 37C1, or 4C7 and binding
fragments thereof, disclosed herein. For example, one application
for immunoconjugates is the treatment of malignant cells expressing
Langerin. Exemplary malignant cells include those of chronic
lymphocytic leukemia and hairy cell leukemia.
[0145] In another embodiment, this invention provides kits for the
delivery of antigens, e.g., Langerin or an immunoreactive fragment
thereof, conjugated or in the form of a fusion protein with one or
more T cell or B cell epitopes. A "biological sample" as used
herein is a sample of biological tissue or fluid that contains the
antigen. Such samples include, but are not limited to, tissue from
biopsy, blood, and blood cells (e.g., white cells). Preferably, the
cells are lymphocytes, e.g., dendritic cells. Biological samples
also include sections of tissues, such as frozen sections taken for
histological purposes. A biological sample is typically obtained
from a multicellular eukaryote, preferably a mammal such as rat,
mouse, cow, dog, guinea pig, or rabbit, and more preferably a
primate, such as a macaque, chimpanzee, or human. Most preferably,
the sample is from a human. The antibodies of the invention may
also be used in vivo, for example, as a diagnostic tool for in vivo
imaging.
[0146] Kits will typically comprise a nucleic acid sequence that
encodes an antibody of the present invention (or binding fragment
thereof) with one or more framework portions or multiple cloning
sites at the carboxy-terminal end into which the coding sequences
for one or more antigens may be inserted. In some embodiments, the
antibody will be a humanized anti-Langerin Fv fragment, such as an
scFv or dsFv fragment. In addition the kits will typically include
instructional materials disclosing methods of use of an antibody of
the present invention (e.g. for loading into dendritic cells prior
to immunization with the dendritic cells, which can be autologous
dendritic cells). The kits may also include additional components
to facilitate the particular application for which the kit is
designed. Thus, for example, the kit may additionally contain
methods of detecting the label (e.g. enzyme substrates for
enzymatic labels, filter sets to detect fluorescent labels,
appropriate secondary labels such as a sheep anti-mouse-HRP, or the
like). The kits may additionally include buffers and other reagents
routinely used for the practice of a particular method. Such kits
and appropriate contents are well known to those of skill in the
art.
[0147] In another set of uses for the invention, immunoconjugates
targeted by antibodies of the invention can be used to purge
targeted cells from a population of cells in a culture. For
example, if a specific population of T cells is preferred, the
immunoconjugates of the present invention may be used to enrich a
population of T cells having the opposite effect of the on-going
immune response. Thus, for example, cells cultured from a patient
having a cancer can be purged of cancer cells by providing the
patient with dendritic cells that were antigen loaded using the
antibodies of the invention as a targeting moiety for the antigens
that will trigger an immune response against the cancer, virus or
other pathogen. Likewise, the immunoconjugates can be used to
increase the population of regulatory T cells or drive the immune
response toward or away from a cytotoxic T cell response or even
drive a B cell response.
[0148] Differential functions of DC subsets: The present inventors
have demonstrated that LCs and intDCs derived from CD34+
hematopoietic progenitor cells differ in their capacity to activate
lymphocytes (FIG. 1). IntDCs induce the differentiation of naive B
cells into immunoglobulin-secreting plasma cells and
differentiation of CD4+T cells into follicular helper T cells
(TFH).sup.17,18, while LCs are particularly efficient activators of
cytotoxic CD8+ lymphocytes (CTLs). In addition, only interstitial
DCs produce IL-10 and their enzymatic activity, which might be
fundamental for the selection of peptides that will be presented to
T cells, is not the same. Indeed, different enzymes are likely to
degrade a antigen into different peptide repertoires, as shown for
HIV nef protein.sup.19. This will lead to different sets of
MHC/peptide complexes being presented and to a distinct
antigen-specific T-cell repertoire. Dudziak, et al..sup.20 have
shown that antigens delivered to DCs through the subset-specific
lectin Dectin-1 were presented differentially on MHC class II,
while those presented through DEC-205 were mostly on MHC Class I
and this difference was intrinsic to the DC subsets.
[0149] DC subsets play an important role in determining CD4+T cell
responses. Either polarized DCs or distinct DC subsets provide T
cells with different signals that determine the types of immune
response (Type 1 versus Type 2).sup.21. Thus, in mice, splenic
CD8+DCs prime naive CD4+T cells to make Th1 cytokines in a process
involving IL-12, whereas splenic CD8+DCs prime naive CD4+T cells to
make Th2 cytokines.sup.22,23. Furthermore, different signals from
the same DCs can induce different T-cell polarization, as shown by
the induction of IL-12 production and Th1-cell polarization when
DCs are activated with Escherichia coli lipopolysaccharide (LPS),
but no IL-12 production and Th2-cell polarization when DCs are
exposed to LPS from Porphyromonas gingivalis.sup.24. CD40-ligand
(CD40L)-activated DCs prime Th1 responses through an
IL-12-dependent mechanism, whereas pDCs activated with IL-3 and
CD40L have been shown to secrete negligible amounts of IL-12 and
prime Th2 responses.sup.25. Soares, et al. also reported that two
DC subsets that express different lectins have innate propensities
to differentially affect the Th1/Th2 balance in vivo by distinct
mechanisms. More interestingly, we have found that delivering the
same antigens to the same type of DCs, but through different
DC-receptors, induces a different quality of CD4+T cell responses
(see preliminary data). Thus, both DC subsets and activation
signals to which DCs are exposed are important factors determining
the nature of immune outcome.
[0150] FIG. 2--Recombinant anti-Langerin antibodies fused to
antigens retain their ability to bind to cell surface Langerin.
CHO--S cells were stably transfected with a plasmid directing the
expression of full-length human Langerin. Pure recombinant
anti-Langerin 2G3 or 15B10 mouse V region-human IgG4 chimeric
antibodies or the same antibodies with C-terminal fusions to
Influenza A Hemagglutinin HA-1 domain from Avian Flu (HA5-1),
Influenza A Hemagglutinin HA-1 from a H1N1 Flu strain (HA1-1),
dockerin domain from C. thermocellum (doc), HIV gag p24 (gag), or a
string of HIV peptides (Hipo5), were titrated against the
Langerin-CHO cells. After incubation on ice, the cells were washed
and treated with an anti-human Fc-PE reagent. After further
incubation on ice, the cells were washed and analyzed on a FACS
Array instrument to determine the amount of cell-bound florescence
(expressed as % MFI compared to untransfected CHO--S cells).
[0151] This data shows that addition of antigen to the H-chain
C-termini does not affect the binding of the antibody to cell
surface Langerin and also demonstrates that these anti-Langerin
antibodies serve as effective vehicles to bring antigen to the
surface of cells bearing human Langerin.
[0152] FIG. 3--demonstration of the ability of recombinant
anti-Langerin antibody fused to the human prostate specific cancer
antigen to elicit the expansion of antigen-specific CD4+T cells
from a health donor. FIG. 3a compares delivering PSA to DCs through
CD40 and Langerin induces IFN.gamma.-producing PSA-specific CD4+T
cells. CD4+T cells from healthy donors were co-cultured with IFNDCs
targeted with anti-CD40-PSA or anti-Langerin-PSA for 8 days. Cells
were stimulated with individual peptides (59 peptides of 15-mers)
of PSA (5 .mu.M). After 2 days, culture supernatants were analyzed
for measuring IFN.gamma.. Dotted lines represent upper limits of
average.+-.SD for no peptides and responses above this line are
considered significant. FIG. 3b shows that CD4+T cells were stained
for measuring the frequency of peptide-specific intracellular
IFN.gamma.+ cells.
[0153] These data show that an anti-Langerin vaccine bearing a
cancer antigen can prime a potent antigen-specific anti-CD4+T cell
response in vitro using immune cells from a normal individual. In
this in vitro culture system this agent is as potent as an
anti-CD40 based vaccine--these DCs express both receptors. In vivo,
an anti-Langerin-based vaccine would target antigen only to
Langerhans cells (LCs), and based on recent research [Immunity,
Volume 29, Issue 3, 497-510, 19 Sep. 2008] LCs preferentially
induce the differentiation of CD4+T cells secreting T helper 2
(Th2) cell cytokines and are particularly efficient at priming and
cross priming naive CD8+T cells--the latter characteristic is
particularly desirable for evoking anti-cancer CTL responses. In
contrast, anti-CD40 targeting agents would deliver antigen to a
much broader array of APC in vivo.
[0154] FIG. 4--demonstration of the ability of recombinant
anti-Langerin antibody fused to the human prostate specific cancer
antigen to elicit the expansion of antigen-specific CD8+T cells
from a prostate cancer patient. DCs targeted with anti-CD40-PSA and
anti-Langerin-PSA targeted to DCs induces PSA-specific CD8+T cell
responses. (a) IFNDCs were targeted with 1 mg mAb fusion proteins
with PSA. Purified autologous CD8+T cells were co-cultured for 10
days. Cells were stained with anti-CD8 and PSA
(KLQCVDLHV)-tetramer. Cells are from HLA-A*0201 positive prostate
cancer patients. The PSA tetramer reagent identified T cells
bearing T cell receptors specifically reactive with HLA-A*0201
complexes bearing the PSA KLQCVDLHV peptide.
[0155] These data show that an anti-Langerin vaccine bearing a
cancer antigen can prime a potent antigen-specific anti-CD8+T cell
response in vitro using immune cells from a prostate cancer. In
this in vitro culture system this agent is as potent as a anti-CD40
based vaccine--these DCs express both receptors. In vivo, an
anti-Langerin-based vaccine would target antigen only to Langerhans
cells (LCs), and based on recent research [Immunity, Volume 29,
Issue 3, 497-510, 19 Sep. 2008] LCs preferentially induce the
differentiation of CD4+T cells secreting T helper 2 (Th2) cell
cytokines and are particularly efficient at priming and cross
priming naive CD8+T cells--the latter characteristic is
particularly desirable for evoking anti-cancer CTL responses. In
contrast, anti-CD40 targeting agents would deliver antigen to a
much broader array of APC in vivo.
[0156] FIG. 5--Anti-Langerin preferentially targets epidermal LCs.
Purified skin DC subsets (Epidermal LCs, dermal CD1a+DCs and
CD14+DCs) from HLA-A201 donor were cultured with 8 nM
anti-Langerin, IgG4 conjugates mAbs, free FluMP or without antigen
for 3 h. Syngeneic purified CD8+T cells were cultured with the
antigen-pulsed DCs at a DC/T ratio 1:20. CD40L (100 ng/ml; R&D)
was added to the culture after 24 h. CD40-ligation enhances
crosspresentation by DCs. The cocultures were incubated at
37.degree. C. for 8-10 days. IL-2 (10 U/ml) was added at day 3. The
response of FluMP-specific CD8+T cells was evaluated using
HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer.
[0157] The data in panel FIG. 5A: 2D FACs-plots showing
FluMP-specific CD8+T cell expansion as evaluated by specific
HLA-A201-FluMP (58-66) tetramer staining demonstrating that
targeting antigen via anti-Langerin elicits antigen-specific CD8+T
cell expansion only through LCs, which is more robust than other
methods of antigen delivery such as free FluMP. Some response is
induced by the dermal CD1a+DCs, in concordance with the ability of
these cells to upregulate Langerin in culture. FIG. 5B summarizes
the data in a graph shows mean.+-.sd, N=3. FIG. 5C. IFN-.gamma.
levels in the culture supernatants of human LCs that were culture
for 8 days with either Langerin-FluMP, control IgG4-FluMP, free
FluMP or no antigen after 8 days.
[0158] FIG. 6 shows the differential expression of Langerin by
human skin DCs. FIG. 6A shows the expression of Langerin on
isolated human skin DC subsets. Data show restricted expression of
Langerin on human LCs, but not on dermal CD1a+ or CD14+DCs. FIG. 6B
show a gene expression analysis of Langerin by skin DCs isolated
from 3 different specimens. RNA was prepared from sorted migrated
skin mDC subsets: epidermal LCs, dermal CD1a+DCs and CD14+DCs. FIG.
6C shows the immunofluorescent staining of normal human skin using
Langerin and HLA-DR mAbs.
[0159] FIG. 7--Anti-Langerin 15B10 antibody (produced by hybridoma
ATCC Accession No. PTA-9852) specifically stains human Langerhans
cells. Human epithelial sheet was prepared and stained with
Alexa568 [red]-labeled anti-Langerin 15B10 and a commercial
anti-HLA antibody labeled green. The top image shows the red and
green image superimposed highlighting the co-localization of these
two markers.
[0160] Constructs.
[0161] mAnti-Langerin15B10K--Nucleotide and mature protein amino
acid sequence of the light chain of the mouse anti-Langerin 15B10
antibody cDNA, respectively. The variable region residues are
underlined.
TABLE-US-00006 (SEQ ID NO. 1)
ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCT
TCCAGCAGTGATGTTGTGATGACCCAAACTCCACTCTCCCTGCCTGTC
CGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTT
GTACACAGTAATGGAAACACCTATTTACATTGGTACCTGCAGAAGCCA
GGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCT
GGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAAATTTCACA
CTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGACTTTATTTCTGC
TCTCAAAGTACACATGTTCCGTACACGTTCGGAGGGGGGACCAAGCTG
GAAATAAAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCA
TCCAGTGAGCAGTTAACATCTGGAGGTGCCTCAGTCGTGTGCTTCTTG
AACAACTTCTACCCCAAAGACATCAATGTCAAGTGGAAGATTGATGGC
AGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAGC
AAAGACAGCACCTACAGCATGAACAGCACCCTCACGTTGACCAAGGAC
GAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACA
TCAACTTCACCCATCGTCAAGAGCTTCAACAGGAATGAGTGTTAG (SEQ ID NO. 2)
DVVMTQTPLSLPVRLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQS
PKLLIYKVSNRFSGVPDRFSGSGSGTNFTLKISRVEAEDLGLYFCSQS
THVPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNF
YPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMNSTLTLTKDEYE
RHNSYTCEATHKTSTSPIVKSFNRNEC
[0162] mAnti-Langerin15B10H-LV-hIgG4H-C--Nucleotide and mature
protein amino acid sequence of the heavy chain variable region of
the mouse anti-Langerin 15B10 antibody fused to human IgG4,
respectively. The variable region residues are underlined.
TABLE-US-00007 (SEQ ID NO. 3)
ATGGAATGGAGGATCTTTCTCTTCATCCTGTCAGGAACTGCAGGTGTC
CACTCCCAGGTTCAGCTGCGGCAGTCTGGACCTGAGCTGGTGAAGCCT
GGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACATTTACT
GACTATGTTATAAGTTGGGTGAAGCAGAGAACTGGACAGGGCCTTGAG
TGGATTGGAGATATTTATCCTGGAAGTGGTTATTCTTTCTACAATGAG
AACTTCAAGGGCAAGGCCACACTGACTGCAGACAAATCCTCCACCACA
GCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTAT
TTCTGTGCAACCTACTATAACTACCCTTTTGCTTACTGGGGCCAAGGG
ACTCTGGTCACTGTCTCTGCAGCCAAAACAACGGGCCCATCCGTCTTC
CCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTG
GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGG
AACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA
CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCC
AGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCA
TGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTC
CTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCT
GAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTC
CAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACA
AAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC
CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCC
AAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCA
TCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGG
CAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC
AACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGC TGA (SEQ ID NO. 4)
QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWI
GDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSAVYFC
ATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH YTQKSLSLSLGKAS
[0163] mAnti-Langerin2G3L (produced by hybridoma ATCC Accession No.
PTA-9853)--Nucleotide and mature protein amino acid sequence of the
light chain of the mouse anti-Langerin 2G3 antibody cDNA,
respectively. The variable region residues are underlined.
TABLE-US-00008 (SEQ ID NO. 5)
ATGGCCTGGATTTCACTTATACTCTCTCTCCTGGCTCTCAGCTCAGGG
GCCATTTCCCAGGCTGTTGTGACTCAGGAATCTGCACTCACCACATCA
CCTGGTGAAACAGTCACACTCACTTGTCGCTCAAGTACTGGGGCTGTT
ACAACTAGTAACTATGCCAACTGGGTCCAAGAAAAACCAGATCATTTA
TTCACTGGTCTAATAGGTGGTACCAACAACCGAGTTTCAGGTGTTCCT
GCCAGATTCTCAGGCTCCCTGATTGGAGACAAGGCTGCCCTCACCATC
ACAGGGGCACAGACTGAGGATGAGGCAATATATTTCTGTGCTCTATGG
TACAGCAACCATTGGGTGTTCGGTGGAGGAACCAAACTGACTGTCCTA
GGCCAGCCCAAGTCTTCGCCATCAGTCACCCTGTTTCCACCTTCCTCT
GAAGAGCTCGAGACTAACAAGGCCACACTGGTGTGTACGATCACTGAT
TTCTACCCAGGTGTGGTGACAGTGGACTGGAAGGTAGATGGTACCCCT
GTCACTCAGGGTATGGAGACAACCCAGCCTTCCAAACAGAGCAACAAC
AAGTACATGGCTAGCAGCTACCTGACCCTGACAGCAAGAGCATGGGAA
AGGCATAGCAGTTACAGCTGCCAGGTCACTCATGAAGGTCACACTGTG
GAGAAGAGTTTGTCCCGTGCTGACTGTTCCTAG (SEQ ID NO. 6)
QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTG
LIGGTNNRVSGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSN
HWVFGGGTKLTVLGQPKSSPSVTLFPPSSEELETNKATLVCTITDFYP
GVVTVDWKVDGTPVTQGMETTQPSKQSNNKYMASSYLTLTARAWERHS
SYSCQVTHEGHTVEKSLSRADCS
[0164] mAnti-Langerin2G3H--Nucleotide and mature protein amino acid
sequence of the heavy chain of the mouse anti-Langerin 2G3 antibody
cDNA, respectively. The variable region residues are
underlined.
TABLE-US-00009 (SEQ ID NO. 7)
ATGACATTGAACATGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTT
TTTTATCAAGGTGTGCATTGTGAGGTGCAGCTTGTTGAGTCTGGTGGA
GGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCT
GGATTAACCTTCAATATCTACGCCATGAACTGGGTCCGCCAGGCTCCA
GGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAAT
TATGCAACATATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCC
AGAGATGATTCACAAAGCTTGCTCTATCTGCAAATGAACAACTTGAAA
ACTGAGGACACAGCCATGTATTACTGTGTGGGACGGGACTGGTTTGAT
TACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGACA
CCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAAC
TCCATGGTGACCCTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCA
GTGACAGTGACCTGGAACTCTGGATCCCTGTCCAGCGGTGTGCACACC
TTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTG
ACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTT
GCCCACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGG
GATTGTGGTTGTAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCT
GTCTTCATCTTCCCCCCAAAGCCCAAGGATGTGCTCACCATTACTCTG
ACTCCTAAGGTCACGTGTGTTGTGGTAGACATCAGCAAGGATGATCCC
GAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGTGCACACAGCT
CAGACGCAACCCCGGGAGGAGCAGTTCAACAGCACTTTCCGCTCAGTC
AGTGAACTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTC
AAATGCAGGGTCAACAGTGCAGCTTTCCCTGCCCCCATCGAGAAAACC
ATCTCCAAAACCAAAGGCAGACCGAAGGCTCCACAGGTGTACACCATT
CCACCTCCCAAGGAGCAGATGGCCAAGGATAAAGTCAGTCTGACCTGC
ATGATAACAGACTTCTTCCCTGAAGACATTACTGTGGAGTGGCAGTGG
AATGGGCAGCCAGCGGAGAACTACAAGAACACTCAGCCCATCATGGAC
ACAGATGGCTCTTACTTCGTCTACAGCAAGCTCAATGTGCAGAAGAGC
AACTGGGAGGCAGGAAATACTTTCACCTGCTCTGTGTTACATGAGGGC
CTGCACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCTGGTAAA GCTAGCTGA (SEQ ID
NO. 8) EVQLVESGGGLVQPKGSLKLSCAASGLTFNIYAMNWVRQAPGKGLEWV
ARIRNKSNNYATYYADSVKDRFTISRDDSQSLLYLQMNNLKTEDTAMY
YCVGRDWFDYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGC
LVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTW
PSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPK
PKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREE
QFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGR
PKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAEN
YKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTE KSLSHSPGKAS
[0165] C84 rAB-pIRES2 [mAnti-Langerin2G3H-LV-hIgG4H-C-Dockerin] The
coding region for this H chain-dockerin fusion protein is shown
below. Start and stop codons are in bold, as is the joining GCTAGC
restriction site.
TABLE-US-00010 (SEQ ID NO. 57)
ATGACATTGAACATGCTGTTGGGGCTGAGGTGGGTTTTCTTTGTTGTT
TTTTATCAAGGTGTGCATTGTGAGGTGCAGCTTGTTGAGTCTGGTGGA
GGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCT
GGATTAACCTTCAATATCTACGCCATGAACTGGGTCCGCCAGGCTCCA
GGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAAT
TATGCAACATATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCC
AGAGATGATTCACAAAGCTTGCTCTATCTGCAAATGAACAACTTGAAA
ACTGAGGACACAGCCATGTATTACTGTGTGGGACGGGACTGGTTTGAT
TACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGAAG
GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG
AGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCG
GTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC
TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
GTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAAC
GTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC
AAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGG
GGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATG
ATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAG
GAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC
CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGC
AAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATC
GAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTG
TACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGC
CTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
GTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTG
GACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCT
CTGGGTAAAGCTAGCAATTCTCCTCAAAATGAAGTACTGTACGGAGAT
GTGAATGATGACGGAAAAGTAAACTCCACTGACTTGACTTTGTTAAAA
AGATATGTTCTTAAAGCCGTCTCAACTCTCCCTTCTTCCAAAGCTGAA
AAGAACGCAGATGTAAATCGTGACGGAAGAGTTAATTCCAGTGATGTC
ACAATACTTTCAAGATATTTGATAAGGGTAATCGAGAAATTACCAATA TAA
[0166] The mature H chain sequence for C84 heavy chain is shown
below. Joining sequence AS is bold and dockerin is underlined.
TABLE-US-00011 (SEQ ID NO. 58)
EVQLVESGGGLVQPKGSLKLSCAASGLTFNIYAMNWVRQAPGKGLEWV
ARIRNKSNNYATYYADSVKDRFTISRDDSQSLLYLQMNNLKTEDTAMY
YCVGRDWFDYWGQGTLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASNSPQNEVLYGDVNDDGKVNSTDLTLLKRYVLKAV
STLPSSKAEKNADVNRDGRVNSSDVTILSRYLIRVIEKLPI
[0167] C85 rAB-pIRES2
[mAnti-Langerin2G3H-LV-hIgG4H-C-Flex-FluHA1-1-6xHis] The coding
region for this H chain-Flu HA1-1 fusion protein is shown below.
Start and stop codons are in bold, as is the joining GCTAGC
restriction site.
TABLE-US-00012 (SEQ ID NO. 59)
ATGACATTGAACATGCTGTTGGGGCTGAGGTGGGTTTTCTTTGTTGTT
TTTTATCAAGGTGTGCATTGTGAGGTGCAGCTTGTTGAGTCTGGTGGA
GGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCT
GGATTAACCTTCAATATCTACGCCATGAACTGGGTCCGCCAGGCTCCA
GGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAAT
TATGCAACATATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCC
AGAGATGATTCACAAAGCTTGCTCTATCTGCAAATGAACAACTTGAAA
ACTGAGGACACAGCCATGTATTACTGTGTGGGACGGGACTGGTTTGAT
TACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGAAG
GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG
AGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCG
GTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC
TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
GTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAAC
GTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC
AAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGG
GGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATG
ATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAG
GAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC
CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGC
AAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATC
GAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTG
TACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGC
CTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
GTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTG
GACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCT
CTGGGTAAAGCTAGCGATACAACAGAACCTGCAACACCTACAACACCT
GTAACAACAGACACAATATGTATAGGCTACCATGCGAACAATTCAACC
GACACTGTTGACACAGTACTCGAGAAGAATGTGACAGTGACACACTCT
GTTAACCTGCTCGAAGACAGCCACAACGGAAAACTATGTAGATTAAAA
GGAATAGCCCCACTACAATTGGGGAAATGTAACATCGCCGGATGGCTC
TTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCATGGTCC
TACATTGTAGAAACACCAAACTCTGAGAATGGAATATGTTATCCAGGA
GATTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAGCTCAGTGTCA
TCATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGGCCCAAC
CACAACACAAACGGAGTAACGGCAGCATGCTCCCATGAGGGGAAAAGC
AGTTTTTACAGAAATTTGCTATGGCTGACGGAGAAGGAGGGCTCATAC
CCAAAGCTGAAAAATTCTTATGTGAACAAAAAAGGGAAAGAAGTCCTT
GTACTGTGGGGTATTCATCACCCGCCTAACAGTAAGGAACAACAGAAT
CTCTATCAGAATGAAAATGCTTATGTCTCTGTAGTGACTTCAAATTAT
AACAGGAGATTTACCCCGGAAATAGCAGAAAGACCCAAAGTAAGAGAT
CAAGCTGGGAGGATGAACTATTACTGGACCTTGCTAAAACCCGGAGAC
ACAATAATATTTGAGGCAAATGGAAATCTAATAGCACCAATGTATGCT
TTCGCACTGAGTAGAGGCTTTGGGTCCGGCATCATCACCTCAAACGCA
TCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCTGGGAGCTATA
AACAGCAGTCTCCCTTACCAGAATATACACCCAGTCACAATAGGAGAG
TGCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTCACCATCA CCATCACCATTGA
[0168] The mature H chain sequence for C85 heavy chain is shown
below. Joining sequence AS is bold and Flu HA1-1 is underlined. A
flexible linker joining sequence is italicized.
TABLE-US-00013 (SEQ ID NO. 60)
EVQLVESGGGLVQPKGSLKLSCAASGLTFNIYAMNWVRQAPGKGLEWV
ARIRNKSNNYATYYADSVKDRFTISRDDSQSLLYLQMNNLKTEDTAMY
YCVGRDWFDYWGQGTLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASDTTEPATPTTPVTTDTICIGYHANNSTDTVDTVL
EKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECD
PLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEI
FPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSY
VNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPE
IAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGF
GSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRS AKLRMVHHHHHH
[0169] C86 rAB-pIRES2
[mAnti-Langerin2G3H-LV-hIgG4H-C-Flex-FluHA5-1-6xHis] The coding
region for this H chain-Flu HA5-1 fusion protein is shown below.
Start and stop codons are in bold, as is the joining GCTAGC
restriction site.
TABLE-US-00014 (SEQ ID NO. 61)
ATGACATTGAACATGCTGTTGGGGCTGAGGTGGGTTTTCTTTGTTGTT
TTTTATCAAGGTGTGCATTGTGAGGTGCAGCTTGTTGAGTCTGGTGGA
GGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCT
GGATTAACCTTCAATATCTACGCCATGAACTGGGTCCGCCAGGCTCCA
GGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAAT
TATGCAACATATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCC
AGAGATGATTCACAAAGCTTGCTCTATCTGCAAATGAACAACTTGAAA
ACTGAGGACACAGCCATGTATTACTGTGTGGGACGGGACTGGTTTGAT
TACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGAAG
GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAG
AGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCG
GTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC
TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
GTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAAC
GTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCC
AAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGG
GGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATG
ATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAG
GAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTAC
CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGC
AAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATC
GAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTG
TACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGC
CTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG
TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCC
GTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTG
GACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG
CATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCT
CTGGGTAAAGCTAGCGATACAACAGAACCTGCAACACCTACAACACCT
GTAACAACAGATCAGATTTGCATTGGTTACCATGCAAACAACTCGACA
GAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTTACACATGCC
CAAGACATACTGGAAAAGAAACACAACGGGAAGCTCTGCGATCTAGAT
GGAGTGAAGCCTCTAATTTTGAGAGATTGTAGCGTAGCTGGATGGCTC
CTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTCT
TACATAGTGGAGAAGGCCAATCCAGTCAATGACCTCTGTTACCCAGGG
GATTTCAATGACTATGAAGAATTGAAACACCTATTGAGCAGAATAAAC
CATTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCAGTCAT
GAAGCCTCATTAGGGGTGAGCTCAGCATGTCCATACCAGGGAAAGTCC
TCCTTTTTCAGAAATGTGGTATGGCTTATCAAAAAGAACAGTACATAC
CCAACAATAAAGAGGAGCTACAATAATACCAACCAAGAAGATCTTTTG
GTACTGTGGGGGATTCACCATCCTAATGATGCGGCAGAGCAGACAAAG
CTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACATCAACACTA
AACCAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAACGGG
CAAAGTGGAAGGATGGAGTTCTTCTGGACAATTTTAAAGCCGAATGAT
GCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATATGCA
TACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAATTG
GAATATGGTAACTGCAACACCAAGTGTCAAACTCCAATGGGGGCGATA
AACTCTAGCATGCCATTCCACAATATACACCCTCTCACCATTGGGGAA
TGCCCCAAATATGTGAAATCAAACAGATTAGTCCTTGCGCACCATCAC CATCACCATTGA
[0170] The mature H chain sequence for C86 heavy chain is shown
below. Joining sequence AS is bold and Flu HA5-1 is underlined. A
flexible linker joining sequence is italicized.
TABLE-US-00015 (SEQ ID NO. 62)
EVQLVESGGGLVQPKGSLKLSCAASGLTFNIYAMNWVRQAPGKGLEWV
ARIRNKSNNYATYYADSVKDRFTISRDDSQSLLYLQMNNLKTEDTAMY
YCVGRDWFDYWGQGTLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASDTTEPATPTTPVTTDQICIGYHANNSTEQVDTIM
EKNVTVTHAQDILEKKHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCD
EFINVPEWSYIVEKANPVNDLCYPGDFNDYEELKHLLSRINHFEKIQI
IPKSSWSSHEASLGVSSACPYQGKSSFFRNVVWLIKKNSTYPTIKRSY
NNTNQEDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPR
IATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKG
DSTIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECPKYVKS NRLVLAHHHHHH
[0171] C804 rAB-cetHS-puro [mAnti-L angerin2
G3H-LV-hIgGK-C-Flex-hPSA] The coding region for this H chain-PSA
fusion protein is shown below. Start and stop codons are in bold,
as is the joining GCTAGC restriction site.
TABLE-US-00016 (SEQ ID NO. 63)
ATGACATTGAACATGCTGTTGGGGCTGAAGTGGGTTTTCTTTGTTGTT
TTTTATCAAGGTGTGCATTGTGAGGTGCAGCTTGTTGAGTCTGGTGGA
GGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCT
GGATTAACCTTCAATATCTACGCCATGAACTGGGTCCGCCAGGCTCCA
GGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAAT
TATGCAACATATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCC
AGAGATGATTCACAAAGCTTGCTCTATCTGCAAATGAACAACTTGAAA
ACTGAGGACACAGCCATGTATTACTGTGTGGGACGGGACTGGTTTGAT
TACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGAAG
GGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGA
GAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACC
GGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACAC
CTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGT
GGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAA
CGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTC
CAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGG
GGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCAT
GATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCA
GGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGT
GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTA
CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGG
CAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCAT
CGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGT
GTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAG
CCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGA
GTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCC
CGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGT
GGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGAT
GCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTC
TCTGGGTAAAGCTAGCGATACAACAGAACCTGCAACACCTACAACACC
TGTAACAACACCGACAACAACACTTCTAGCGCCCCTCATCCTGTCTCG
GATTGTGGGAGGCTGGGAGTGCGAGAAGCATTCCCAACCCTGGCAGGT
GCTTGTGGCCTCTCGTGGCAGGGCAGTCTGCGGCGGTGTTCTGGTGCA
CCCCCAGTGGGTCCTCACAGCTGCCCACTGCATCAGGAACAAAAGCGT
GATCTTGCTGGGTCGGCACAGCCTGTTTCATCCTGAAGACACAGGCCA
GGTATTTCAGGTCAGCCACAGCTTCCCACACCCGCTCTACGATATGAG
CCTCCTGAAGAATCGATTCCTCAGGCCAGGTGATGACTCCAGCCACGA
CCTCATGCTGCTCCGCCTGTCAGAGCCTGCCGAGCTCACGGATGCTGT
GAAGGTCATGGACCTGCCCACCCAGGAGCCAGCACTGGGGACCACCTG
CTACGCCTCAGGCTGGGGCAGCATTGAACCAGAGGAGTTCTTGACCCC
AAAGAAACTTCAGTGTGTGGACCTCCATGTTATTTCCAATGACGTGTG
TGCGCAAGTTCACCCTCAGAAGGTGACCAAGTTCATGCTGTGTGCTGG
ACGCTGGACAGGGGGCAAAAGCACCTGCTCGGGTGATTCTGGGGGCCC
ACTTGTCTGTAATGGTGTGCTTCAAGGTATCACGTCATGGGGCAGTGA
ACCATGTGCCCTGCCCGAAAGGCCTTCCCTGTACACCAAGGTGGTGCA
TTACCGGAAGTGGATCAAGGACACCATCGTGGCCAACCCCTGA
[0172] The mature H chain sequence for C804 heavy chain is shown
below. Joining sequence AS is bold and PSA is underlined. A
flexible linker joining sequence is italicized.
TABLE-US-00017 (SEQ ID NO. 64)
EVQLVESGGGLVQPKGSLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVA
RIRNKSNNYATYYADSVKDRFTISRDDSQSLLYLQMNNLKTEDTAMYYC
VGRDWFDYWGQGTLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK
TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREP
QVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS
LGKASDTTEPATPTTPVTTPTTTLLAPLILSRIVGGWECEKHSQPWQVL
VASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILLGRHSLFHPEDTGQVF
QVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTDAVKVM
DLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVH
PQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALP
ERPSLYTKVVHYRKWIKDTIVANP
[0173] C87 rAB-pIRES2
[mAnti-Langerin15B10H-SLAML-V-hIgG4H-Flex-FluHA5-1-6xHis] The
coding region for this H chain-Flu HA5-1 fusion protein is shown
below. Start and stop codons are in bold, as is the joining GCTAGC
restriction site.
TABLE-US-00018 (SEQ ID NO. 65)
ATGGACCCCAAAGGCTCCCTTTCCTGGAGAATACTTCTGTTTCTCTCC
CTGGCTTTTGAGTTGTCGTACGGACAGGTTCAGCTGCGGCAGTCTGGA
CCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCT
TCTGGATACACATTTACTGACTATGTTATAAGTTGGGTGAAGCAGAGA
ACTGGACAGGGCCTTGAGTGGATTGGAGATATTTATCCTGGAAGTGGT
TATTCTTTCTACAATGAGAACTTCAAGGGCAAGGCCACACTGACTGCA
GACAAATCCTCCACCACAGCCTACATGCAGCTCAGCAGCCTGACATCT
GAGGACTCTGCGGTCTATTTCTGTGCAACCTACTATAACTACCCTTTT
GCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACA
ACGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCC
GAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCAC
ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC
GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG
TCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAA
GGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC
CAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAG
GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAC
GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC
AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTG
GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACC
GTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTG
ATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
TCTCTGGGTAAAGCTAGCGATACAACAGAACCTGCAACACCTACAACA
CCTGTAACAACAGATCAGATTTGCATTGGTTACCATGCAAACAACTCG
ACAGAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTTACACAT
GCCCAAGACATACTGGAAAAGAAACACAACGGGAAGCTCTGCGATCTA
GATGGAGTGAAGCCTCTAATTTTGAGAGATTGTAGCGTAGCTGGATGG
CTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGG
TCTTACATAGTGGAGAAGGCCAATCCAGTCAATGACCTCTGTTACCCA
GGGGATTTCAATGACTATGAAGAATTGAAACACCTATTGAGCAGAATA
AACCATTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCAGT
CATGAAGCCTCATTAGGGGTGAGCTCAGCATGTCCATACCAGGGAAAG
TCCTCCTTTTTCAGAAATGTGGTATGGCTTATCAAAAAGAACAGTACA
TACCCAACAATAAAGAGGAGCTACAATAATACCAACCAAGAAGATCTT
TTGGTACTGTGGGGGATTCACCATCCTAATGATGCGGCAGAGCAGACA
AAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACATCAACA
CTAAACCAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAAC
GGGCAAAGTGGAAGGATGGAGTTCTTCTGGACAATTTTAAAGCCGAAT
GATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATAT
GCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAA
TTGGAATATGGTAACTGCAACACCAAGTGTCAAACTCCAATGGGGGCG
ATAAACTCTAGCATGCCATTCCACAATATACACCCTCTCACCATTGGG
GAATGCCCCAAATATGTGAAATCAAACAGATTAGTCCTTGCGCACCAT
CACCATCACCATTGA
[0174] The mature H chain sequence for C87 heavy chain is shown
below. Joining sequence AS is bold and Flu HA5-1 is underlined.
TABLE-US-00019 (SEQ ID NO. 66)
QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWI
GDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSAVYFC
ATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASDTTEPATPTTPVTTDQICIGYHANNSTEQVDTIM
EKNVTVTHAQDILEKKHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCD
EFINVPEWSYIVEKANPVNDLCYPGDFNDYEELKHLLSRINHFEKIQI
IPKSSWSSHEASLGVSSACPYQGKSSFFRNVVWLIKKNSTYPTIKRSY
NNTNQEDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPR
IATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKG
DSTIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECPKYVKS NRLVLAHHHHHH
[0175] C88 rAB-pIRES2
[mAnti-Langerin15B10H-SLAML-V-hIgG4H-C-Dockerin] The coding region
for this H chain-dockerin fusion protein is shown below. Start and
stop codons are in bold, as is the joining GCTAGC restriction
site.
TABLE-US-00020 (SEQ ID NO. 67)
ATGGACCCCAAAGGCTCCCTTTCCTGGAGAATACTTCTGTTTCTCTCC
CTGGCTTTTGAGTTGTCGTACGGACAGGTTCAGCTGCGGCAGTCTGGA
CCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCT
TCTGGATACACATTTACTGACTATGTTATAAGTTGGGTGAAGCAGAGA
ACTGGACAGGGCCTTGAGTGGATTGGAGATATTTATCCTGGAAGTGGT
TATTCTTTCTACAATGAGAACTTCAAGGGCAAGGCCACACTGACTGCA
GACAAATCCTCCACCACAGCCTACATGCAGCTCAGCAGCCTGACATCT
GAGGACTCTGCGGTCTATTTCTGTGCAACCTACTATAACTACCCTTTT
GCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACA
ACGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCC
GAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCAC
ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC
GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG
TCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAA
GGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC
CAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAG
GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAC
GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC
AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTG
GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACC
GTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTG
ATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
TCTCTGGGTAAAGCTAGCAATTCTCCTCAAAATGAAGTACTGTACGGA
GATGTGAATGATGACGGAAAAGTAAACTCCACTGACTTGACTTTGTTA
AAAAGATATGTTCTTAAAGCCGTCTCAACTCTCCCTTCTTCCAAAGCT
GAAAAGAACGCAGATGTAAATCGTGACGGAAGAGTTAATTCCAGTGAT
GTCACAATACTTTCAAGATATTTGATAAGGGTAATCGAGAAATTACCA ATATAA
[0176] The mature H chain sequence for C88 heavy chain is shown
below. Joining sequence AS is bold and dockerin is shaded grey. A
flexible linker joining sequence is underlined.
TABLE-US-00021 (SEQ ID NO. 68)
QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWI
GDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSAVYFC
ATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPR
EEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHY
TQKSLSLSLGKASNSPQNEVLYGDVNDDGKVNSTDLTLLKRYVLKAVS
TLPSSKAEKNADVNRDGRVNSSDVTILSRYLIRVIEKLPI
[0177] C89
rAB-pIRES2[mAnti-Langerin15B10H-SLAML-V-hIgG4H-Flex-FluHA1-1-6x-
His] The coding region for this H chain-Flu HA1-1 fusion protein is
shown below. Start and stop codons are in bold, as is the joining
GCTAGC restriction site.
TABLE-US-00022 (SEQ ID NO. 69)
ATGGACCCCAAAGGCTCCCTTTCCTGGAGAATACTTCTGTTTCTCTCC
CTGGCTTTTGAGTTGTCGTACGGACAGGTTCAGCTGCGGCAGTCTGGA
CCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCT
TCTGGATACACATTTACTGACTATGTTATAAGTTGGGTGAAGCAGAGA
ACTGGACAGGGCCTTGAGTGGATTGGAGATATTTATCCTGGAAGTGGT
TATTCTTTCTACAATGAGAACTTCAAGGGCAAGGCCACACTGACTGCA
GACAAATCCTCCACCACAGCCTACATGCAGCTCAGCAGCCTGACATCT
GAGGACTCTGCGGTCTATTTCTGTGCAACCTACTATAACTACCCTTTT
GCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACA
ACGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCC
GAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCAC
ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC
GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG
TCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAA
GGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC
CAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAG
GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAC
GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC
AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTG
GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACC
GTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTG
ATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
TCTCTGGGTAAAGCTAGCGATACAACAGAACCTGCAACACCTACAACA
CCTGTAACAACAGACACAATATGTATAGGCTACCATGCGAACAATTCA
ACCGACACTGTTGACACAGTACTCGAGAAGAATGTGACAGTGACACAC
TCTGTTAACCTGCTCGAAGACAGCCACAACGGAAAACTATGTAGATTA
AAAGGAATAGCCCCACTACAATTGGGGAAATGTAACATCGCCGGATGG
CTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCATGG
TCCTACATTGTAGAAACACCAAACTCTGAGAATGGAATATGTTATCCA
GGAGATTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAGCTCAGTG
TCATCATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGGCCC
AACCACAACACAAACGGAGTAACGGCAGCATGCTCCCATGAGGGGAAA
AGCAGTTTTTACAGAAATTTGCTATGGCTGACGGAGAAGGAGGGCTCA
TACCCAAAGCTGAAAAATTCTTATGTGAACAAAAAAGGGAAAGAAGTC
CTTGTACTGTGGGGTATTCATCACCCGCCTAACAGTAAGGAACAACAG
AATCTCTATCAGAATGAAAATGCTTATGTCTCTGTAGTGACTTCAAAT
TATAACAGGAGATTTACCCCGGAAATAGCAGAAAGACCCAAAGTAAGA
GATCAAGCTGGGAGGATGAACTATTACTGGACCTTGCTAAAACCCGGA
GACACAATAATATTTGAGGCAAATGGAAATCTAATAGCACCAATGTAT
GCTTTCGCACTGAGTAGAGGCTTTGGGTCCGGCATCATCACCTCAAAC
GCATCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCTGGGAGCT
ATAAACAGCAGTCTCCCTTACCAGAATATACACCCAGTCACAATAGGA
GAGTGCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTCACCAT
CACCATCACCATTGA
[0178] The mature H chain sequence for C89 heavy chain is shown
below. Joining sequence AS is bold and Flu HA1-1 is underlined. A
flexible linker joining sequence is italicized.
TABLE-US-00023 (SEQ ID NO. 70)
QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWI
GDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSAVYFC
ATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASDTTEPATPTTPVTTDTICIGYHANNSTDTVDTVL
EKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECD
PLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEI
FPKESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSY
VNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVTSNYNRRFTPE
IAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRGF
GSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRS AKLRMVHHHHHH
[0179] C246
rAB-pIRES2[mAnti-Langerin15B10H-SLAML-V-hIgG4H-Viralgag] The coding
region for this H chain-gag fusion protein is shown below. Start
and stop codons are in bold, as is the joining GCTAGC restriction
site.
TABLE-US-00024 (SEQ ID NO. 71)
ATGGACCCCAAAGGCTCCCTTTCCTGGAGAATACTTCTGTTTCTCTCC
CTGGCTTTTGAGTTGTCGTACGGACAGGTTCAGCTGCGGCAGTCTGGA
CCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCT
TCTGGATACACATTTACTGACTATGTTATAAGTTGGGTGAAGCAGAGA
ACTGGACAGGGCCTTGAGTGGATTGGAGATATTTATCCTGGAAGTGGT
TATTCTTTCTACAATGAGAACTTCAAGGGCAAGGCCACACTGACTGCA
GACAAATCCTCCACCACAGCCTACATGCAGCTCAGCAGCCTGACATCT
GAGGACTCTGCGGTCTATTTCTGTGCAACCTACTATAACTACCCTTTT
GCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACA
ACGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCC
GAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCAC
ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC
GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAG
TCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAA
GGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGC
CAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAG
GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAC
GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCC
ATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC
AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTG
GAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACC
GTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTG
ATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
TCTCTGGGTAAAGCTAGCGACATGGCCAAGAAGGAGACAGTCTGGAGG
CTCGAGGAGTTCGGTAGGCCTATAGTGCAGAACATCCAGGGGCAAATG
GTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTA
GTAGAAGAGAAGGCTTTCAGCCCAGAAGTAATACCCATGTTTTCAGCA
TTATCAGAAGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACA
GTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAAT
GAGGAAGCTGCAGAATGGGATAGAGTACATCCAGTGCATGCAGGGCCT
ATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGA
ACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCA
CCTATCCCAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTA
AATAAAATAGTAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGA
CAAGGACCAAAAGAACCTTTTAGAGACTATGTAGACCGGTTCTATAAA
ACTCTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACA
GAAACCTTGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTTTA
AAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATGT
CAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGTGA
[0180] The mature H chain sequence for C89 heavy chain is shown
below. Joining sequence AS is bold and Gag p24 is underlined. A
flexible linker joining sequence is italicized.
TABLE-US-00025 (SEQ ID NO. 72)
QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWI
GDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSAVYFC
ATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASDMAKKETVWRLEEFGRPIVQNIQGQMVHQAISPR
TLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAM
QMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQ
IGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFR
DYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAAT
LEEMMTACQGVGGPGHKARVL
[0181] C742 rAB-cetHS-puro
[mAnti-Langerin-15B10H-LV-hIgG4H-C-Flex-hPSA] The coding region for
this H chain-PSA fusion protein is shown below. Start and stop
codons are in bold, as is the joining GCTAGC restriction site.
TABLE-US-00026 (SEQ ID NO. 73)
ATGGAATGGAGGATCTTTCTCTTCATCCTGTCAGGAACTGCAGGTGTC
CACTCCCAGGTTCAGCTGCGGCAGTCTGGACCTGAGCTGGTGAAGCCT
GGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACATTTACT
GACTATGTTATAAGTTGGGTGAAGCAGAGAACTGGACAGGGCCTTGAG
TGGATTGGAGATATTTATCCTGGAAGTGGTTATTCTTTCTACAATGAG
AACTTCAAGGGCAAGGCCACACTGACTGCAGACAAATCCTCCACCACA
GCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTAT
TTCTGTGCAACCTACTATAACTACCCTTTTGCTTACTGGGGCCAAGGG
ACTCTGGTCACTGTCTCTGCAGCCAAAACAACGGGCCCATCCGTCTTC
CCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTG
GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGG
AACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA
CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCC
AGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCA
TGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTC
CTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCT
GAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTC
CAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACA
AAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC
CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC
AGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCA
AAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCAT
CCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCA
AAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC
AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG
GCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGC
AGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCG
ATACAACAGAACCTGCAACACCTACAACACCTGTAACAACACCGACAA
CAACACTTCTAGCGCCCCTCATCCTGTCTCGGATTGTGGGAGGCTGGG
AGTGCGAGAAGCATTCCCAACCCTGGCAGGTGCTTGTGGCCTCTCGTG
GCAGGGCAGTCTGCGGCGGTGTTCTGGTGCACCCCCAGTGGGTCCTCA
CAGCTGCCCACTGCATCAGGAACAAAAGCGTGATCTTGCTGGGTCGGC
ACAGCCTGTTTCATCCTGAAGACACAGGCCAGGTATTTCAGGTCAGCC
ACAGCTTCCCACACCCGCTCTACGATATGAGCCTCCTGAAGAATCGAT
TCCTCAGGCCAGGTGATGACTCCAGCCACGACCTCATGCTGCTCCGCC
TGTCAGAGCCTGCCGAGCTCACGGATGCTGTGAAGGTCATGGACCTGC
CCACCCAGGAGCCAGCACTGGGGACCACCTGCTACGCCTCAGGCTGGG
GCAGCATTGAACCAGAGGAGTTCTTGACCCCAAAGAAACTTCAGTGTG
TGGACCTCCATGTTATTTCCAATGACGTGTGTGCGCAAGTTCACCCTC
AGAAGGTGACCAAGTTCATGCTGTGTGCTGGACGCTGGACAGGGGGCA
AAAGCACCTGCTCGGGTGATTCTGGGGGCCCACTTGTCTGTAATGGTG
TGCTTCAAGGTATCACGTCATGGGGCAGTGAACCATGTGCCCTGCCCG
AAAGGCCTTCCCTGTACACCAAGGTGGTGCATTACCGGAAGTGGATCA
AGGACACCATCGTGGCCAACCCCTGA
[0182] The mature H chain sequence for C742 heavy chain is shown
below. Joining sequence AS is bold and PSA is underlined. A
flexible linker joining sequence is italicized.
TABLE-US-00027 (SEQ ID NO. 74)
QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWI
GDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSAVYFC
ATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASDTTEPATPTTPVTTPTTTLLAPLILSRIVGGWEC
EKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILLGRHS
LFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLS
EPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVD
LHVISNDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVL
QGITSWGSEPCALPERPSLYTKVVHYRKWIKDTIVANP
[0183] C1011 rAB-cetHS-puro
[mAnti-Langerin15B10H-LV-hIgG4H-C-Flex-v1-Pep-gag17-f1-gag253-f2-nef116-f-
3-nef66-f4-pol 158] a.k.a. Anti-Langerin15B10H-HIPO5. The coding
region for this H chain-HIV peptides fusion protein is shown below.
Start and stop codons are in bold, as is the joining GCTAGT
restriction site.
TABLE-US-00028 (SEQ ID NO. 75)
ATGGAATGGAGGATCTTTCTCTTCATCCTGTCAGGAACTGCAGGTGTC
CACTCCCAGGTTCAGCTGCGGCAGTCTGGACCTGAGCTGGTGAAGCCT
GGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACATTTACT
GACTATGTTATAAGTTGGGTGAAGCAGAGAACTGGACAGGGCCTTGAG
TGGATTGGAGATATTTATCCTGGAAGTGGTTATTCTTTCTACAATGAG
AACTTCAAGGGCAAGGCCACACTGACTGCAGACAAATCCTCCACCACA
GCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTAT
TTCTGTGCAACCTACTATAACTACCCTTTTGCTTACTGGGGCCAAGGG
ACTCTGGTCACTGTCTCTGCAGCCAAAACAACGGGCCCATCCGTCTTC
CCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTG
GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGG
AACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA
CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC
AGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCC
AGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCA
TGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTC
CTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCT
GAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTC
CAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACA
AAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC
CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC
AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCC
AAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCA
TCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC
AAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC
GGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGG
CAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC
AACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGT
CAGACCCCCACCAACACCATCAGCGTGACCCCCACCAACAACAGCACC
CCCACCAACAACAGCAACCCCAAGCCCAACCCCGCTAGTGAGAAGATC
CGGCTGCGGCCCGGCGGCAAGAAGAAGTACAAGCTGAAGCACATCGTG
GCTAGTAGCAGCGTGAGCCCCACCACCAGCGTGCACCCCACCCCCACC
AGCGTGCCCCCCACCCCCACCAAGAGCAGCCCCGCTAGTAACCCCCCC
ATCCCCGTGGGCGAGATCTACAAGCGGTGGATCATCCTGGGCCTGAAC
AAGATCGTGCGGATGTACAGCCCCACCAGCATCCTGGACGCTAGTCCC
ACCAGCACCCCCGCCGACAGCAGCACCATCACCCCCACCGCCACCCCC
ACCGCCACCCCCACCATCAAGGGCGCTAGTCACACCCAGGGCTACTTC
CCCGACTGGCAGAACTACACCCCCGGCCCCGGCGTGCGGTACCCCCTG
ACCTTCGGCTGGCTGTACAAGCTGGCTAGTACCGTGACCCCCACCGCC
ACCGCCACCCCCAGCGCCATCGTGACCACCATCACCCCCACCGCCACC
ACCAAGCCCGCTAGTGTGGGCTTCCCCGTGACCCCCCAGGTGCCCCTG
CGGCCCATGACCTACAAGGCCGCCGTGGACCTGAGCCACTTCCTGAAG
GAGAAGGGCGGCCTGGCTAGTACCAACGGCAGCATCACCGTGGCCGCC
ACCGCCCCCACCGTGACCCCCACCGTGAACGCCACCCCCAGCGCCGCC
GCTAGTGCCATCTTCCAGAGCAGCATGACCAAGATCCTGGAGCCCTTC
CGGAAGCAGAACCCCGACATCGTGATCTACCAGTACATGGACGACCTG TACGCTAGCTGA
[0184] The mature H chain sequence for C1011 heavy chain is shown
below. Joining sequences AS are bold and HIV peptides are
underlined. A flexible linker joining sequence is italicized.
TABLE-US-00029 (SEQ ID NO. 76)
QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWI
GDIYPGSGYSFYNENFKGKATLTADKSSTTAYMQLSSLTSEDSAVYFC
ATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCSRSTSESTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKA
KGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNH
YTQKSLSLSLGKASQTPTNTISVTPTNNSTPTNNSNPKPNPASEKIRL
RPGGKKKYKLKHIVASSSVSPTTSVHPTPTSVPPTPTKSSPASNPPIP
VGEIYKRWIILGLNKIVRMYSPTSILDASPTSTPADSSTITPTATPTA
TPTIKGASHTQGYFPDWQNYTPGPGVRYPLTFGWLYKLASTVTPTATA
TPSAIVTTITPTATTKPASVGFPVTPQVPLRPMTYKAAVDLSHFLKEK
GGLASTNGSITVAATAPTVTPTVNATPSAAASAIFQSSMTKILEPFRK
QNPDIVIYQYMDDLYAS
[0185] FIG. 8 shows the binding of recombinant anti-Langerin
antibodies fused to antigens retain their ability to bind to beads
decorated with human and non-human primate (NHP) Langerin
ectodomain proteins. Luminex beads of different colors were
covalently linked to cellulose binding protein fused to dockerin.
The beads were then mixed with either human Langerin ectodomain
fused to cohesin, or with NHP (Rhesus macaque) Langerin ectodomain
fused to cohesin. The beads were washed and mixed, then incubated
with serial dilutions of various pure recombinant anti-Langerin 2G3
or 15B10 mouse V region-human IgG4 chimeric antibodies or the same
antibodies with C-terminal fusions to human prostate specific
antigen (PSA), or control pure recombinant anti-CD40 12E12 mouse V
region-human IgG4 chimeric antibody. After washing, the beads were
incubated with an anti-human Fc-PE reagent, washed again, and then
read on a BioPlex instrument to detect florescence bound to the
different colored beads (expressed as % MFI relative to the maximal
signal seen on each bead type.
[0186] FIG. 9 shows the ability of recombinant anti-Langerin 15B10
antibody fused to Influenza A Hemagglutinin HA-1 from a H1N1 Flu
strain to evoke potent antigen-specific antibody production in NHP.
NHP were injected intramuscularly (im) with 10E6 pr8 Flu virus and
subcutaneously (sc) HIV gag p24 protein (First boost); .about.2
months later the NHP were again injected with HIV gag p24 protein
(Second boost); about 6 weeks and 4 months later, the NHP were
injected intradermal (id) with 100 .mu.g anti-Langerin 15B10 HA1-1
fusion protein with poly IC as adjuvant, or with anti-DCIR HA1-1
fusion protein with poly IC, or with a standard dose of commercial
Vaccigrip Flu vaccine and 10E6 pr8 Flu virus. At the indicated
dates, serum samples were taken and pooled (4 NHP per group) and
serial dilutions were tested for HA1-1 specific IgG antibodies by a
baed-based assay. The data shows that the anti-Langerin-HA1-1
vaccine raises potent high titer anti-HA1-1 antibody responses in
NHP--the titers observed were 1-2 logs higher than observed with
the Vaccigrip control group.
[0187] These data show that both anti-Langerin 15B10 and 2G3
recombinant antibodies or such antibodies linked to a cancer
antigen retain significant binding to NHP Langerin--a very
desirable property for commercial development of these antibodies
as antigen-targeting vaccines [this enables mechanism-based
preclinical testing of safety and efficacy in NHP models].
[0188] FIG. 10 shows that recombinant fusion proteins of anti-human
DC receptors and antigens induce antigen-specific immune responses
in NHP: Rhesus macaques (4 animals in each group) immunized i.m.
with live influenza virus (A/PR8, H1N1) and HIVgag-derived p24-PLA
on day 0. On day 28, animals were boosted with p24-PLA alone. On
day 77 and day 119, each group of animals was immunized as
described in FIG. 18 (below). Anti-Langerin-HA1 response in Rhesus
macaque--IFN-.gamma. response measured by ELISPOT after ex vivo
stimulation with HA peptides. Red arrows indicate priming
injections with live influenza virus (A/PR8, H1N1). Blue arrows
indicate boost injections. Control group (4 animals) were immunized
i.m. with live influenza virus and commercial flu vaccine,
VACCIGRIP, with 100 ug poly I:C per animal. Experimental group (4
animals) were boosted i.d. with anti-DCIR-HA1 (100 .mu.g/animals)
with 100 .mu.g of poly I:C per animal. The data above show that
anti-Langerin-HA1 elicited potent HA1-specific T cells responses as
measured by IFN.gamma. ELISPOT.
[0189] FIG. 11 shows that the Anti-Langerin G3 antibody
specifically stains NHP Langerhans cells. Rhesus macaque skin
sections were prepared and stained with anti-Langerin 2G3 and then
Texas Red-labeled goat ant-mouse reagent. Cell nuclei were stained
with DAPI [blue]. This shows specific staining of NHP LC
demonstrating the specific cross-reactivity of this anti-human
Langerin antibody with NHP Langerin.
[0190] The 15B10.3 hydridoma has been deposited under the Budapest
Treaty with the U.S. American Type Culture Collection and received
Deposit No. PTA-9852; and the 2G3.6 hybridoma received Deposit No.
PTA-9853.
[0191] FIG. 12 shows the antibody titers for anti-HIV-gag
antibodies in NHP vaccination with a gag-microparticle, an
anti-hIGG4-gag antibody, an anti-DCIR-gag vaccine and an
anti-Langerin-gag-p24 vaccine, all with or without poly I:C as an
adjuvant. Briefly, non-human primates (NHP) were immunized and
anti-Langerin-gag24 antibody responses were determined. It was
found that more potent were possible with the anti-Langerin-gagp24
constructs than with gag p24 on a microcarrier or control
antibody-p24. Unlike anti-DCIR targeting, it was found that
anti-Langerin-Ag vaccination is relatively independent of poly I:C
adjuvant. Each curve is an individual monkey, the assay is serum
dilutions tested for antibodies against p24. Cynomolgus macaques
were injected i.d. with 250 ug of each antibody-HIV gag p24 vaccine
or gag p24 attached to a microcarrier (p24 amount was normalized to
correspond to the actual amount of p24 mass injected). The animals
were then injected twice more at 6 week intervals. The FIG. 12
graph shows represents ELISA assay for antigen-specific anti-gag
p24 titers of serum samples taken 2 weeks after the third
injection. FIG. 12 shows serial dilutions of the sera graphed for
each individual monkey [graph lines shown in blue]. A parallel
group of monkeys were co-injected with the p24 proteins and poly
I:C adjuvant [graph lines shown in red].
[0192] FIG. 13--FACS analysis on Langerin clones: 293F cells were
transiently transfected with vectors directing the expression of
full-length (cell surface) langerin from human, Rhesus macaque, and
mouse. Cells were stained with a dilution series of the pure
monoclonal antibodies, washed, then counterstained with an
anti-mouse IgG-PE conjugate, then washed again. Cells were analyzed
by flow cytometry. The data are expressed as % cells giving a
positive cell surface staining signal relative to the control
untransfected cells.
[0193] FIG. 14--ELISA analysis in two formats--direct (antigen
bound to plate directly and bound antibody detected with an
anti-mouse IgG-HRP conjugate) and capture (antibody bound to plate,
capturing a fixed concentration of biotinylated Langerin ectodomain
protein, detected with a neutravidin-HRP reagent). ELISA data for
human, Rhesus macaque, and mouse Langerin ectodomain proteins are
shown.
TABLE-US-00030 TABLE 1 Immunogenicity in cynomolgus macaques of
anti-Langerin- Gag and anti-DCIR-Gag fusion protein, for FIG. 12.
Group 1 (n = 6) 0.25 mg anti-Langerin-Gag Group 2 (n = 6) 0.25 mg
anti-Langerin-Gag + 0.25 mg PolyIC Group 3 (n = 6) 0.25 mg
anti-DCIR-Gag Group 4 (n = 6) 0.25 mg anti-DCIR-Gag + 0.25 mg
PolyIC Group 5 (n = 3) 0.25 mg IgG4-Gag Group 6 (n = 3) 0.25 mg
IgG4-Gag + 0.25 mg PolyIC Group 7 (n = 3) 0.0635 mg Gag Group 8 (n
= 3) 0.0635 mg Gag + 0.25 mg PolyIC Timepoints Blood (weeks) Micor-
Rectal post priming PBMC array Plasma Wash -3 X X X -2 X X X -1 X X
Vaccination 0 X X 2 X X X Vaccination 6 X X X 8 X X X X 10 X X
Vaccination 12 X X 13 X X X 14 X X X 15 X X X 16 X X X 18 X X X 22
X X X X
TABLE-US-00031 mAnti-Langerin 91E7K light chain sequence (SEQ ID
NO.: 51) ATGGATTTTCAGATGCAGATTATCAGCTTGCTGCTAATCAGTGTCACA
GTCATAGTGTCTAATGGAGAAATTGTGCTCACCCAGTCTCCAACCACC
ATGGCTGCATCTCCCGGGGAGAAGATCACTATCACCTGCAGTGCCAGC
TCAAGTATAAGTTCCCATTACTTACATTGGTATCAGCAGAAGCCAGGA
TTCTCCCCTAAACTCTTGATTTATAGGACATCCAATCTGGCTTCTGGA
GTCCCAGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTC
ACAATTGACACCATGGAGGCTGAAGATGTTGCCACTTACTACTGCCAG
CAGGGTAGTAGTATACCATTCACGTTCGGCTCGGGGACAAAGTTGGAA
ATAAAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCC
AGTGAGCAGTTAACATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAAC
AACTTCTACCCCAAAGACATCAATGTCAAGTGGAAGATTGATGGCAGT
GAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAGCAAA
GACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAG
TATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCA
ACTTCACCCATCGTCAAGAGCTTCAACAGGAATGAGTGTTAG mAnti-Langerin 91E7K
light chain sequence (SEQ ID NO.: 52)
EIVLTQSPTTMAASPGEKITITCSASSSISSHYLHWYQQKPGFSPKWY
RTSNLASGVPARFSGSGSGTSYSLTIDTMEAEDVATYYCQQGSSIPFT
FGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDIN
VKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYT
CEATHKTSTSPIVKSFNRNEC mAnti-Langerin 91E7H [mouse IgG2a] heavy
chain (SEQ ID NO.: 53)
ATGAGATCACTGTTCTCTTTACAGTTACTGAGCACACAGGACCTCGCC
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGT
GTCCACTCTCAGGTCCAACTGCAGCAGCCTGGGGCTGAACTTGTGAAG
CCTGGGGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTC
ACCAGTTACTGGATGCAGTGGGTAAAGCAGAGGCCTGGACAGGGCCTT
GAGTGGATCGGAGAGATTGATCCTTCTGATAGCTATACTAACTACAAT
CAAAGGTTCAAGGGCAAGGCCACATTGACTGTGGACACATCCTCCAGC
ACAGCCTACATACAGCTCAGCAGCCTGACGTCTGAGGACTCTGCGGTC
TGTTTCTGTGCAAGACGCTACTATGGTAACTACGATGGGTTTGCTTAC
TGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACAACAGCC
CCATCGGTCTATCCACTGGCCCCTGTGTGTGGAGGTACAACTGGCTCC
TCGGTGACTCTAGGATGCCTGGTCAAGGGTTATTTCCCTGAGCCAGTG
ACCTTGACCTGGAACTCTGGATCCCTGTCCAGTGGTGTGCACACCTTC
CCAGCTCTCCTGCAGTCTGGCCTCTACACCCTCAGCAGCTCAGTGACT
GTAACCTCGAACACCTGGCCCAGCCAGACCATCACCTGCAATGTGGCC
CACCCGGCAAGCAGCACCAAAGTGGACAAGAAAATTGAGCCCAGAGTG
CCCATAACACAGAACCCCTGTCCTCCACTCAAAGAGTGTCCCCCATGC
GCAGCTCCAGACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCA
AAGATCAAGGATGTACTCATGATCTCCCCGAGCCCCATGGTCACATGT
GTGGTGGTGGATGTGAGCGAGGATGACCCAGACGTCCAGATCAGCTGG
TTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGA
GAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAG
CACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAAC
AGAGCCCTCCCATCCCCCATCGAGAAAACCATCTCAAAACCCAGAGGG
CCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGCAGAAGAG
ATGACTAAGAAAGAGTTCAGTCTGACCTGCATGATCACAGGCTTCTTA
CCTGCCGAAATTGCTGTGGACTGGACCAGCAATGGGCGTACAGAGCAA
AACTACAAGAACACCGCAACAGTCCTGGACTCTGATGGTTCTTACTTC
ATGTACAGCAAGCTCAGAGTACAAAAGAGCACTTGGGAAAGAGGAAGT
CTTTTCGCCTGCTCAGTGGTCCACGAGGGTCTGCACAATCACCTTACG
ACTAAGACCATCTCCCGGTCTCTGGGTAAAGCTAGCTGA [GCTAGC in bold is for the
in-frame fusion of antigens at the H-chain C-terminus]
mAnti-Langerin 91E7H [mouse IgG2a] Mature H heavy chain sequence
(SEQ ID NO.: 54) QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLEWI
GEIDPSDSYTNYNQRFKGKATLTVDTSSSTAYIQLSSLTSEDSAVCFC
ARRYYGNYDGFAYWGQGTLVTVSAAKTTAPSVYPLAPVCGGTTGSSVT
LGCLVKGYFPEPVTLTWNSGSLSSGVHTFPALLQSGLYTLSSSVTVTS
NTWPSQTITCNVAHPASSTKVDKKIEPRVPITQNPCPPLKECPPCAAP
DLLGGPSVFIFPPKIKDVLMISPSPMVTCVVVDVSEDDPDVQISWFVN
NVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNRAL
PSPIEKTISKPRGPVRAPQVYVLPPPAEEMTKKEFSLTCMITGFLPAE
IAVDWTSNGRTEQNYKNTATVLDSDGSYFMYSKLRVQKSTWERGSLFA
CSVVHEGLHNHLTTKTISRSLGKAS mAnti-Langerin 37C1K light chain (SEQ ID
NO.: 55) ATGAGGGCCCCTGCTCAGTTTTTTGGGATCTTGTTGCTCTGGTTTCCA
GGTATCAGATGTGACATCAAGATGACCCAGTCTCCATCCTCCATGTAT
GCATCGCTGGGAGAGAGAGTCACTATTACTTGCAAGGCGAGTCAGGAC
ATTAAAAGCTATTTAACTTGGTACCAGCAGAAACCATGGAAATCTCCT
AAGACCCTGATCAATTATGCAACAAGCTTGGCAGATGGGGTCCCATCA
AGATTCAGTGGCAGTGGATCTGGACAAGATTATTCTCTAACCATCAGC
AGCCTGGAGTCTGACGATACAGCAACTTATTACTGTCTACAGCATGGT
CAGAGTCCGTTCACGTTCGGAGGGGGGACCAGGCTGGAGATAAAACGG
GCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAG
TTAACATCTGGAGGTGCCTCGGTCGTGTGCTTCTTGAACAACTTCTAC
CCCAAAGACATCAATGTCAAGTGGAAGATTGATGGCAGTGAACGACAA
AATGGCGTCCTGAACAGTTGGACTGATCAGGACAGCAAAGACAGCACC
TACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGAACGA
CATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCC
ATCGTCAAGAGCTTCAACAGGAATGAGTGTTAG mAnti-Langerin 37C1K light chain
(SEQ ID NO.: 56) DIKMTQSPSSMYASLGERVTITCKASQDIKSYLTWYQQKPWKSPKTLI
NYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGQSPF
TFGGGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDI
NVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSY
TCEATHKTSTSPIVKSFNRNEC mAnti-Langerin 37C1H [mouse IgG2a] heavy
chain (SEQ ID NO.: 57)
ATGAGATCACTGTTCTCTTTACAGTTACTGAGCACACAGGACCTCGCC
ATGGGATGGAGCTGTATCATCCTCTTCTTGGTAGCAACAGCTACAGGT
GTCCACTCTCAGGTCCAACTGCAGCAGCCTGGGGCTGAGCTTGTGAAG
CCTGGGGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTC
ACCAGTTACTGGATGCAGTGGGTAAAGCAGAGGCCTGGACAGGGCCTT
GAGTGGACCGGAGAGATTGATCCTTCTGATAGCTATACTAACTACAAT
CAAAGGTTCAAGGGCAAGGCCACATTGACTGTGGACACATCCTCCAGC
ACAGCCTACACACAGCTCAGCAGCCTGACGTCTGAGGACTCTGCGGTC
CATTTCTGTGCAAGACGCTACTATGGTAACTACGATGGGTTTGCTTAC
TGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACAACAGCC
CCATCGGTCTATCCACTGGCCCCTGTGTGTGGAGGTACAACTGGCTCC
TCGGTGACTCTAGGATGCCTGGTCAAGGGTTATTTCCCTGAGCCAGTG
ACCTTGACCTGGAACTCTGGATCCCTGTCCAGTGGTGTGCACACCTTC
CCAGCTCTCCTGCAGTCTGGCCTCTACACCCTCAGCAGCTCAGTGACT
GTAACCTCGAACACCTGGCCCAGCCAGACCATCACCTGCAATGTGGCC
CACCCGGCAAGCAGCACCAAAGTGGACAAGAAAATTGAGCCCAGAGTG
CCCATAACACAGAACCCCTGTCCTCCACTCAAAGAGTGTCCCCCATGC
GCAGCTCCAGACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCA
AAGGTCAAGGATGTACTCATGATCTCCCTGAGCCCCATGGTCACATGT
GTGGTGGTGGATGTGAGCGAGGATGACCCAGACGTCCAGATCAGCTGG
TTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGA
GAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAG
CACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAAC
AGAGCCCTCCCATCCCCCATCGAGAAAACCATCTCAAAACCCAGAGGG
CCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGCAGAAGAG
ATGACTAAGAAAGAGTTCAGTCTGACCTGCATGATCACAGGCTTCTTA
CCTGCCGAAATTGCTGTGGACTGGACCAGCAATGGGCGTACAGAGCAA
AACTACAAGAACACCGCAACAGTCCTGGACTCTGATGGTTCTTACTTC
ATGTACAGCAAGCTCAGAGTACAAAAGAGCACTTGGGAAAGAGGAAGT
CTTTTCGCCTGCTCAGTGGTCCACGAGGGTCTGCACAATCACCTTACG
ACTAAGACCATCTCCCGGTCTCTGGGTAAAGCTAGCTGA mAnti-Langerin 37C1H [mouse
IgG2a] heavy chain (SEQ ID NO.: 58)
QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLEWT
GEIDPSDSYTNYNQRFKGKATLTVDTSSSTAYTQLSSLTSEDSAVHFC
ARRYYGNYDGFAYWGQGTLVTVSAAKTTAPSVYPLAPVCGGTTGSSVT
LGCLVKGYFPEPVTLTWNSGSLSSGVHTFPALLQSGLYTLSSSVTVTS
NTWPSQTITCNVAHPASSTKVDKKIEPRVPITQNPCPPLKECPPCAAP
DLLGGPSVFIFPPKVKDVLMISLSPMVTCVVVDVSEDDPDVQISWFVN
NVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNRAL
PSPIEKTISKPRGPVRAPQVYVLPPPAEEMTKKEFSLTCMITGFLPAE
IAVDWTSNGRTEQNYKNTATVLDSDGSYFMYSKLRVQKSTWERGSLFA
CSVVHEGLHNHLTTKTISRSLGKAS mAnti-Langerin 4C7K (light chain) (SEQ ID
NO.: 77) ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCTTCA
GTCATAATGTCCAGAGGACAAATTGTTCTCTCCCAGTCTCCAGCAATC
CTGTCTGCATCTCCAGGGGAGAAGGTCACAATGACTTGCAGGGCCAGC
TCAAGTGTAAGTTACATGCACTGGTACCAGCGGAAGCCAGGATCCTCC
CCCAAACCCTGGATTTATGCCACATCCAACCTGGCTTCTGGAGTCCCT
GCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTATTCTCTCACAATC
AGCAGAGTGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTGG
AGTAGTAACCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA
CGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAG
CAGTTAACATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTC
TACCCCAAAGACATCAATGTCAAGTGGAAGATTGATGGCAGTGAACGA
CAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAGCAAAGACAGC
ACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGAA
CGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCA
CCCATCGTCAAGAGCTTCAACAGGAATGAGTGTTAG (SEQ ID NO.: 78)
QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQRKPGSSPKPWIY
ATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLT
FGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDIN
VKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYT
CEATHKTSTSPIVKSFNRNEC mAnti-Langerin 4C7H [mouse IgG2a] Heavy Chain
(SEQ ID NO.: 79) ATGGAATGGAGCTGGGTCTTTCTCTTCCTCCTGTCAGTAATTGCAGGT
GTCCAATCCCAGGTTCAGCTGCAGCAGTCTGGGGCTGAGCTGGTGAGG
CCTGGGGCTTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACACATTT
ATTGACCATGATATGCACTGGGTGCAGCAGACACCTGTGTATGGCCTG
GAATGGATCGGAGCTATTGATCCTGAAACTGGTGATACTGGCTACAAT
CAGAAGTTCAAGGGCAAGGCCATACTGACTGCAGACAAATCCTCCAGG
ACAGCCTACATGGAACTCCGCAGCCTGACATCTGAGGACTCTGCCGTC
TATTACTGTACAATCCCCTTCTACTATAGTAACTACAGCCCGTTTGCT
TACTGGGGCCAAGGGGCTCTGGTCACTGTCTCTGCAGCCAAAACAACA
GCCCCATCGGTCTATCCACTGGCCCCTGTGTGTGGAGGTACAACTGGC
TCCTCGGTGACTCTAGGATGCCTGGTCAAGGGTTATTTCCCTGAGCCA
GTGACCTTGACCTGGAACTCTGGATCCCTGTCCAGTGGTGTGCACACC
TTCCCAGCTCTCCTGCAGTCTGGCCTCTACACCCTCAGCAGCTCAGTG
ACTGTAACCTCGAACACCTGGCCCAGCCAGACCATCACCTGCAATGTG
GCCCACCCGGCAAGCAGCACCAAAGTGGACAAGAAAATTGAGCCCAGA
GTGCCCATAACACAGAACCCCTGTCCTCCACTCAAAGAGTGTCCCCCA
TGCGCAGACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAG
ATCAAGGATGTACTCATGATCTCCCTGAGCCCCATGGTCACATGTGTG
GTGGTGGATGTGAGCGAGGATGACCCAGACGCCCAGATCAGCTGGTTT
GTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAG
GATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCAC
CAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAGA
GCCCTCCCATCCCCCATCGAGAAAACCATCTCAAAACCCAGAGGGCCA
GTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGCAGAAGAGATG
ACTAAGAAAGAGTTCAGTCTGACCTGCATGATCACAGGCTTCTTACCT
GCCGAAATTGCTGTGGACTGGACCAGCAATGGGCGTACAGAGCAAAAC
TACAAGAACACCGCAACAGTCCTGGACTCTGATGGTTCTTACTTCATG
TACAGCAAGCTCAGAGTACAAAAGAGCACTTGGGAAAGAGGAAGTCTT
TTCGCCTGCTCAGTGGTCCACGAGGGTCTGCACAATCACCTTACGACT
AAGACCATCTCCCGGTCTCTGGGTAAAGCTAGCTGA mAnti-Langerin 4C7H [mouse
IgG2a] Heavy Chain (SEQ ID NO.: 80)
QVQLQQSGAELVRPGASVTLSCKASGYTFIDHDMHWVQQTPVYGLEWI
GAIDPETGDTGYNQKFKGKAILTADKSSRTAYMELRSLTSEDSAVYYC
TIPFYYSNYSPFAYWGQGALVTVSAAKTTAPSVYPLAPVCGGTTGSSV
TLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPALLQSGLYTLSSSVTVT
SNTWPSQTITCNVAHPASSTKVDKKIEPRVPITQNPCPPLKECPPCAD
LLGGPSVFIFPPKIKDVLMISLSPMVTCVVVDVSEDDPDAQISWFVNN
VEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNRALP
SPIEKTISKPRGPVRAPQVYVLPPPAEEMTKKEFSLTCMITGFLPAEI
AVDWTSNGRTEQNYKNTATVLDSDGSYFMYSKLRVQKSTWERGSLFAC
SVVHEGLHNHLTTKTISRSLGKAS
[0194] It is contemplated that any embodiment discussed in this
specification can be implemented with respect to any method, kit,
reagent, or composition of the invention, and vice versa.
Furthermore, compositions of the invention can be used to achieve
methods of the invention.
[0195] It will be understood that particular embodiments described
herein are shown by way of illustration and not as limitations of
the invention. The principal features of this invention can be
employed in various embodiments without departing from the scope of
the invention. Those skilled in the art will recognize, or be able
to ascertain using no more than routine experimentation, numerous
equivalents to the specific procedures described herein. Such
equivalents are considered to be within the scope of this invention
and are covered by the claims.
[0196] All publications and patent applications mentioned in the
specification are indicative of the level of skill of those skilled
in the art to which this invention pertains. All publications and
patent applications are herein incorporated by reference to the
same extent as if each individual publication or patent application
was specifically and individually indicated to be incorporated by
reference.
[0197] The use of the word "a" or "an" when used in conjunction
with the term "comprising" in the claims and/or the specification
may mean "one," but it is also consistent with the meaning of "one
or more," "at least one," and "one or more than one." The use of
the term "or" in the claims is used to mean "and/or" unless
explicitly indicated to refer to alternatives only or the
alternatives are mutually exclusive, although the disclosure
supports a definition that refers to only alternatives and
"and/or." Throughout this application, the term "about" is used to
indicate that a value includes the inherent variation of error for
the device, the method being employed to determine the value, or
the variation that exists among the study subjects.
[0198] As used in this specification and claim(s), the words
"comprising" (and any form of comprising, such as "comprise" and
"comprises"), "having" (and any form of having, such as "have" and
"has"), "including" (and any form of including, such as "includes"
and "include") or "containing" (and any form of containing, such as
"contains" and "contain") are inclusive or open-ended and do not
exclude additional, unrecited elements or method steps. As used
herein, the phrase "consisting essentially of" limits the scope of
a claim to the specified materials or steps and those that do not
materially affect the basic and novel characteristic(s) of the
claimed invention. As used herein, the phrase "consisting of"
excludes any element, step, or ingredient not specified in the
claim except for, e.g., impurities ordinarily associated with the
element or limitation.
[0199] The term "or combinations thereof" as used herein refers to
all permutations and combinations of the listed items preceding the
term. For example, "A, B, C, or combinations thereof" is intended
to include at least one of: A, B, C, AB, AC, BC, or ABC, and if
order is important in a particular context, also BA, CA, CB, CBA,
BCA, ACB, BAC, or CAB. Continuing with this example, expressly
included are combinations that contain repeats of one or more item
or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so
forth. The skilled artisan will understand that typically there is
no limit on the number of items or terms in any combination, unless
otherwise apparent from the context.
[0200] As used herein, words of approximation such as, without
limitation, "about", "substantial" or "substantially" refers to a
condition that when so modified is understood to not necessarily be
absolute or perfect but would be considered close enough to those
of ordinary skill in the art to warrant designating the condition
as being present. The extent to which the description may vary will
depend on how great a change can be instituted and still have one
of ordinary skilled in the art recognize the modified feature as
still having the required characteristics and capabilities of the
unmodified feature. In general, but subject to the preceding
discussion, a numerical value herein that is modified by a word of
approximation such as "about" may vary from the stated value by at
least.+-.1, 2, 3, 4, 5, 6, 7, 10, 12 or 15%.
[0201] All of the compositions and/or methods disclosed and claimed
herein can be made and executed without undue experimentation in
light of the present disclosure. While the compositions and methods
of this invention have been described in terms of preferred
embodiments, it will be apparent to those of skill in the art that
variations may be applied to the compositions and/or methods and in
the steps or in the sequence of steps of the method described
herein without departing from the concept, spirit and scope of the
invention. All such similar substitutes and modifications apparent
to those skilled in the art are deemed to be within the spirit,
scope and concept of the invention as defined by the appended
claims.
REFERENCES
[0202] 1. Banchereau J, Steinman R M. Dendritic cells and the
control of immunity. Nature. 1998; 392:245-252. [0203] 2. Pascual
V, Banchereau J, Palucka A. The Central Role of Dendritic Cells and
Interferon-alpha in SLE. Curr Opin Rheumatol. 2003;in press. [0204]
3. Palucka K, Banchereau J. Dendritic cells: a link between innate
and adaptive immunity. J Clin Immunol. 1999; 19:12-25. [0205] 4. Di
Pucchio T, Chatterjee B, Smed-Sorensen A, et al. Direct
proteasome-independent cross-presentation of viral antigen by
plasmacytoid dendritic cells on major histocompatibility complex
class I. Nat. Immunol. 2008; 9:551-557. [0206] 5. Kadowaki N,
Antonenko S, Lau J Y, Liu Y J. Natural interferon
alpha/beta-producing cells link innate and adaptive immunity. J Exp
Med. 2000; 192:219-226. [0207] 6. Fonteneau J F, Gilliet M, Larsson
M, et al. Activation of influenza virus-specific CD4+ and CD8+T
cells: a new role for plasmacytoid dendritic cells in adaptive
immunity. Blood. 2003; 101:3520-3526. [0208] 7. Randolph G J,
Beaulieu S, Lebecque S, Steinman R M, Muller W A. Differentiation
of monocytes into dendritic cells in a model of transendothelial
trafficking Science. 1998; 282:480-483. [0209] 8. Chomarat P,
Dantin C, Bennett L, Banchereau J, Palucka A K. TNF skews monocyte
differentiation from macrophages to dendritic cells. J. Immunol.
2003; 171:2262-2269. [0210] 9. Romani N, Gruner S, Brang D, et al.
Proliferating dendritic cell progenitors in human blood. J Exp Med.
1994; 180:83-93. [0211] 10. Sallusto F, Lanzavecchia A. Efficient
presentation of soluble antigen by cultured human dendritic cells
is maintained by granulocyte/macrophage colony-stimulating factor
plus interleukin 4 and downregulated by tumor necrosis factor a.
JExpMed. 1994; 179:1109-1118. [0212] 11. Peters J H, Xu H, Ruppert
J, Ostermeier D, Friedrichs D, Gieseler R K. Signals required for
differentiating dendritic cells from human monocytes in vitro. Adv
Exp Med. Biol. 1993; 329:275-280. [0213] 12. Paquette R L, Hsu N C,
Kiertscher S M, et al. Interferon-alpha and granulocyte-macrophage
colony-stimulating factor differentiate peripheral blood monocytes
into potent antigen-presenting cells. J Leukoc Biol. 1998;
64:358-367. [0214] 13. Luft T, Jefford M, Luetjens P, et al.
Functionally distinct dendritic cell (DC) populations induced by
physiologic stimuli: prostaglandin E(2) regulates the migratory
capacity of specific DC subsets. Blood. 2002; 100:1362-1372. [0215]
14. He B, Xu W, Santini P A, et al. Intestinal bacteria trigger T
cell-independent immunoglobulin A(2) class switching by inducing
epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;
26:812-826. [0216] 15. Blanco P, Palucka A K, Gill M, Pascual V,
Banchereau J. Induction of dendritic cell differentiation by
IFN-alpha in systemic lupus erythematosus. Science. 2001;
294:1540-1543. [0217] 16. Mohamadzadeh M, Berard F, Essert G, et
al. Interleukin 15 skews monocyte differentiation into dendritic
cells with features of Langerhans cells. J Exp Med. 2001;
194:1013-1020. [0218] 17. Caux C, Massacrier C, Vanbervliet B, et
al. CD34+ hematopoietic progenitors from human cord blood
differentiate along two independent dendritic cell pathways in
response to granulocyte-macrophage colony-stimulating factor plus
tumor necrosis factor alpha: II. Functional analysis. Blood. 1997;
90:1458-1470. [0219] 18. Caux C, Vanbervliet B, Massacrier C, et
al. CD34+ hematopoietic progenitors from human cord blood
differentiate along two independent dendritic cell pathways in
response to GM-CSF+TNF alpha. J Exp Med. 1996; 184:695-706. [0220]
19. Seifert U, Maranon C, Shmueli A, et al. An essential role for
tripeptidyl peptidase in the generation of an MHC class I epitope.
Nat. Immunol. 2003; 4:375-379. [0221] 20. Dudziak D, Kamphorst A O,
Heidkamp G F, et al. Differential antigen processing by dendritic
cell subsets in vivo. Science. 2007; 315:107-111. [0222] 21.
Shortman K, Liu Y J. Mouse and human dendritic cell subtypes.
Nature Rev Immunol. 2002; 2:151-161. [0223] 22. Maldonado-Lopez R,
De Smedt T, Michel P, et al. CD8alpha+ and CD8alpha-subclasses of
dendritic cells direct the development of distinct T helper cells
in vivo. J Exp Med. 1999; 189:587-592. [0224] 23. Pulendran B,
Smith J L, Caspary G, et al. Distinct dendritic cell subsets
differentially regulate the class of immune response in vivo. Proc
Natl Acad Sci. 1999; 96:1036-1041. [0225] 24. Pulendran B, Kumar P,
Cutler C W, Mohamadzadeh M, Van Dyke T, Banchereau J.
Lipopolysaccharides from distinct pathogens induce different
classes of immune responses in vivo. J. Immunol. 2001;
167:5067-5076. [0226] 25. Rissoan M C, Soumelis V, Kadowaki N, et
al. Reciprocal control of T helper cell and dendritic cell
differentiation. Science. 1999; 283:1183-1186.
Sequence CWU 1
1
8011395DNAArtificial SequenceSynthetic oligonucleotide. 1atggaatgga
ggatctttct cttcatcctg tcaggaactg caggtgtcca ctcccaggtt 60cagctgcggc
agtctggacc tgagctggtg aagcctgggg cttcagtgaa gatgtcctgc
120aaggcttctg gatacacatt tactgactat gttataagtt gggtgaagca
gagaactgga 180cagggccttg agtggattgg agatatttat cctggaagtg
gttattcttt ctacaatgag 240aacttcaagg gcaaggccac actgactgca
gacaaatcct ccaccacagc ctacatgcag 300ctcagcagcc tgacatctga
ggactctgcg gtctatttct gtgcaaccta ctataactac 360ccttttgctt
actggggcca agggactctg gtcactgtct ctgcagccaa aacaacgggc
420ccatccgtct tccccctggc gccctgctcc aggagcacct ccgagagcac
agccgccctg 480ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg
tgtcgtggaa ctcaggcgcc 540ctgaccagcg gcgtgcacac cttcccggct
gtcctacagt cctcaggact ctactccctc 600agcagcgtgg tgaccgtgcc
ctccagcagc ttgggcacga agacctacac ctgcaacgta 660gatcacaagc
ccagcaacac caaggtggac aagagagttg agtccaaata tggtccccca
720tgcccaccct gcccagcacc tgagttcgaa gggggaccat cagtcttcct
gttcccccca 780aaacccaagg acactctcat gatctcccgg acccctgagg
tcacgtgcgt ggtggtggac 840gtgagccagg aagaccccga ggtccagttc
aactggtacg tggatggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaac ggcaaggagt acaagtgcaa ggtctccaac
1020aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggca
gccccgagag 1080ccacaggtgt acaccctgcc cccatcccag gaggagatga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctaccccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
ggctaaccgt ggacaagagc aggtggcagg aggggaatgt cttctcatgc
1320tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc
cctgtctctg 1380ggtaaagcta gctga 13952446PRTArtificial
SequenceSynthetic peptide. 2Gln Val Gln Leu Arg Gln Ser Gly Pro Glu
Leu Val Lys Pro Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Asp Tyr 20 25 30Val Ile Ser Trp Val Lys Gln Arg
Thr Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Pro Gly Ser
Gly Tyr Ser Phe Tyr Asn Glu Asn Phe 50 55 60Lys Gly Lys Ala Thr Leu
Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu Ser
Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Thr Tyr
Tyr Asn Tyr Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val
Thr Val Ser Ala Ala Lys Thr Thr Gly Pro Ser Val Phe Pro Leu 115 120
125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
130 135 140Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
Asn Ser145 150 155 160Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
Ala Val Leu Gln Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser Ser Val
Val Thr Val Pro Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr Tyr Thr
Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205Thr Lys Val Asp Lys
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro Cys Pro
Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe225 230 235
240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val
Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly Leu
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly Gln
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350Glu
Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360
365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser385 390 395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys
Ser Arg Trp Gln Glu 405 410 415Gly Asn Val Phe Ser Cys Ser Val Met
His Glu Ala Leu His Asn His 420 425 430Tyr Thr Gln Lys Ser Leu Ser
Leu Ser Leu Gly Lys Ala Ser 435 440 4453705DNAArtificial
SequenceSyntehtic oligonucleotide. 3atggcctgga tttcacttat
actctctctc ctggctctca gctcaggggc catttcccag 60gctgttgtga ctcaggaatc
tgcactcacc acatcacctg gtgaaacagt cacactcact 120tgtcgctcaa
gtactggggc tgttacaact agtaactatg ccaactgggt ccaagaaaaa
180ccagatcatt tattcactgg tctaataggt ggtaccaaca accgagtttc
aggtgttcct 240gccagattct caggctccct gattggagac aaggctgccc
tcaccatcac aggggcacag 300actgaggatg aggcaatata tttctgtgct
ctatggtaca gcaaccattg ggtgttcggt 360ggaggaacca aactgactgt
cctaggccag cccaagtctt cgccatcagt caccctgttt 420ccaccttcct
ctgaagagct cgagactaac aaggccacac tggtgtgtac gatcactgat
480ttctacccag gtgtggtgac agtggactgg aaggtagatg gtacccctgt
cactcagggt 540atggagacaa cccagccttc caaacagagc aacaacaagt
acatggctag cagctacctg 600accctgacag caagagcatg ggaaaggcat
agcagttaca gctgccaggt cactcatgaa 660ggtcacactg tggagaagag
tttgtcccgt gctgactgtt cctag 7054215PRTArtificial SequenceSynthetic
peptide. 4Gln Ala Val Val Thr Gln Glu Ser Ala Leu Thr Thr Ser Pro
Gly Glu1 5 10 15Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val
Thr Thr Ser 20 25 30Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Asp His
Leu Phe Thr Gly 35 40 45Leu Ile Gly Gly Thr Asn Asn Arg Val Ser Gly
Val Pro Ala Arg Phe 50 55 60Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala
Leu Thr Ile Thr Gly Ala65 70 75 80Gln Thr Glu Asp Glu Ala Ile Tyr
Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95His Trp Val Phe Gly Gly Gly
Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110Lys Ser Ser Pro Ser
Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125Glu Thr Asn
Lys Ala Thr Leu Val Cys Thr Ile Thr Asp Phe Tyr Pro 130 135 140Gly
Val Val Thr Val Asp Trp Lys Val Asp Gly Thr Pro Val Thr Gln145 150
155 160Gly Met Glu Thr Thr Gln Pro Ser Lys Gln Ser Asn Asn Lys Tyr
Met 165 170 175Ala Ser Ser Tyr Leu Thr Leu Thr Ala Arg Ala Trp Glu
Arg His Ser 180 185 190Ser Tyr Ser Cys Gln Val Thr His Glu Gly His
Thr Val Glu Lys Ser 195 200 205Leu Ser Arg Ala Asp Cys Ser 210
21551401DNAArtificial SequenceSynthetic oligonucleotide.
5atgacattga acatgctgtt ggggctgaag tgggttttct ttgttgtttt ttatcaaggt
60gtgcattgtg aggtgcagct tgttgagtct ggtggaggat tggtgcagcc taaagggtca
120ttgaaactct catgtgcagc ctctggatta accttcaata tctacgccat
gaactgggtc 180cgccaggctc caggaaaggg tttggaatgg gttgctcgca
taagaaataa aagtaataat 240tatgcaacat attatgccga ttcagtgaaa
gacaggttca ccatctccag agatgattca 300caaagcttgc tctatctgca
aatgaacaac ttgaaaactg aggacacagc catgtattac 360tgtgtgggac
gggactggtt tgattactgg ggccaaggga ctctggtcac tgtctctgca
420gccaaaacga cacccccatc tgtctatcca ctggcccctg gatctgctgc
ccaaactaac 480tccatggtga ccctgggatg cctggtcaag ggctatttcc
ctgagccagt gacagtgacc 540tggaactctg gatccctgtc cagcggtgtg
cacaccttcc cagctgtcct gcagtctgac 600ctctacactc tgagcagctc
agtgactgtc ccctccagca cctggcccag cgagaccgtc 660acctgcaacg
ttgcccaccc ggccagcagc accaaggtgg acaagaaaat tgtgcccagg
720gattgtggtt gtaagccttg catatgtaca gtcccagaag tatcatctgt
cttcatcttc 780cccccaaagc ccaaggatgt gctcaccatt actctgactc
ctaaggtcac gtgtgttgtg 840gtagacatca gcaaggatga tcccgaggtc
cagttcagct ggtttgtaga tgatgtggag 900gtgcacacag ctcagacgca
accccgggag gagcagttca acagcacttt ccgctcagtc 960agtgaacttc
ccatcatgca ccaggactgg ctcaatggca aggagttcaa atgcagggtc
1020aacagtgcag ctttccctgc ccccatcgag aaaaccatct ccaaaaccaa
aggcagaccg 1080aaggctccac aggtgtacac cattccacct cccaaggagc
agatggccaa ggataaagtc 1140agtctgacct gcatgataac agacttcttc
cctgaagaca ttactgtgga gtggcagtgg 1200aatgggcagc cagcggagaa
ctacaagaac actcagccca tcatggacac agatggctct 1260tacttcgtct
acagcaagct caatgtgcag aagagcaact gggaggcagg aaatactttc
1320acctgctctg tgttacatga gggcctgcac aaccaccata ctgagaagag
cctctcccac 1380tctcctggta aagctagctg a 14016443PRTArtificial
SequenceSynthetic peptide. 6Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Lys Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser
Gly Leu Thr Phe Asn Ile Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Arg Asn Lys Ser
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60Ser Val Lys Asp Arg Phe
Thr Ile Ser Arg Asp Asp Ser Gln Ser Leu65 70 75 80Leu Tyr Leu Gln
Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr 85 90 95Tyr Cys Val
Gly Arg Asp Trp Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val
Thr Val Ser Ala Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu 115 120
125Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys
130 135 140Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp
Asn Ser145 150 155 160Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro
Ala Val Leu Gln Ser 165 170 175Asp Leu Tyr Thr Leu Ser Ser Ser Val
Thr Val Pro Ser Ser Thr Trp 180 185 190Pro Ser Glu Thr Val Thr Cys
Asn Val Ala His Pro Ala Ser Ser Thr 195 200 205Lys Val Asp Lys Lys
Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys 210 215 220Ile Cys Thr
Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys225 230 235
240Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val
245 250 255Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser
Trp Phe 260 265 270Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln
Pro Arg Glu Glu 275 280 285Gln Phe Asn Ser Thr Phe Arg Ser Val Ser
Glu Leu Pro Ile Met His 290 295 300Gln Asp Trp Leu Asn Gly Lys Glu
Phe Lys Cys Arg Val Asn Ser Ala305 310 315 320Ala Phe Pro Ala Pro
Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg 325 330 335Pro Lys Ala
Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met 340 345 350Ala
Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro 355 360
365Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn
370 375 380Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr
Phe Val385 390 395 400Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp
Glu Ala Gly Asn Thr 405 410 415Phe Thr Cys Ser Val Leu His Glu Gly
Leu His Asn His His Thr Glu 420 425 430Lys Ser Leu Ser His Ser Pro
Gly Lys Ala Ser 435 44071635DNAArtificial SequenceSyntehtic
oligonucleotide. 7atgacattga acatgctgtt ggggctgagg tgggttttct
ttgttgtttt ttatcaaggt 60gtgcattgtg aggtgcagct tgttgagtct ggtggaggat
tggtgcagcc taaagggtca 120ttgaaactct catgtgcagc ctctggatta
accttcaata tctacgccat gaactgggtc 180cgccaggctc caggaaaggg
tttggaatgg gttgctcgca taagaaataa aagtaataat 240tatgcaacat
attatgccga ttcagtgaaa gacaggttca ccatctccag agatgattca
300caaagcttgc tctatctgca aatgaacaac ttgaaaactg aggacacagc
catgtattac 360tgtgtgggac gggactggtt tgattactgg ggccaaggga
ctctggtcac tgtctctgca 420gccaaaacga agggcccatc cgtcttcccc
ctggcgccct gctccaggag cacctccgag 480agcacagccg ccctgggctg
cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 540tggaactcag
gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca
600ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg
cacgaagacc 660tacacctgca acgtagatca caagcccagc aacaccaagg
tggacaagag agttgagtcc 720aaatatggtc ccccatgccc accctgccca
gcacctgagt tcgaaggggg accatcagtc 780ttcctgttcc ccccaaaacc
caaggacact ctcatgatct cccggacccc tgaggtcacg 840tgcgtggtgg
tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat
900ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa
cagcacgtac 960cgtgtggtca gcgtcctcac cgtcctgcac caggactggc
tgaacggcaa ggagtacaag 1020tgcaaggtct ccaacaaagg cctcccgtcc
tccatcgaga aaaccatctc caaagccaaa 1080gggcagcccc gagagccaca
ggtgtacacc ctgcccccat cccaggagga gatgaccaag 1140aaccaggtca
gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag
1200tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gctggactcc 1260gacggctcct tcttcctcta cagcaggcta accgtggaca
agagcaggtg gcaggagggg 1320aatgtcttct catgctccgt gatgcatgag
gctctgcaca accactacac acagaagagc 1380ctctccctgt ctctgggtaa
agctagcaat tctcctcaaa atgaagtact gtacggagat 1440gtgaatgatg
acggaaaagt aaactccact gacttgactt tgttaaaaag atatgttctt
1500aaagccgtct caactctccc ttcttccaaa gctgaaaaga acgcagatgt
aaatcgtgac 1560ggaagagtta attccagtga tgtcacaata ctttcaagat
atttgataag ggtaatcgag 1620aaattaccaa tataa 16358521PRTArtificial
SequenceSynthetic peptide. 8Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Lys Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser
Gly Leu Thr Phe Asn Ile Tyr 20 25 30Ala Met Asn Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Arg Asn Lys Ser
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60Ser Val Lys Asp Arg Phe
Thr Ile Ser Arg Asp Asp Ser Gln Ser Leu65 70 75 80Leu Tyr Leu Gln
Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr 85 90 95Tyr Cys Val
Gly Arg Asp Trp Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val
Thr Val Ser Ala Ala Lys Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120
125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
130 135 140Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
Asn Ser145 150 155 160Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
Ala Val Leu Gln Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser Ser Val
Val Thr Val Pro Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr Tyr Thr
Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205Thr Lys Val Asp Lys
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro Cys Pro
Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe225 230 235
240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val
Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly Leu
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly Gln
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350Glu
Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360
365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser385 390 395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys
Ser Arg Trp Gln Glu 405 410 415Gly Asn Val Phe Ser Cys Ser Val Met
His Glu Ala Leu His Asn His 420 425 430Tyr Thr Gln Lys Ser Leu Ser
Leu Ser Leu
Gly Lys Ala Ser Asn Ser 435 440 445Pro Gln Asn Glu Val Leu Tyr Gly
Asp Val Asn Asp Asp Gly Lys Val 450 455 460Asn Ser Thr Asp Leu Thr
Leu Leu Lys Arg Tyr Val Leu Lys Ala Val465 470 475 480Ser Thr Leu
Pro Ser Ser Lys Ala Glu Lys Asn Ala Asp Val Asn Arg 485 490 495Asp
Gly Arg Val Asn Ser Ser Asp Val Thr Ile Leu Ser Arg Tyr Leu 500 505
510Ile Arg Val Ile Glu Lys Leu Pro Ile 515 520960PRTArtificial
SequenceSynthetic peptide. 9Met Trp Val Pro Val Val Phe Leu Thr Leu
Ser Val Thr Trp Ile Gly1 5 10 15Ala Ala Pro Leu Ile Leu Ser Arg Ile
Val Gly Gly Trp Glu Cys Glu 20 25 30Lys His Ser Gln Pro Trp Gln Val
Leu Val Ala Ser Arg Gly Arg Ala 35 40 45Val Cys Gly Gly Val Leu Val
His Pro Gln Trp Val 50 55 601060PRTArtificial SequenceSyhthetic
peptide. 10Leu Thr Ala Ala His Cys Ile Arg Asn Lys Ser Val Ile Leu
Leu Gly1 5 10 15Arg His Ser Leu Phe His Pro Glu Asp Thr Gly Gln Val
Phe Gln Val 20 25 30Ser His Ser Phe Pro His Pro Leu Tyr Asp Met Ser
Leu Leu Lys Asn 35 40 45Arg Phe Leu Arg Pro Gly Asp Asp Ser Ser His
Asp 50 55 601160PRTArtificial SequenceSynthetic peptide. 11Leu Met
Leu Leu Arg Leu Ser Glu Pro Ala Glu Leu Thr Asp Ala Val1 5 10 15Lys
Val Met Asp Leu Pro Thr Gln Glu Pro Ala Leu Gly Thr Thr Cys 20 25
30Tyr Ala Ser Gly Trp Gly Ser Ile Glu Pro Glu Glu Phe Leu Thr Pro
35 40 45Lys Lys Leu Gln Cys Val Asp Leu His Val Ile Ser 50 55
601260PRTArtificial SequenceSynthetic peptide. 12Asn Asp Val Cys
Ala Gln Val His Pro Gln Lys Val Thr Lys Phe Met1 5 10 15Leu Cys Ala
Gly Arg Trp Thr Gly Gly Lys Ser Thr Cys Ser Gly Asp 20 25 30Ser Gly
Gly Pro Leu Val Cys Asn Gly Val Leu Gln Gly Ile Thr Ser 35 40 45Trp
Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro 50 55
601321PRTArtificial SequenceSynthetic peptide. 13Ser Leu Tyr Thr
Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr1 5 10 15Ile Val Ala
Asn Pro 20149PRTArtificial SequenceSynthetic peptide. 14Ile Met Asp
Gln Val Pro Phe Ser Val1 5159PRTArtificial SequenceSynthetic
peptide. 15Ile Thr Asp Gln Val Pro Phe Ser Val1 5169PRTArtificial
SequenceSynthetic peptide. 16Tyr Leu Glu Pro Gly Pro Val Thr Val1
5179PRTArtificial SequenceSynthetic peptide. 17Tyr Leu Glu Pro Gly
Pro Val Thr Ala1 5189PRTArtificial SequenceSyntehtic peptide. 18Lys
Thr Trp Gly Gln Tyr Trp Gln Val1 519244PRTArtificial
SequenceSynthetic peptide. 19Ala Pro Leu Ile Leu Ser Arg Ile Val
Gly Gly Trp Glu Cys Glu Lys1 5 10 15His Ser Gln Pro Trp Gln Val Leu
Val Ala Ser Arg Gly Arg Ala Val 20 25 30Cys Gly Gly Val Leu Val His
Pro Gln Trp Val Leu Thr Ala Ala His 35 40 45Cys Ile Arg Asn Lys Ser
Val Ile Leu Leu Gly Arg His Ser Leu Phe 50 55 60His Pro Glu Asp Thr
Gly Gln Val Phe Gln Val Ser His Ser Phe Pro65 70 75 80His Pro Leu
Tyr Asp Met Ser Leu Leu Lys Asn Arg Phe Leu Arg Pro 85 90 95Gly Asp
Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu Pro 100 105
110Ala Glu Leu Thr Asp Ala Val Lys Val Met Asp Leu Pro Thr Gln Glu
115 120 125Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser
Ile Glu 130 135 140Pro Glu Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys
Val Asp Leu His145 150 155 160Val Ile Ser Asn Asp Val Cys Ala Gln
Val His Pro Gln Lys Val Thr 165 170 175Lys Phe Met Leu Cys Ala Gly
Arg Trp Thr Gly Gly Lys Ser Thr Cys 180 185 190Ser Gly Asp Ser Gly
Gly Pro Leu Val Cys Asn Gly Val Leu Gln Gly 195 200 205Ile Thr Ser
Trp Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro Ser 210 215 220Leu
Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr Ile225 230
235 240Val Ala Asn Pro20230PRTArtificial SequenceSynthetic peptide.
20Asp Thr Thr Glu Pro Ala Thr Pro Thr Thr Pro Val Thr Thr Pro Thr1
5 10 15Thr Thr Lys Val Pro Arg Asn Gln Asp Trp Leu Gly Val Ser Arg
Gln 20 25 30Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu Tyr Pro Glu Trp
Thr Glu 35 40 45Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly Gln Val Ser
Leu Lys Val 50 55 60Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala Asn Ala
Ser Phe Ser Ile65 70 75 80Ala Leu Asn Phe Pro Gly Ser Gln Lys Val
Leu Pro Asp Gly Gln Val 85 90 95Ile Trp Val Asn Asn Thr Ile Ile Asn
Gly Ser Gln Val Trp Gly Gly 100 105 110Gln Pro Val Tyr Pro Gln Glu
Thr Asp Asp Ala Cys Ile Phe Pro Asp 115 120 125Gly Gly Pro Cys Pro
Ser Gly Ser Trp Ser Gln Lys Arg Ser Phe Val 130 135 140Tyr Val Trp
Lys Thr Trp Gly Gln Tyr Trp Gln Val Leu Gly Gly Pro145 150 155
160Val Ser Gly Leu Ser Ile Gly Thr Gly Arg Ala Met Leu Gly Thr His
165 170 175Thr Met Glu Val Thr Val Tyr His Arg Arg Gly Ser Gln Ser
Tyr Val 180 185 190Pro Leu Ala His Ser Ser Ser Ala Phe Thr Ile Thr
Asp Gln Val Pro 195 200 205Phe Ser Val Ser Val Ser Gln Leu Arg Ala
Leu Asp Gly Gly Asn Lys 210 215 220His Phe Leu Arg Asn Gln225
2302173PRTArtificial SequenceSynthetic peptide. 21Pro Leu Thr Phe
Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala1 5 10 15Glu Ala Asp
Leu Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr 20 25 30Leu Ile
Ser Arg Ala Xaa Val Val Thr His Thr Tyr Leu Glu Pro Gly 35 40 45Pro
Val Thr Ala Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser 50 55
60Cys Gly Ser Ser Pro Val Pro Ala Ser65 7022109PRTArtificial
SequenceSynthetic peptide. 22Gly Thr Thr Asp Gly His Arg Pro Thr
Ala Glu Ala Pro Asn Thr Thr1 5 10 15Ala Gly Gln Val Pro Thr Thr Glu
Val Val Gly Thr Thr Pro Gly Gln 20 25 30Ala Pro Thr Ala Glu Pro Ser
Gly Thr Thr Ser Val Gln Val Pro Thr 35 40 45Thr Glu Val Ile Ser Thr
Ala Pro Val Gln Met Pro Thr Ala Glu Ser 50 55 60Thr Gly Met Thr Pro
Glu Lys Val Pro Val Ser Glu Val Met Gly Thr65 70 75 80Thr Leu Ala
Glu Met Ser Thr Pro Glu Ala Thr Gly Met Thr Pro Ala 85 90 95Glu Val
Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala 100
1052375PRTArtificial SequenceSynthetic peptide. 23Gln Val Thr Thr
Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro1 5 10 15Ile Pro Glu
Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu 20 25 30Ser Ile
Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu 35 40 45Arg
Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr 50 55
60Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln65 70
7524109PRTArtificial SequenceSynthetic peptide. 24Gly Ile Glu Ser
Ala Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly1 5 10 15Asp Ala Phe
Glu Leu Thr Val Ser Cys Gln Gly Gly Leu Pro Lys Glu 20 25 30Ala Cys
Met Glu Ile Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg 35 40 45Leu
Cys Gln Pro Val Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His 50 55
60Gln Ile Leu Lys Gly Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu65
70 75 80Ala Asp Thr Asn Ser Leu Ala Val Val Ser Thr Gln Leu Ile Val
Pro 85 90 95Gly Ile Leu Leu Thr Gly Gln Glu Ala Gly Leu Gly Gln 100
1052550PRTARtificial SequenceSynthetic peptide. 25Met Glu Met Lys
Ile Leu Arg Ala Leu Asn Phe Gly Leu Gly Arg Pro1 5 10 15Leu Pro Leu
His Phe Leu Arg Arg Ala Ser Lys Ile Gly Glu Val Asp 20 25 30Val Glu
Gln His Thr Leu Ala Lys Tyr Leu Met Glu Leu Thr Met Leu 35 40 45Asp
Tyr 502636PRTArtificial SequenceSynthetic peptide. 26Asp Trp Leu
Val Gln Val Gln Met Lys Phe Arg Leu Leu Gln Glu Thr1 5 10 15Met Tyr
Met Thr Val Ser Ile Ile Asp Arg Phe Met Gln Asn Asn Cys 20 25 30Val
Pro Lys Lys 352748PRTArtificial SequenceSyntehtic peptide. 27Met
Glu His Gln Leu Leu Cys Cys Glu Val Glu Thr Ile Arg Arg Ala1 5 10
15Tyr Pro Asp Ala Asn Leu Leu Asn Asp Arg Val Leu Arg Ala Met Leu
20 25 30Lys Ala Glu Glu Thr Cys Ala Pro Ser Val Ser Tyr Phe Lys Cys
Val 35 40 452895PRTArtificial SequenceSynthetic peptide. 28Gln Lys
Glu Val Leu Pro Ser Met Arg Lys Ile Val Ala Thr Trp Met1 5 10 15Leu
Glu Val Cys Glu Glu Gln Lys Cys Glu Glu Glu Val Phe Pro Leu 20 25
30Ala Met Asn Tyr Leu Asp Arg Phe Leu Ser Leu Glu Pro Val Lys Lys
35 40 45Ser Arg Leu Gln Leu Leu Gly Ala Thr Cys Met Phe Val Ala Ser
Lys 50 55 60Met Lys Glu Thr Ile Pro Leu Thr Ala Glu Lys Leu Cys Ile
Tyr Thr65 70 75 80Asp Asn Ser Ile Arg Pro Glu Glu Leu Leu Gln Met
Glu Leu Leu 85 90 952960PRTArtificial SequenceSynthetic peptide.
29Leu Val Asn Lys Leu Lys Trp Asn Leu Ala Ala Met Thr Pro His Asp1
5 10 15Phe Ile Glu His Phe Leu Ser Lys Met Pro Glu Ala Glu Glu Asn
Lys 20 25 30Gln Ile Ile Arg Lys His Ala Gln Thr Phe Val Ala Leu Cys
Ala Thr 35 40 45Asp Val Lys Phe Ile Ser Asn Pro Pro Ser Met Val 50
55 603092PRTArtificial SequenceSynthetic peptide. 30Ala Ala Gly Ser
Val Val Ala Ala Val Gln Gly Leu Asn Leu Arg Ser1 5 10 15Pro Asn Asn
Phe Leu Ser Tyr Tyr Arg Leu Thr Arg Phe Leu Ser Arg 20 25 30Val Ile
Lys Cys Asp Pro Asp Cys Leu Arg Ala Cys Gln Glu Gln Ile 35 40 45Glu
Ala Leu Leu Glu Ser Ser Leu Arg Gln Ala Gln Gln Asn Met Asp 50 55
60Pro Lys Ala Ala Glu Glu Glu Glu Glu Glu Glu Glu Glu Val Asp Leu65
70 75 80Ala Cys Thr Pro Thr Asp Val Arg Asp Val Asp Ile 85
903132PRTArtificial SequenceSynthetic peptide. 31Val Gly Phe Pro
Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr Tyr1 5 10 15Lys Ala Ala
Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu 20 25
303230PRTArtificial SequenceSynthetic peptide. 32His Thr Gln Gly
Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro1 5 10 15Gly Val Arg
Tyr Pro Leu Thr Phe Gly Trp Leu Tyr Lys Leu 20 25
303319PRTArtificial SequenceSynthetic peptide. 33Glu Lys Ile Arg
Leu Arg Pro Gly Gly Lys Lys Lys Tyr Lys Leu Lys1 5 10 15His Ile
Val3432PRTArtificial SequenceSyntehtic peptide. 34Asn Pro Pro Ile
Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu1 5 10 15Gly Leu Asn
Lys Ile Val Arg Met Tyr Ser Pro Thr Ser Ile Leu Asp 20 25
303531PRTArtificial SequenceSyntehtic peptide. 35Ala Ile Phe Gln
Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys1 5 10 15Gln Asn Pro
Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr 20 25
3036314PRTArtificial SequenceSyntehtic peptide. 36Asp Thr Ile Cys
Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val1 5 10 15Asp Thr Val
Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn Leu 20 25 30Leu Glu
Asp Ser His Asn Gly Lys Leu Cys Arg Leu Lys Gly Ile Ala 35 40 45Pro
Leu Gln Leu Gly Lys Cys Asn Ile Ala Gly Trp Leu Leu Gly Asn 50 55
60Pro Glu Cys Asp Pro Leu Leu Pro Val Arg Ser Trp Ser Tyr Ile Val65
70 75 80Glu Thr Pro Asn Ser Glu Asn Gly Ile Cys Tyr Pro Gly Asp Phe
Ile 85 90 95Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser
Phe Glu 100 105 110Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro
Asn His Asn Thr 115 120 125Asn Gly Val Thr Ala Ala Cys Ser His Glu
Gly Lys Ser Ser Phe Tyr 130 135 140Arg Asn Leu Leu Trp Leu Thr Glu
Lys Glu Gly Ser Tyr Pro Lys Leu145 150 155 160Lys Asn Ser Tyr Val
Asn Lys Lys Gly Lys Glu Val Leu Val Leu Trp 165 170 175Gly Ile His
His Pro Pro Asn Ser Lys Glu Gln Gln Asn Leu Tyr Gln 180 185 190Asn
Glu Asn Ala Tyr Val Ser Val Val Thr Ser Asn Tyr Asn Arg Arg 195 200
205Phe Thr Pro Glu Ile Ala Glu Arg Pro Lys Val Arg Asp Gln Ala Gly
210 215 220Arg Met Asn Tyr Tyr Trp Thr Leu Leu Lys Pro Gly Asp Thr
Ile Ile225 230 235 240Phe Glu Ala Asn Gly Asn Leu Ile Ala Pro Met
Tyr Ala Phe Ala Leu 245 250 255Ser Arg Gly Phe Gly Ser Gly Ile Ile
Thr Ser Asn Ala Ser Met His 260 265 270Glu Cys Asn Thr Lys Cys Gln
Thr Pro Leu Gly Ala Ile Asn Ser Ser 275 280 285Leu Pro Tyr Gln Asn
Ile His Pro Val Thr Ile Gly Glu Cys Pro Lys 290 295 300Tyr Val Arg
Ser Ala Lys Leu Arg Met Val305 31037314PRTArtificial
SequenceSyntehtic peptide. 37Asp Gln Ile Cys Ile Gly Tyr His Ala
Asn Asn Ser Thr Glu Gln Val1 5 10 15Asp Thr Ile Met Glu Lys Asn Val
Thr Val Thr His Ala Gln Asp Ile 20 25 30Leu Glu Lys Lys His Asn Gly
Lys Leu Cys Asp Leu Asp Gly Val Lys 35 40 45Pro Leu Ile Leu Arg Asp
Cys Ser Val Ala Gly Trp Leu Leu Gly Asn 50 55 60Pro Met Cys Asp Glu
Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val65 70 75 80Glu Lys Ala
Asn Pro Val Asn Asp Leu Cys Tyr Pro Gly Asp Phe Asn 85 90 95Asp Tyr
Glu Glu Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu 100 105
110Lys Ile Gln Ile Ile Pro Lys Ser Ser Trp Ser Ser His Glu Ala Ser
115 120 125Leu Gly Val Ser Ser Ala Cys Pro Tyr Gln Gly Lys Ser Ser
Phe Phe 130 135 140Arg Asn Val Val Trp Leu Ile Lys Lys Asn Ser Thr
Tyr Pro Thr Ile145 150 155 160Lys Arg Ser Tyr Asn Asn Thr Asn Gln
Glu Asp Leu Leu Val Leu Trp 165 170 175Gly Ile His His Pro Asn Asp
Ala Ala Glu Gln Thr Lys Leu Tyr Gln 180 185 190Asn Pro Thr Thr Tyr
Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg 195 200 205Leu Val Pro
Arg Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly 210 215 220Arg
Met Glu Phe Phe
Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn225 230 235 240Phe Glu
Ser Asn Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile 245 250
255Val Lys Lys Gly Asp Ser Thr Ile Met Lys Ser Glu Leu Glu Tyr Gly
260 265 270Asn Cys Asn Thr Lys Cys Gln Thr Pro Met Gly Ala Ile Asn
Ser Ser 275 280 285Met Pro Phe His Asn Ile His Pro Leu Thr Ile Gly
Glu Cys Pro Lys 290 295 300Tyr Val Lys Ser Asn Arg Leu Val Leu
Ala305 31038231PRTArtificial SequenceSyntehtic peptide. 38Pro Ile
Val Gln Asn Ile Gln Gly Gln Met Val His Gln Ala Ile Ser1 5 10 15Pro
Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala Phe 20 25
30Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala Thr
35 40 45Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln
Ala 50 55 60Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu Glu Ala Ala
Glu Trp65 70 75 80Asp Arg Val His Pro Val His Ala Gly Pro Ile Ala
Pro Gly Gln Met 85 90 95Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr
Thr Ser Thr Leu Gln 100 105 110Glu Gln Ile Gly Trp Met Thr Asn Asn
Pro Pro Ile Pro Val Gly Glu 115 120 125Ile Tyr Lys Arg Trp Ile Ile
Leu Gly Leu Asn Lys Ile Val Arg Met 130 135 140Tyr Ser Pro Thr Ser
Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu Pro145 150 155 160Phe Arg
Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala Glu Gln 165 170
175Ala Ser Gln Glu Val Lys Asn Trp Met Thr Glu Thr Leu Leu Val Gln
180 185 190Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala Leu Gly
Pro Ala 195 200 205Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly
Val Gly Gly Pro 210 215 220Gly His Lys Ala Arg Val Leu225
2303925PRTArtificial SequenceSynthetic peptide. 39Ser Ser Val Ser
Pro Thr Thr Ser Val His Pro Thr Pro Thr Ser Val1 5 10 15Pro Pro Thr
Pro Thr Lys Ser Ser Pro 20 254025PRTArtificial SequenceSynthetic
peptide. 40Pro Thr Ser Thr Pro Ala Asp Ser Ser Thr Ile Thr Pro Thr
Ala Thr1 5 10 15Pro Thr Ala Thr Pro Thr Ile Lys Gly 20
254125PRTArtificial SequenceSynthetic peptide. 41Thr Val Thr Pro
Thr Ala Thr Ala Thr Pro Ser Ala Ile Val Thr Thr1 5 10 15Ile Thr Pro
Thr Ala Thr Thr Lys Pro 20 254225PRTArtificial SequenceSynthetic
peptide. 42Thr Asn Gly Ser Ile Thr Val Ala Ala Thr Ala Pro Thr Val
Thr Pro1 5 10 15Thr Val Asn Ala Thr Pro Ser Ala Ala 20
25439PRTArtificial SequenceSynthetic peptide. 43Gly Ile Leu Gly Phe
Val Phe Thr Leu1 5449PRTArtificial SequenceSynthetic peptide. 44Lys
Leu Gln Cys Val Asp Leu His Val1 54576PRTArtificial
SequenceSynthetic peptide. 45Ala Ser Ile Ser Cys Arg Ser Ser Gln
Ser Leu Val His Ser Asn Gly1 5 10 15Asn Thr Tyr Leu His Trp Tyr Leu
Gln Lys Pro Gly Gln Ser Pro Lys 20 25 30Leu Leu Ile Tyr Lys Val Ser
Asn Arg Phe Ser Gly Val Pro Asp Arg 35 40 45Phe Ser Gly Ser Gly Ser
Gly Thr Asn Phe Thr Leu Lys Ile Ser Arg 50 55 60Val Glu Ala Glu Asp
Leu Gly Leu Tyr Phe Cys Ser65 70 754681PRTArtificial
SequenceSynthetic peptide. 46Ser Val Lys Met Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Asp Tyr1 5 10 15Val Ile Ser Trp Val Lys Gln Arg
Thr Gly Gln Gly Leu Glu Trp Ile 20 25 30Gly Asp Ile Tyr Pro Gly Ser
Gly Tyr Ser Phe Tyr Asn Glu Asn Phe 35 40 45Lys Gly Lys Ala Thr Leu
Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr 50 55 60Met Gln Leu Ser Ser
Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys65 70 75
80Ala4774PRTArtificial SequenceSynthetic peptide. 47Val Thr Leu Thr
Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn1 5 10 15Tyr Ala Asn
Trp Val Gln Glu Lys Pro Asp His Leu Phe Thr Gly Leu 20 25 30Ile Gly
Gly Thr Asn Asn Arg Val Ser Gly Val Pro Ala Arg Phe Ser 35 40 45Gly
Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln 50 55
60Thr Glu Asp Glu Ala Ile Tyr Phe Cys Ala65 704882PRTArtificial
SequenceSynthetic peptide. 48Ser Leu Lys Leu Ser Cys Ala Ala Ser
Gly Leu Thr Phe Asn Ile Tyr1 5 10 15Ala Met Asn Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 20 25 30Ala Arg Ile Arg Asn Lys Ser
Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 35 40 45Ser Val Lys Asp Arg Phe
Thr Ile Ser Arg Asp Asp Ser Gln Ser Leu 50 55 60Leu Tyr Leu Gln Met
Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr65 70 75 80Tyr
Cys49717DNAArtificial SequenceSyntehtic oligonucleotide.
49atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat
60gttgtgatga cccaaactcc actctccctg cctgtccgtc ttggagatca agcctccatc
120tcttgcagat ctagtcagag ccttgtacac agtaatggaa acacctattt
acattggtac 180ctgcagaagc caggccagtc tccaaagctc ctgatctaca
aagtttccaa ccgattttct 240ggggtcccag acaggttcag tggcagtgga
tcagggacaa atttcacact caagatcagc 300agagtggagg ctgaggatct
gggactttat ttctgctctc aaagtacaca tgttccgtac 360acgttcggag
gggggaccaa gctggaaata aaacgggctg atgctgcacc aactgtatcc
420atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt
gtgcttcttg 480aacaacttct accccaaaga catcaatgtc aagtggaaga
ttgatggcag tgaacgacaa 540aatggcgtcc tgaacagttg gactgatcag
gacagcaaag acagcaccta cagcatgaac 600agcaccctca cgttgaccaa
ggacgagtat gaacgacata acagctatac ctgtgaggcc 660actcacaaga
catcaacttc acccatcgtc aagagcttca acaggaatga gtgttag
71750219PRTArtificial SequenceSyntehtic peptide. 50Asp Val Val Met
Thr Gln Thr Pro Leu Ser Leu Pro Val Arg Leu Gly1 5 10 15Asp Gln Ala
Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30Asn Gly
Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45Pro
Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asn Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Phe Cys Ser Gln
Ser 85 90 95Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys 100 105 110Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro
Pro Ser Ser Glu 115 120 125Gln Leu Thr Ser Gly Gly Ala Ser Val Val
Cys Phe Leu Asn Asn Phe 130 135 140Tyr Pro Lys Asp Ile Asn Val Lys
Trp Lys Ile Asp Gly Ser Glu Arg145 150 155 160Gln Asn Gly Val Leu
Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser 165 170 175Thr Tyr Ser
Met Asn Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu 180 185 190Arg
His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser 195 200
205Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 210
21551714DNAArtificial SequenceSynthetic oligonucleotide.
51atggattttc agatgcagat tatcagcttg ctgctaatca gtgtcacagt catagtgtct
60aatggagaaa ttgtgctcac ccagtctcca accaccatgg ctgcatctcc cggggagaag
120atcactatca cctgcagtgc cagctcaagt ataagttccc attacttaca
ttggtatcag 180cagaagccag gattctcccc taaactcttg atttatagga
catccaatct ggcttctgga 240gtcccagctc gcttcagtgg cagtgggtct
gggacctctt actctctcac aattgacacc 300atggaggctg aagatgttgc
cacttactac tgccagcagg gtagtagtat accattcacg 360ttcggctcgg
ggacaaagtt ggaaataaaa cgggctgatg ctgcaccaac tgtatccatc
420ttcccaccat ccagtgagca gttaacatct ggaggtgcct cagtcgtgtg
cttcttgaac 480aacttctacc ccaaagacat caatgtcaag tggaagattg
atggcagtga acgacaaaat 540ggcgtcctga acagttggac tgatcaggac
agcaaagaca gcacctacag catgagcagc 600accctcacgt tgaccaagga
cgagtatgaa cgacataaca gctatacctg tgaggccact 660cacaagacat
caacttcacc catcgtcaag agcttcaaca ggaatgagtg ttag
71452215PRTArtificial SequenceSynthetic peptide. 52Glu Ile Val Leu
Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly1 5 10 15Glu Lys Ile
Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser His 20 25 30Tyr Leu
His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu 35 40 45Ile
Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 50 55
60Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Asp Thr Met Glu65
70 75 80Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Ile
Pro 85 90 95Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala
Asp Ala 100 105 110Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
Gln Leu Thr Ser 115 120 125Gly Gly Ala Ser Val Val Cys Phe Leu Asn
Asn Phe Tyr Pro Lys Asp 130 135 140Ile Asn Val Lys Trp Lys Ile Asp
Gly Ser Glu Arg Gln Asn Gly Val145 150 155 160Leu Asn Ser Trp Thr
Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met 165 170 175Ser Ser Thr
Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser 180 185 190Tyr
Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys 195 200
205Ser Phe Asn Arg Asn Glu Cys 210 215531479DNAArtificial
SequenceSynthetic oligonucleotide. 53atgagatcac tgttctcttt
acagttactg agcacacagg acctcgccat gggatggagc 60tgtatcatcc tcttcttggt
agcaacagct acaggtgtcc actctcaggt ccaactgcag 120cagcctgggg
ctgaacttgt gaagcctggg gcttcagtga agctgtcctg caaggcttct
180ggctacacct tcaccagtta ctggatgcag tgggtaaagc agaggcctgg
acagggcctt 240gagtggatcg gagagattga tccttctgat agctatacta
actacaatca aaggttcaag 300ggcaaggcca cattgactgt ggacacatcc
tccagcacag cctacataca gctcagcagc 360ctgacgtctg aggactctgc
ggtctgtttc tgtgcaagac gctactatgg taactacgat 420gggtttgctt
actggggcca agggactctg gtcactgtct ctgcagccaa aacaacagcc
480ccatcggtct atccactggc ccctgtgtgt ggaggtacaa ctggctcctc
ggtgactcta 540ggatgcctgg tcaagggtta tttccctgag ccagtgacct
tgacctggaa ctctggatcc 600ctgtccagtg gtgtgcacac cttcccagct
ctcctgcagt ctggcctcta caccctcagc 660agctcagtga ctgtaacctc
gaacacctgg cccagccaga ccatcacctg caatgtggcc 720cacccggcaa
gcagcaccaa agtggacaag aaaattgagc ccagagtgcc cataacacag
780aacccctgtc ctccactcaa agagtgtccc ccatgcgcag ctccagacct
cttgggtgga 840ccatccgtct tcatcttccc tccaaagatc aaggatgtac
tcatgatctc cccgagcccc 900atggtcacat gtgtggtggt ggatgtgagc
gaggatgacc cagacgtcca gatcagctgg 960tttgtgaaca acgtggaagt
acacacagct cagacacaaa cccatagaga ggattacaac 1020agtactctcc
gggtggtcag tgccctcccc atccagcacc aggactggat gagtggcaag
1080gagttcaaat gcaaggtcaa caacagagcc ctcccatccc ccatcgagaa
aaccatctca 1140aaacccagag ggccagtaag agctccacag gtatatgtct
tgcctccacc agcagaagag 1200atgactaaga aagagttcag tctgacctgc
atgatcacag gcttcttacc tgccgaaatt 1260gctgtggact ggaccagcaa
tgggcgtaca gagcaaaact acaagaacac cgcaacagtc 1320ctggactctg
atggttctta cttcatgtac agcaagctca gagtacaaaa gagcacttgg
1380gaaagaggaa gtcttttcgc ctgctcagtg gtccacgagg gtctgcacaa
tcaccttacg 1440actaagacca tctcccggtc tctgggtaaa gctagctga
147954457PRTArtificial SequenceSynthetic peptide. 54Gln Val Gln Leu
Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Val Lys
Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Trp Met
Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly
Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Arg Phe 50 55
60Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr65
70 75 80Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Cys Phe
Cys 85 90 95Ala Arg Arg Tyr Tyr Gly Asn Tyr Asp Gly Phe Ala Tyr Trp
Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr
Ala Pro Ser Val 115 120 125Tyr Pro Leu Ala Pro Val Cys Gly Gly Thr
Thr Gly Ser Ser Val Thr 130 135 140Leu Gly Cys Leu Val Lys Gly Tyr
Phe Pro Glu Pro Val Thr Leu Thr145 150 155 160Trp Asn Ser Gly Ser
Leu Ser Ser Gly Val His Thr Phe Pro Ala Leu 165 170 175Leu Gln Ser
Gly Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser 180 185 190Asn
Thr Trp Pro Ser Gln Thr Ile Thr Cys Asn Val Ala His Pro Ala 195 200
205Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Val Pro Ile Thr
210 215 220Gln Asn Pro Cys Pro Pro Leu Lys Glu Cys Pro Pro Cys Ala
Ala Pro225 230 235 240Asp Leu Leu Gly Gly Pro Ser Val Phe Ile Phe
Pro Pro Lys Ile Lys 245 250 255Asp Val Leu Met Ile Ser Pro Ser Pro
Met Val Thr Cys Val Val Val 260 265 270Asp Val Ser Glu Asp Asp Pro
Asp Val Gln Ile Ser Trp Phe Val Asn 275 280 285Asn Val Glu Val His
Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr 290 295 300Asn Ser Thr
Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp305 310 315
320Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Arg Ala Leu
325 330 335Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Pro Arg Gly Pro
Val Arg 340 345 350Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Ala Glu
Glu Met Thr Lys 355 360 365Lys Glu Phe Ser Leu Thr Cys Met Ile Thr
Gly Phe Leu Pro Ala Glu 370 375 380Ile Ala Val Asp Trp Thr Ser Asn
Gly Arg Thr Glu Gln Asn Tyr Lys385 390 395 400Asn Thr Ala Thr Val
Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser 405 410 415Lys Leu Arg
Val Gln Lys Ser Thr Trp Glu Arg Gly Ser Leu Phe Ala 420 425 430Cys
Ser Val Val His Glu Gly Leu His Asn His Leu Thr Thr Lys Thr 435 440
445Ile Ser Arg Ser Leu Gly Lys Ala Ser 450 45555705DNAArtificial
SequenceSynthetic oligonucleotide. 55atgagggccc ctgctcagtt
ttttgggatc ttgttgctct ggtttccagg tatcagatgt 60gacatcaaga tgacccagtc
tccatcctcc atgtatgcat cgctgggaga gagagtcact 120attacttgca
aggcgagtca ggacattaaa agctatttaa cttggtacca gcagaaacca
180tggaaatctc ctaagaccct gatcaattat gcaacaagct tggcagatgg
ggtcccatca 240agattcagtg gcagtggatc tggacaagat tattctctaa
ccatcagcag cctggagtct 300gacgatacag caacttatta ctgtctacag
catggtcaga gtccgttcac gttcggaggg 360gggaccaggc tggagataaa
acgggctgat gctgcaccaa ctgtatccat cttcccacca 420tccagtgagc
agttaacatc tggaggtgcc tcggtcgtgt gcttcttgaa caacttctac
480cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa
tggcgtcctg 540aacagttgga ctgatcagga cagcaaagac agcacctaca
gcatgagcag caccctcacg 600ttgaccaagg acgagtatga acgacataac
agctatacct gtgaggccac tcacaagaca 660tcaacttcac ccatcgtcaa
gagcttcaac aggaatgagt gttag 70556214PRTArtificial SequenceSynthetic
peptide. 56Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser
Leu Gly1 5 10 15Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile
Lys Ser Tyr 20 25 30Leu Thr Trp Tyr Gln Gln Lys Pro Trp Lys Ser Pro
Lys Thr Leu Ile 35 40 45Asn Tyr Ala Thr Ser Leu Ala Asp Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr
Ile Ser Ser Leu Glu Ser65 70 75 80Asp Asp Thr Ala Thr Tyr Tyr Cys
Leu Gln His Gly Gln Ser Pro Phe 85 90 95Thr Phe Gly Gly Gly Thr Arg
Leu Glu Ile Lys Arg Ala Asp Ala Ala 100 105
110Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
115 120 125Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys
Asp Ile 130 135 140Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
Asn Gly Val Leu145 150 155 160Asn Ser Trp Thr Asp Gln Asp Ser Lys
Asp Ser Thr Tyr Ser Met Ser 165 170 175Ser Thr Leu Thr Leu Thr Lys
Asp Glu Tyr Glu Arg His Asn Ser Tyr 180 185 190Thr Cys Glu Ala Thr
His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser 195 200 205Phe Asn Arg
Asn Glu Cys 210571479DNAArtificial SequenceSynthetic peptide.
57atgagatcac tgttctcttt acagttactg agcacacagg acctcgccat gggatggagc
60tgtatcatcc tcttcttggt agcaacagct acaggtgtcc actctcaggt ccaactgcag
120cagcctgggg ctgagcttgt gaagcctggg gcttcagtga agctgtcctg
caaggcttct 180ggctacacct tcaccagtta ctggatgcag tgggtaaagc
agaggcctgg acagggcctt 240gagtggaccg gagagattga tccttctgat
agctatacta actacaatca aaggttcaag 300ggcaaggcca cattgactgt
ggacacatcc tccagcacag cctacacaca gctcagcagc 360ctgacgtctg
aggactctgc ggtccatttc tgtgcaagac gctactatgg taactacgat
420gggtttgctt actggggcca agggactctg gtcactgtct ctgcagccaa
aacaacagcc 480ccatcggtct atccactggc ccctgtgtgt ggaggtacaa
ctggctcctc ggtgactcta 540ggatgcctgg tcaagggtta tttccctgag
ccagtgacct tgacctggaa ctctggatcc 600ctgtccagtg gtgtgcacac
cttcccagct ctcctgcagt ctggcctcta caccctcagc 660agctcagtga
ctgtaacctc gaacacctgg cccagccaga ccatcacctg caatgtggcc
720cacccggcaa gcagcaccaa agtggacaag aaaattgagc ccagagtgcc
cataacacag 780aacccctgtc ctccactcaa agagtgtccc ccatgcgcag
ctccagacct cttgggtgga 840ccatccgtct tcatcttccc tccaaaggtc
aaggatgtac tcatgatctc cctgagcccc 900atggtcacat gtgtggtggt
ggatgtgagc gaggatgacc cagacgtcca gatcagctgg 960tttgtgaaca
acgtggaagt acacacagct cagacacaaa cccatagaga ggattacaac
1020agtactctcc gggtggtcag tgccctcccc atccagcacc aggactggat
gagtggcaag 1080gagttcaaat gcaaggtcaa caacagagcc ctcccatccc
ccatcgagaa aaccatctca 1140aaacccagag ggccagtaag agctccacag
gtatatgtct tgcctccacc agcagaagag 1200atgactaaga aagagttcag
tctgacctgc atgatcacag gcttcttacc tgccgaaatt 1260gctgtggact
ggaccagcaa tgggcgtaca gagcaaaact acaagaacac cgcaacagtc
1320ctggactctg atggttctta cttcatgtac agcaagctca gagtacaaaa
gagcacttgg 1380gaaagaggaa gtcttttcgc ctgctcagtg gtccacgagg
gtctgcacaa tcaccttacg 1440actaagacca tctcccggtc tctgggtaaa
gctagctga 147958457PRTArtificial SequenceSynthetic peptide. 58Gln
Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala1 5 10
15Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
Thr 35 40 45Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln
Arg Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser
Thr Ala Tyr65 70 75 80Thr Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser
Ala Val His Phe Cys 85 90 95Ala Arg Arg Tyr Tyr Gly Asn Tyr Asp Gly
Phe Ala Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ala
Ala Lys Thr Thr Ala Pro Ser Val 115 120 125Tyr Pro Leu Ala Pro Val
Cys Gly Gly Thr Thr Gly Ser Ser Val Thr 130 135 140Leu Gly Cys Leu
Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr145 150 155 160Trp
Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Leu 165 170
175Leu Gln Ser Gly Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser
180 185 190Asn Thr Trp Pro Ser Gln Thr Ile Thr Cys Asn Val Ala His
Pro Ala 195 200 205Ser Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg
Val Pro Ile Thr 210 215 220Gln Asn Pro Cys Pro Pro Leu Lys Glu Cys
Pro Pro Cys Ala Ala Pro225 230 235 240Asp Leu Leu Gly Gly Pro Ser
Val Phe Ile Phe Pro Pro Lys Val Lys 245 250 255Asp Val Leu Met Ile
Ser Leu Ser Pro Met Val Thr Cys Val Val Val 260 265 270Asp Val Ser
Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn 275 280 285Asn
Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr 290 295
300Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln
Asp305 310 315 320Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn
Asn Arg Ala Leu 325 330 335Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys
Pro Arg Gly Pro Val Arg 340 345 350Ala Pro Gln Val Tyr Val Leu Pro
Pro Pro Ala Glu Glu Met Thr Lys 355 360 365Lys Glu Phe Ser Leu Thr
Cys Met Ile Thr Gly Phe Leu Pro Ala Glu 370 375 380Ile Ala Val Asp
Trp Thr Ser Asn Gly Arg Thr Glu Gln Asn Tyr Lys385 390 395 400Asn
Thr Ala Thr Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser 405 410
415Lys Leu Arg Val Gln Lys Ser Thr Trp Glu Arg Gly Ser Leu Phe Ala
420 425 430Cys Ser Val Val His Glu Gly Leu His Asn His Leu Thr Thr
Lys Thr 435 440 445Ile Ser Arg Ser Leu Gly Lys Ala Ser 450
455592412DNAArtificial SequenceSynthetic oligonucleotide.
59atgacattga acatgctgtt ggggctgagg tgggttttct ttgttgtttt ttatcaaggt
60gtgcattgtg aggtgcagct tgttgagtct ggtggaggat tggtgcagcc taaagggtca
120ttgaaactct catgtgcagc ctctggatta accttcaata tctacgccat
gaactgggtc 180cgccaggctc caggaaaggg tttggaatgg gttgctcgca
taagaaataa aagtaataat 240tatgcaacat attatgccga ttcagtgaaa
gacaggttca ccatctccag agatgattca 300caaagcttgc tctatctgca
aatgaacaac ttgaaaactg aggacacagc catgtattac 360tgtgtgggac
gggactggtt tgattactgg ggccaaggga ctctggtcac tgtctctgca
420gccaaaacga agggcccatc cgtcttcccc ctggcgccct gctccaggag
cacctccgag 480agcacagccg ccctgggctg cctggtcaag gactacttcc
ccgaaccggt gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg
cacaccttcc cggctgtcct acagtcctca 600ggactctact ccctcagcag
cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 660tacacctgca
acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc
720aaatatggtc ccccatgccc accctgccca gcacctgagt tcgaaggggg
accatcagtc 780ttcctgttcc ccccaaaacc caaggacact ctcatgatct
cccggacccc tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac
cccgaggtcc agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc
caagacaaag ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca
gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag
1020tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc
caaagccaaa 1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat
cccaggagga gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa
ggcttctacc ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc
ggagaacaac tacaagacca cgcctcccgt gctggactcc 1260gacggctcct
tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg
1320aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac
acagaagagc 1380ctctccctgt ctctgggtaa agctagcgat acaacagaac
ctgcaacacc tacaacacct 1440gtaacaacag acacaatatg tataggctac
catgcgaaca attcaaccga cactgttgac 1500acagtactcg agaagaatgt
gacagtgaca cactctgtta acctgctcga agacagccac 1560aacggaaaac
tatgtagatt aaaaggaata gccccactac aattggggaa atgtaacatc
1620gccggatggc tcttgggaaa cccagaatgc gacccactgc ttccagtgag
atcatggtcc 1680tacattgtag aaacaccaaa ctctgagaat ggaatatgtt
atccaggaga tttcatcgac 1740tatgaggagc tgagggagca attgagctca
gtgtcatcat tcgaaagatt cgaaatattt 1800cccaaagaaa gctcatggcc
caaccacaac acaaacggag taacggcagc atgctcccat 1860gaggggaaaa
gcagttttta cagaaatttg ctatggctga cggagaagga gggctcatac
1920ccaaagctga aaaattctta tgtgaacaaa aaagggaaag aagtccttgt
actgtggggt 1980attcatcacc cgcctaacag taaggaacaa cagaatctct
atcagaatga aaatgcttat 2040gtctctgtag tgacttcaaa ttataacagg
agatttaccc cggaaatagc agaaagaccc 2100aaagtaagag atcaagctgg
gaggatgaac tattactgga ccttgctaaa acccggagac 2160acaataatat
ttgaggcaaa tggaaatcta atagcaccaa tgtatgcttt cgcactgagt
2220agaggctttg ggtccggcat catcacctca aacgcatcaa tgcatgagtg
taacacgaag 2280tgtcaaacac ccctgggagc tataaacagc agtctccctt
accagaatat acacccagtc 2340acaataggag agtgcccaaa atacgtcagg
agtgccaaat tgaggatggt tcaccatcac 2400catcaccatt ga
241260780PRTArtificial SequenceSynthetic peptide. 60Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gly1 5 10 15Ser Leu Lys
Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Asn Ile Tyr 20 25 30Ala Met
Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala
Arg Ile Arg Asn Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55
60Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Leu65
70 75 80Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met
Tyr 85 90 95Tyr Cys Val Gly Arg Asp Trp Phe Asp Tyr Trp Gly Gln Gly
Thr Leu 100 105 110Val Thr Val Ser Ala Ala Lys Thr Lys Gly Pro Ser
Val Phe Pro Leu 115 120 125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
Thr Ala Ala Leu Gly Cys 130 135 140Leu Val Lys Asp Tyr Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser145 150 155 160Gly Ala Leu Thr Ser
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190Leu
Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200
205Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
210 215 220Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe
Leu Phe225 230 235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val 245 250 255Thr Cys Val Val Val Asp Val Ser Gln
Glu Asp Pro Glu Val Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315
320Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Gln 340 345 350Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly 355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser385 390 395 400Phe Phe Leu Tyr Ser
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser Asp Thr 435 440
445Thr Glu Pro Ala Thr Pro Thr Thr Pro Val Thr Thr Asp Thr Ile Cys
450 455 460Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr Val Asp Thr
Val Leu465 470 475 480Glu Lys Asn Val Thr Val Thr His Ser Val Asn
Leu Leu Glu Asp Ser 485 490 495His Asn Gly Lys Leu Cys Arg Leu Lys
Gly Ile Ala Pro Leu Gln Leu 500 505 510Gly Lys Cys Asn Ile Ala Gly
Trp Leu Leu Gly Asn Pro Glu Cys Asp 515 520 525Pro Leu Leu Pro Val
Arg Ser Trp Ser Tyr Ile Val Glu Thr Pro Asn 530 535 540Ser Glu Asn
Gly Ile Cys Tyr Pro Gly Asp Phe Ile Asp Tyr Glu Glu545 550 555
560Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe Glu Arg Phe Glu Ile
565 570 575Phe Pro Lys Glu Ser Ser Trp Pro Asn His Asn Thr Asn Gly
Val Thr 580 585 590Ala Ala Cys Ser His Glu Gly Lys Ser Ser Phe Tyr
Arg Asn Leu Leu 595 600 605Trp Leu Thr Glu Lys Glu Gly Ser Tyr Pro
Lys Leu Lys Asn Ser Tyr 610 615 620Val Asn Lys Lys Gly Lys Glu Val
Leu Val Leu Trp Gly Ile His His625 630 635 640Pro Pro Asn Ser Lys
Glu Gln Gln Asn Leu Tyr Gln Asn Glu Asn Ala 645 650 655Tyr Val Ser
Val Val Thr Ser Asn Tyr Asn Arg Arg Phe Thr Pro Glu 660 665 670Ile
Ala Glu Arg Pro Lys Val Arg Asp Gln Ala Gly Arg Met Asn Tyr 675 680
685Tyr Trp Thr Leu Leu Lys Pro Gly Asp Thr Ile Ile Phe Glu Ala Asn
690 695 700Gly Asn Leu Ile Ala Pro Met Tyr Ala Phe Ala Leu Ser Arg
Gly Phe705 710 715 720Gly Ser Gly Ile Ile Thr Ser Asn Ala Ser Met
His Glu Cys Asn Thr 725 730 735Lys Cys Gln Thr Pro Leu Gly Ala Ile
Asn Ser Ser Leu Pro Tyr Gln 740 745 750Asn Ile His Pro Val Thr Ile
Gly Glu Cys Pro Lys Tyr Val Arg Ser 755 760 765Ala Lys Leu Arg Met
Val His His His His His His 770 775 780612412DNAArtificial
SequenceSyntehtic oligonucleotide. 61atgacattga acatgctgtt
ggggctgagg tgggttttct ttgttgtttt ttatcaaggt 60gtgcattgtg aggtgcagct
tgttgagtct ggtggaggat tggtgcagcc taaagggtca 120ttgaaactct
catgtgcagc ctctggatta accttcaata tctacgccat gaactgggtc
180cgccaggctc caggaaaggg tttggaatgg gttgctcgca taagaaataa
aagtaataat 240tatgcaacat attatgccga ttcagtgaaa gacaggttca
ccatctccag agatgattca 300caaagcttgc tctatctgca aatgaacaac
ttgaaaactg aggacacagc catgtattac 360tgtgtgggac gggactggtt
tgattactgg ggccaaggga ctctggtcac tgtctctgca 420gccaaaacga
agggcccatc cgtcttcccc ctggcgccct gctccaggag cacctccgag
480agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt
gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg cacaccttcc
cggctgtcct acagtcctca 600ggactctact ccctcagcag cgtggtgacc
gtgccctcca gcagcttggg cacgaagacc 660tacacctgca acgtagatca
caagcccagc aacaccaagg tggacaagag agttgagtcc 720aaatatggtc
ccccatgccc accctgccca gcacctgagt tcgaaggggg accatcagtc
780ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc
tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc
agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc caagacaaag
ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca gcgtcctcac
cgtcctgcac caggactggc tgaacggcaa ggagtacaag 1020tgcaaggtct
ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa
1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga
gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa ggcttctacc
ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc ggagaacaac
tacaagacca cgcctcccgt gctggactcc 1260gacggctcct tcttcctcta
cagcaggcta accgtggaca agagcaggtg gcaggagggg 1320aatgtcttct
catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc
1380ctctccctgt ctctgggtaa agctagcgat acaacagaac ctgcaacacc
tacaacacct 1440gtaacaacag atcagatttg cattggttac catgcaaaca
actcgacaga gcaggttgac 1500acaataatgg aaaagaacgt tactgttaca
catgcccaag acatactgga aaagaaacac 1560aacgggaagc tctgcgatct
agatggagtg aagcctctaa ttttgagaga ttgtagcgta 1620gctggatggc
tcctcggaaa cccaatgtgt gacgaattca tcaatgtgcc ggaatggtct
1680tacatagtgg agaaggccaa tccagtcaat gacctctgtt acccagggga
tttcaatgac 1740tatgaagaat tgaaacacct attgagcaga ataaaccatt
ttgagaaaat tcagatcatc 1800cccaaaagtt cttggtccag tcatgaagcc
tcattagggg tgagctcagc atgtccatac 1860cagggaaagt cctccttttt
cagaaatgtg gtatggctta tcaaaaagaa cagtacatac 1920ccaacaataa
agaggagcta caataatacc aaccaagaag atcttttggt actgtggggg
1980attcaccatc ctaatgatgc ggcagagcag acaaagctct atcaaaaccc
aaccacctat 2040atttccgttg ggacatcaac actaaaccag agattggtac
caagaatagc tactagatcc 2100aaagtaaacg ggcaaagtgg aaggatggag
ttcttctgga caattttaaa gccgaatgat 2160gcaatcaact tcgagagtaa
tggaaatttc attgctccag aatatgcata caaaattgtc 2220aagaaagggg
actcaacaat tatgaaaagt gaattggaat atggtaactg caacaccaag
2280tgtcaaactc caatgggggc gataaactct agcatgccat tccacaatat
acaccctctc 2340accattgggg aatgccccaa atatgtgaaa tcaaacagat
tagtccttgc gcaccatcac 2400catcaccatt ga 241262780PRTArtificial
SequenceSyntehtic peptide. 62Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Lys Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala
Ser Gly Leu Thr Phe Asn Ile Tyr 20 25
30Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ala Arg Ile Arg Asn Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala
Asp 50 55 60Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln
Ser Leu65 70 75 80Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp
Thr Ala Met Tyr 85 90 95Tyr Cys Val Gly Arg Asp Trp Phe Asp Tyr Trp
Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ala Ala Lys Thr Lys
Gly Pro Ser Val Phe Pro Leu 115 120 125Ala Pro Cys Ser Arg Ser Thr
Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140Leu Val Lys Asp Tyr
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser145 150 155 160Gly Ala
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170
175Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
Ser Asn 195 200 205Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly
Pro Pro Cys Pro 210 215 220Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly
Pro Ser Val Phe Leu Phe225 230 235 240Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255Thr Cys Val Val Val
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285Arg
Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295
300Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val305 310 315 320Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr
Ile Ser Lys Ala 325 330 335Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
Thr Leu Pro Pro Ser Gln 340 345 350Glu Glu Met Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys Gly 355 360 365Phe Tyr Pro Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380Glu Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser385 390 395 400Phe
Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410
415Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser
Asp Thr 435 440 445Thr Glu Pro Ala Thr Pro Thr Thr Pro Val Thr Thr
Asp Gln Ile Cys 450 455 460Ile Gly Tyr His Ala Asn Asn Ser Thr Glu
Gln Val Asp Thr Ile Met465 470 475 480Glu Lys Asn Val Thr Val Thr
His Ala Gln Asp Ile Leu Glu Lys Lys 485 490 495His Asn Gly Lys Leu
Cys Asp Leu Asp Gly Val Lys Pro Leu Ile Leu 500 505 510Arg Asp Cys
Ser Val Ala Gly Trp Leu Leu Gly Asn Pro Met Cys Asp 515 520 525Glu
Phe Ile Asn Val Pro Glu Trp Ser Tyr Ile Val Glu Lys Ala Asn 530 535
540Pro Val Asn Asp Leu Cys Tyr Pro Gly Asp Phe Asn Asp Tyr Glu
Glu545 550 555 560Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu
Lys Ile Gln Ile 565 570 575Ile Pro Lys Ser Ser Trp Ser Ser His Glu
Ala Ser Leu Gly Val Ser 580 585 590Ser Ala Cys Pro Tyr Gln Gly Lys
Ser Ser Phe Phe Arg Asn Val Val 595 600 605Trp Leu Ile Lys Lys Asn
Ser Thr Tyr Pro Thr Ile Lys Arg Ser Tyr 610 615 620Asn Asn Thr Asn
Gln Glu Asp Leu Leu Val Leu Trp Gly Ile His His625 630 635 640Pro
Asn Asp Ala Ala Glu Gln Thr Lys Leu Tyr Gln Asn Pro Thr Thr 645 650
655Tyr Ile Ser Val Gly Thr Ser Thr Leu Asn Gln Arg Leu Val Pro Arg
660 665 670Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly Arg Met
Glu Phe 675 680 685Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn
Phe Glu Ser Asn 690 695 700Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr
Lys Ile Val Lys Lys Gly705 710 715 720Asp Ser Thr Ile Met Lys Ser
Glu Leu Glu Tyr Gly Asn Cys Asn Thr 725 730 735Lys Cys Gln Thr Pro
Met Gly Ala Ile Asn Ser Ser Met Pro Phe His 740 745 750Asn Ile His
Pro Leu Thr Ile Gly Glu Cys Pro Lys Tyr Val Lys Ser 755 760 765Asn
Arg Leu Val Leu Ala His His His His His His 770 775
780632202DNAArtificial SequenceSynthetic oligonucleotide.
63atgacattga acatgctgtt ggggctgaag tgggttttct ttgttgtttt ttatcaaggt
60gtgcattgtg aggtgcagct tgttgagtct ggtggaggat tggtgcagcc taaagggtca
120ttgaaactct catgtgcagc ctctggatta accttcaata tctacgccat
gaactgggtc 180cgccaggctc caggaaaggg tttggaatgg gttgctcgca
taagaaataa aagtaataat 240tatgcaacat attatgccga ttcagtgaaa
gacaggttca ccatctccag agatgattca 300caaagcttgc tctatctgca
aatgaacaac ttgaaaactg aggacacagc catgtattac 360tgtgtgggac
gggactggtt tgattactgg ggccaaggga ctctggtcac tgtctctgca
420gccaaaacga agggcccatc cgtcttcccc ctggcgccct gctccaggag
cacctccgag 480agcacagccg ccctgggctg cctggtcaag gactacttcc
ccgaaccggt gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg
cacaccttcc cggctgtcct acagtcctca 600ggactctact ccctcagcag
cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 660tacacctgca
acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc
720aaatatggtc ccccatgccc accctgccca gcacctgagt tcgaaggggg
accatcagtc 780ttcctgttcc ccccaaaacc caaggacact ctcatgatct
cccggacccc tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac
cccgaggtcc agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc
caagacaaag ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca
gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag
1020tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc
caaagccaaa 1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat
cccaggagga gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa
ggcttctacc ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc
ggagaacaac tacaagacca cgcctcccgt gctggactcc 1260gacggctcct
tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg
1320aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac
acagaagagc 1380ctctccctgt ctctgggtaa agctagcgat acaacagaac
ctgcaacacc tacaacacct 1440gtaacaacac cgacaacaac acttctagcg
cccctcatcc tgtctcggat tgtgggaggc 1500tgggagtgcg agaagcattc
ccaaccctgg caggtgcttg tggcctctcg tggcagggca 1560gtctgcggcg
gtgttctggt gcacccccag tgggtcctca cagctgccca ctgcatcagg
1620aacaaaagcg tgatcttgct gggtcggcac agcctgtttc atcctgaaga
cacaggccag 1680gtatttcagg tcagccacag cttcccacac ccgctctacg
atatgagcct cctgaagaat 1740cgattcctca ggccaggtga tgactccagc
cacgacctca tgctgctccg cctgtcagag 1800cctgccgagc tcacggatgc
tgtgaaggtc atggacctgc ccacccagga gccagcactg 1860gggaccacct
gctacgcctc aggctggggc agcattgaac cagaggagtt cttgacccca
1920aagaaacttc agtgtgtgga cctccatgtt atttccaatg acgtgtgtgc
gcaagttcac 1980cctcagaagg tgaccaagtt catgctgtgt gctggacgct
ggacaggggg caaaagcacc 2040tgctcgggtg attctggggg cccacttgtc
tgtaatggtg tgcttcaagg tatcacgtca 2100tggggcagtg aaccatgtgc
cctgcccgaa aggccttccc tgtacaccaa ggtggtgcat 2160taccggaagt
ggatcaagga caccatcgtg gccaacccct ga 220264710PRTArtificial
SequenceSynthetic peptide. 64Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Lys Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala
Ser Gly Leu Thr Phe Asn Ile Tyr 20 25 30Ala Met Asn Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Arg Asn Lys
Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60Ser Val Lys Asp Arg
Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Leu65 70 75 80Leu Tyr Leu
Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr 85 90 95Tyr Cys
Val Gly Arg Asp Trp Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105
110Val Thr Val Ser Ala Ala Lys Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu
Gly Cys 130 135 140Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser145 150 155 160Gly Ala Leu Thr Ser Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205Thr Lys Val
Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro
Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe225 230
235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
Val 245 250 255Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
Val Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly
Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345
350Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser385 390 395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val
Asp Lys Ser Arg Trp Gln Glu 405 410 415Gly Asn Val Phe Ser Cys Ser
Val Met His Glu Ala Leu His Asn His 420 425 430Tyr Thr Gln Lys Ser
Leu Ser Leu Ser Leu Gly Lys Ala Ser Asp Thr 435 440 445Thr Glu Pro
Ala Thr Pro Thr Thr Pro Val Thr Thr Pro Thr Thr Thr 450 455 460Leu
Leu Ala Pro Leu Ile Leu Ser Arg Ile Val Gly Gly Trp Glu Cys465 470
475 480Glu Lys His Ser Gln Pro Trp Gln Val Leu Val Ala Ser Arg Gly
Arg 485 490 495Ala Val Cys Gly Gly Val Leu Val His Pro Gln Trp Val
Leu Thr Ala 500 505 510Ala His Cys Ile Arg Asn Lys Ser Val Ile Leu
Leu Gly Arg His Ser 515 520 525Leu Phe His Pro Glu Asp Thr Gly Gln
Val Phe Gln Val Ser His Ser 530 535 540Phe Pro His Pro Leu Tyr Asp
Met Ser Leu Leu Lys Asn Arg Phe Leu545 550 555 560Arg Pro Gly Asp
Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser 565 570 575Glu Pro
Ala Glu Leu Thr Asp Ala Val Lys Val Met Asp Leu Pro Thr 580 585
590Gln Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser
595 600 605Ile Glu Pro Glu Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys
Val Asp 610 615 620Leu His Val Ile Ser Asn Asp Val Cys Ala Gln Val
His Pro Gln Lys625 630 635 640Val Thr Lys Phe Met Leu Cys Ala Gly
Arg Trp Thr Gly Gly Lys Ser 645 650 655Thr Cys Ser Gly Asp Ser Gly
Gly Pro Leu Val Cys Asn Gly Val Leu 660 665 670Gln Gly Ile Thr Ser
Trp Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg 675 680 685Pro Ser Leu
Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp 690 695 700Thr
Ile Val Ala Asn Pro705 710652415DNAArtificial SequenceSyntehtic
oligonucleotide. 65atggacccca aaggctccct ttcctggaga atacttctgt
ttctctccct ggcttttgag 60ttgtcgtacg gacaggttca gctgcggcag tctggacctg
agctggtgaa gcctggggct 120tcagtgaaga tgtcctgcaa ggcttctgga
tacacattta ctgactatgt tataagttgg 180gtgaagcaga gaactggaca
gggccttgag tggattggag atatttatcc tggaagtggt 240tattctttct
acaatgagaa cttcaagggc aaggccacac tgactgcaga caaatcctcc
300accacagcct acatgcagct cagcagcctg acatctgagg actctgcggt
ctatttctgt 360gcaacctact ataactaccc ttttgcttac tggggccaag
ggactctggt cactgtctct 420gcagccaaaa caacgggccc atccgtcttc
cccctggcgc cctgctccag gagcacctcc 480gagagcacag ccgccctggg
ctgcctggtc aaggactact tccccgaacc ggtgacggtg 540tcgtggaact
caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc
600tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt
gggcacgaag 660acctacacct gcaacgtaga tcacaagccc agcaacacca
aggtggacaa gagagttgag 720tccaaatatg gtcccccatg cccaccctgc
ccagcacctg agttcgaagg gggaccatca 780gtcttcctgt tccccccaaa
acccaaggac actctcatga tctcccggac ccctgaggtc 840acgtgcgtgg
tggtggacgt gagccaggaa gaccccgagg tccagttcaa ctggtacgtg
900gatggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagtt
caacagcacg 960taccgtgtgg tcagcgtcct caccgtcctg caccaggact
ggctgaacgg caaggagtac 1020aagtgcaagg tctccaacaa aggcctcccg
tcctccatcg agaaaaccat ctccaaagcc 1080aaagggcagc cccgagagcc
acaggtgtac accctgcccc catcccagga ggagatgacc 1140aagaaccagg
tcagcctgac ctgcctggtc aaaggcttct accccagcga catcgccgtg
1200gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc
cgtgctggac 1260tccgacggct ccttcttcct ctacagcagg ctaaccgtgg
acaagagcag gtggcaggag 1320gggaatgtct tctcatgctc cgtgatgcat
gaggctctgc acaaccacta cacacagaag 1380agcctctccc tgtctctggg
taaagctagc gatacaacag aacctgcaac acctacaaca 1440cctgtaacaa
cagatcagat ttgcattggt taccatgcaa acaactcgac agagcaggtt
1500gacacaataa tggaaaagaa cgttactgtt acacatgccc aagacatact
ggaaaagaaa 1560cacaacggga agctctgcga tctagatgga gtgaagcctc
taattttgag agattgtagc 1620gtagctggat ggctcctcgg aaacccaatg
tgtgacgaat tcatcaatgt gccggaatgg 1680tcttacatag tggagaaggc
caatccagtc aatgacctct gttacccagg ggatttcaat 1740gactatgaag
aattgaaaca cctattgagc agaataaacc attttgagaa aattcagatc
1800atccccaaaa gttcttggtc cagtcatgaa gcctcattag gggtgagctc
agcatgtcca 1860taccagggaa agtcctcctt tttcagaaat gtggtatggc
ttatcaaaaa gaacagtaca 1920tacccaacaa taaagaggag ctacaataat
accaaccaag aagatctttt ggtactgtgg 1980gggattcacc atcctaatga
tgcggcagag cagacaaagc tctatcaaaa cccaaccacc 2040tatatttccg
ttgggacatc aacactaaac cagagattgg taccaagaat agctactaga
2100tccaaagtaa acgggcaaag tggaaggatg gagttcttct ggacaatttt
aaagccgaat 2160gatgcaatca acttcgagag taatggaaat ttcattgctc
cagaatatgc atacaaaatt 2220gtcaagaaag gggactcaac aattatgaaa
agtgaattgg aatatggtaa ctgcaacacc 2280aagtgtcaaa ctccaatggg
ggcgataaac tctagcatgc cattccacaa tatacaccct 2340ctcaccattg
gggaatgccc caaatatgtg aaatcaaaca gattagtcct tgcgcaccat
2400caccatcacc attga 241566780PRTArtificial SequenceSynthetic
peptide. 66Gln Val Gln Leu Arg Gln Ser Gly Pro Glu Leu Val Lys Pro
Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asp Tyr 20 25 30Val Ile Ser Trp Val Lys Gln Arg Thr Gly Gln Gly
Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Pro Gly Ser Gly Tyr Ser Phe
Tyr Asn Glu Asn Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Thr Tyr Tyr Asn Tyr Pro
Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ala
Ala Lys Thr Thr Gly Pro Ser Val Phe Pro Leu 115 120 125Ala Pro Cys
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser145 150
155 160Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp
His Lys Pro Ser Asn 195 200 205Thr Lys Val Asp Lys Arg Val Glu Ser
Lys Tyr Gly Pro Pro
Cys Pro 210 215 220Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser
Val Phe Leu Phe225 230 235 240Pro Pro Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val 245 250 255Thr Cys Val Val Val Asp Val
Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270Asn Trp Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu
Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300Val
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310
315 320Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys
Ala 325 330 335Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Gln 340 345 350Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly 355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser385 390 395 400Phe Phe Leu Tyr
Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415Gly Asn
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425
430Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser Asp Thr
435 440 445Thr Glu Pro Ala Thr Pro Thr Thr Pro Val Thr Thr Asp Gln
Ile Cys 450 455 460Ile Gly Tyr His Ala Asn Asn Ser Thr Glu Gln Val
Asp Thr Ile Met465 470 475 480Glu Lys Asn Val Thr Val Thr His Ala
Gln Asp Ile Leu Glu Lys Lys 485 490 495His Asn Gly Lys Leu Cys Asp
Leu Asp Gly Val Lys Pro Leu Ile Leu 500 505 510Arg Asp Cys Ser Val
Ala Gly Trp Leu Leu Gly Asn Pro Met Cys Asp 515 520 525Glu Phe Ile
Asn Val Pro Glu Trp Ser Tyr Ile Val Glu Lys Ala Asn 530 535 540Pro
Val Asn Asp Leu Cys Tyr Pro Gly Asp Phe Asn Asp Tyr Glu Glu545 550
555 560Leu Lys His Leu Leu Ser Arg Ile Asn His Phe Glu Lys Ile Gln
Ile 565 570 575Ile Pro Lys Ser Ser Trp Ser Ser His Glu Ala Ser Leu
Gly Val Ser 580 585 590Ser Ala Cys Pro Tyr Gln Gly Lys Ser Ser Phe
Phe Arg Asn Val Val 595 600 605Trp Leu Ile Lys Lys Asn Ser Thr Tyr
Pro Thr Ile Lys Arg Ser Tyr 610 615 620Asn Asn Thr Asn Gln Glu Asp
Leu Leu Val Leu Trp Gly Ile His His625 630 635 640Pro Asn Asp Ala
Ala Glu Gln Thr Lys Leu Tyr Gln Asn Pro Thr Thr 645 650 655Tyr Ile
Ser Val Gly Thr Ser Thr Leu Asn Gln Arg Leu Val Pro Arg 660 665
670Ile Ala Thr Arg Ser Lys Val Asn Gly Gln Ser Gly Arg Met Glu Phe
675 680 685Phe Trp Thr Ile Leu Lys Pro Asn Asp Ala Ile Asn Phe Glu
Ser Asn 690 695 700Gly Asn Phe Ile Ala Pro Glu Tyr Ala Tyr Lys Ile
Val Lys Lys Gly705 710 715 720Asp Ser Thr Ile Met Lys Ser Glu Leu
Glu Tyr Gly Asn Cys Asn Thr 725 730 735Lys Cys Gln Thr Pro Met Gly
Ala Ile Asn Ser Ser Met Pro Phe His 740 745 750Asn Ile His Pro Leu
Thr Ile Gly Glu Cys Pro Lys Tyr Val Lys Ser 755 760 765Asn Arg Leu
Val Leu Ala His His His His His His 770 775 780671638DNAArtificial
SequenceSyntehtic oligonucleotide. 67atggacccca aaggctccct
ttcctggaga atacttctgt ttctctccct ggcttttgag 60ttgtcgtacg gacaggttca
gctgcggcag tctggacctg agctggtgaa gcctggggct 120tcagtgaaga
tgtcctgcaa ggcttctgga tacacattta ctgactatgt tataagttgg
180gtgaagcaga gaactggaca gggccttgag tggattggag atatttatcc
tggaagtggt 240tattctttct acaatgagaa cttcaagggc aaggccacac
tgactgcaga caaatcctcc 300accacagcct acatgcagct cagcagcctg
acatctgagg actctgcggt ctatttctgt 360gcaacctact ataactaccc
ttttgcttac tggggccaag ggactctggt cactgtctct 420gcagccaaaa
caacgggccc atccgtcttc cccctggcgc cctgctccag gagcacctcc
480gagagcacag ccgccctggg ctgcctggtc aaggactact tccccgaacc
ggtgacggtg 540tcgtggaact caggcgccct gaccagcggc gtgcacacct
tcccggctgt cctacagtcc 600tcaggactct actccctcag cagcgtggtg
accgtgccct ccagcagctt gggcacgaag 660acctacacct gcaacgtaga
tcacaagccc agcaacacca aggtggacaa gagagttgag 720tccaaatatg
gtcccccatg cccaccctgc ccagcacctg agttcgaagg gggaccatca
780gtcttcctgt tccccccaaa acccaaggac actctcatga tctcccggac
ccctgaggtc 840acgtgcgtgg tggtggacgt gagccaggaa gaccccgagg
tccagttcaa ctggtacgtg 900gatggcgtgg aggtgcataa tgccaagaca
aagccgcggg aggagcagtt caacagcacg 960taccgtgtgg tcagcgtcct
caccgtcctg caccaggact ggctgaacgg caaggagtac 1020aagtgcaagg
tctccaacaa aggcctcccg tcctccatcg agaaaaccat ctccaaagcc
1080aaagggcagc cccgagagcc acaggtgtac accctgcccc catcccagga
ggagatgacc 1140aagaaccagg tcagcctgac ctgcctggtc aaaggcttct
accccagcga catcgccgtg 1200gagtgggaga gcaatgggca gccggagaac
aactacaaga ccacgcctcc cgtgctggac 1260tccgacggct ccttcttcct
ctacagcagg ctaaccgtgg acaagagcag gtggcaggag 1320gggaatgtct
tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacacagaag
1380agcctctccc tgtctctggg taaagctagc aattctcctc aaaatgaagt
actgtacgga 1440gatgtgaatg atgacggaaa agtaaactcc actgacttga
ctttgttaaa aagatatgtt 1500cttaaagccg tctcaactct cccttcttcc
aaagctgaaa agaacgcaga tgtaaatcgt 1560gacggaagag ttaattccag
tgatgtcaca atactttcaa gatatttgat aagggtaatc 1620gagaaattac caatataa
163868521PRTArtificial SequenceSynthetic peptide. 68Gln Val Gln Leu
Arg Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30Val Ile
Ser Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly
Asp Ile Tyr Pro Gly Ser Gly Tyr Ser Phe Tyr Asn Glu Asn Phe 50 55
60Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr65
70 75 80Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
Cys 85 90 95Ala Thr Tyr Tyr Asn Tyr Pro Phe Ala Tyr Trp Gly Gln Gly
Thr Leu 100 105 110Val Thr Val Ser Ala Ala Lys Thr Thr Gly Pro Ser
Val Phe Pro Leu 115 120 125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
Thr Ala Ala Leu Gly Cys 130 135 140Leu Val Lys Asp Tyr Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser145 150 155 160Gly Ala Leu Thr Ser
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190Leu
Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200
205Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
210 215 220Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe
Leu Phe225 230 235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val 245 250 255Thr Cys Val Val Val Asp Val Ser Gln
Glu Asp Pro Glu Val Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315
320Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Gln 340 345 350Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly 355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser385 390 395 400Phe Phe Leu Tyr Ser
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser Asn Ser 435 440
445Pro Gln Asn Glu Val Leu Tyr Gly Asp Val Asn Asp Asp Gly Lys Val
450 455 460Asn Ser Thr Asp Leu Thr Leu Leu Lys Arg Tyr Val Leu Lys
Ala Val465 470 475 480Ser Thr Leu Pro Ser Ser Lys Ala Glu Lys Asn
Ala Asp Val Asn Arg 485 490 495Asp Gly Arg Val Asn Ser Ser Asp Val
Thr Ile Leu Ser Arg Tyr Leu 500 505 510Ile Arg Val Ile Glu Lys Leu
Pro Ile 515 520692415DNAArtificial SequenceSyntehtic
oligonucleotide. 69atggacccca aaggctccct ttcctggaga atacttctgt
ttctctccct ggcttttgag 60ttgtcgtacg gacaggttca gctgcggcag tctggacctg
agctggtgaa gcctggggct 120tcagtgaaga tgtcctgcaa ggcttctgga
tacacattta ctgactatgt tataagttgg 180gtgaagcaga gaactggaca
gggccttgag tggattggag atatttatcc tggaagtggt 240tattctttct
acaatgagaa cttcaagggc aaggccacac tgactgcaga caaatcctcc
300accacagcct acatgcagct cagcagcctg acatctgagg actctgcggt
ctatttctgt 360gcaacctact ataactaccc ttttgcttac tggggccaag
ggactctggt cactgtctct 420gcagccaaaa caacgggccc atccgtcttc
cccctggcgc cctgctccag gagcacctcc 480gagagcacag ccgccctggg
ctgcctggtc aaggactact tccccgaacc ggtgacggtg 540tcgtggaact
caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc
600tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt
gggcacgaag 660acctacacct gcaacgtaga tcacaagccc agcaacacca
aggtggacaa gagagttgag 720tccaaatatg gtcccccatg cccaccctgc
ccagcacctg agttcgaagg gggaccatca 780gtcttcctgt tccccccaaa
acccaaggac actctcatga tctcccggac ccctgaggtc 840acgtgcgtgg
tggtggacgt gagccaggaa gaccccgagg tccagttcaa ctggtacgtg
900gatggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagtt
caacagcacg 960taccgtgtgg tcagcgtcct caccgtcctg caccaggact
ggctgaacgg caaggagtac 1020aagtgcaagg tctccaacaa aggcctcccg
tcctccatcg agaaaaccat ctccaaagcc 1080aaagggcagc cccgagagcc
acaggtgtac accctgcccc catcccagga ggagatgacc 1140aagaaccagg
tcagcctgac ctgcctggtc aaaggcttct accccagcga catcgccgtg
1200gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc
cgtgctggac 1260tccgacggct ccttcttcct ctacagcagg ctaaccgtgg
acaagagcag gtggcaggag 1320gggaatgtct tctcatgctc cgtgatgcat
gaggctctgc acaaccacta cacacagaag 1380agcctctccc tgtctctggg
taaagctagc gatacaacag aacctgcaac acctacaaca 1440cctgtaacaa
cagacacaat atgtataggc taccatgcga acaattcaac cgacactgtt
1500gacacagtac tcgagaagaa tgtgacagtg acacactctg ttaacctgct
cgaagacagc 1560cacaacggaa aactatgtag attaaaagga atagccccac
tacaattggg gaaatgtaac 1620atcgccggat ggctcttggg aaacccagaa
tgcgacccac tgcttccagt gagatcatgg 1680tcctacattg tagaaacacc
aaactctgag aatggaatat gttatccagg agatttcatc 1740gactatgagg
agctgaggga gcaattgagc tcagtgtcat cattcgaaag attcgaaata
1800tttcccaaag aaagctcatg gcccaaccac aacacaaacg gagtaacggc
agcatgctcc 1860catgagggga aaagcagttt ttacagaaat ttgctatggc
tgacggagaa ggagggctca 1920tacccaaagc tgaaaaattc ttatgtgaac
aaaaaaggga aagaagtcct tgtactgtgg 1980ggtattcatc acccgcctaa
cagtaaggaa caacagaatc tctatcagaa tgaaaatgct 2040tatgtctctg
tagtgacttc aaattataac aggagattta ccccggaaat agcagaaaga
2100cccaaagtaa gagatcaagc tgggaggatg aactattact ggaccttgct
aaaacccgga 2160gacacaataa tatttgaggc aaatggaaat ctaatagcac
caatgtatgc tttcgcactg 2220agtagaggct ttgggtccgg catcatcacc
tcaaacgcat caatgcatga gtgtaacacg 2280aagtgtcaaa cacccctggg
agctataaac agcagtctcc cttaccagaa tatacaccca 2340gtcacaatag
gagagtgccc aaaatacgtc aggagtgcca aattgaggat ggttcaccat
2400caccatcacc attga 241570780PRTArtificial SequenceSynthetic
peptide. 70Gln Val Gln Leu Arg Gln Ser Gly Pro Glu Leu Val Lys Pro
Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asp Tyr 20 25 30Val Ile Ser Trp Val Lys Gln Arg Thr Gly Gln Gly
Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Pro Gly Ser Gly Tyr Ser Phe
Tyr Asn Glu Asn Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Thr Tyr Tyr Asn Tyr Pro
Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ala
Ala Lys Thr Thr Gly Pro Ser Val Phe Pro Leu 115 120 125Ala Pro Cys
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser145 150
155 160Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp
His Lys Pro Ser Asn 195 200 205Thr Lys Val Asp Lys Arg Val Glu Ser
Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro Cys Pro Ala Pro Glu Phe
Glu Gly Gly Pro Ser Val Phe Leu Phe225 230 235 240Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255Thr Cys
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265
270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly Leu Pro Ser Ser Ile
Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350Glu Glu Met Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365Phe Tyr Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380Glu
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser385 390
395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln
Glu 405 410 415Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
His Asn His 420 425 430Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
Lys Ala Ser Asp Thr 435 440 445Thr Glu Pro Ala Thr Pro Thr Thr Pro
Val Thr Thr Asp Thr Ile Cys 450 455 460Ile Gly Tyr His Ala Asn Asn
Ser Thr Asp Thr Val Asp Thr Val Leu465 470 475 480Glu Lys Asn Val
Thr Val Thr His Ser Val Asn Leu Leu Glu Asp Ser 485 490 495His Asn
Gly Lys Leu Cys Arg Leu Lys Gly Ile Ala Pro Leu Gln Leu 500 505
510Gly Lys Cys Asn Ile Ala Gly Trp Leu Leu Gly Asn Pro Glu Cys Asp
515 520 525Pro Leu Leu Pro Val Arg Ser Trp Ser Tyr Ile Val Glu Thr
Pro Asn 530 535 540Ser Glu Asn Gly Ile Cys Tyr Pro Gly Asp Phe Ile
Asp Tyr Glu Glu545 550 555 560Leu Arg Glu Gln Leu Ser Ser Val Ser
Ser Phe Glu Arg Phe Glu Ile 565 570 575Phe Pro Lys Glu Ser Ser Trp
Pro Asn His Asn Thr Asn Gly Val Thr 580 585 590Ala Ala Cys Ser His
Glu Gly Lys Ser Ser Phe Tyr Arg Asn Leu Leu 595 600 605Trp Leu Thr
Glu Lys Glu Gly Ser Tyr Pro Lys Leu Lys Asn Ser Tyr 610 615 620Val
Asn Lys Lys Gly Lys Glu Val Leu Val Leu Trp Gly Ile His His625 630
635 640Pro Pro Asn Ser Lys Glu Gln Gln Asn Leu Tyr Gln Asn Glu Asn
Ala 645 650 655Tyr Val Ser Val Val Thr Ser Asn Tyr Asn Arg Arg Phe
Thr Pro Glu 660 665 670Ile Ala Glu Arg Pro Lys Val Arg Asp Gln
Ala
Gly Arg Met Asn Tyr 675 680 685Tyr Trp Thr Leu Leu Lys Pro Gly Asp
Thr Ile Ile Phe Glu Ala Asn 690 695 700Gly Asn Leu Ile Ala Pro Met
Tyr Ala Phe Ala Leu Ser Arg Gly Phe705 710 715 720Gly Ser Gly Ile
Ile Thr Ser Asn Ala Ser Met His Glu Cys Asn Thr 725 730 735Lys Cys
Gln Thr Pro Leu Gly Ala Ile Asn Ser Ser Leu Pro Tyr Gln 740 745
750Asn Ile His Pro Val Thr Ile Gly Glu Cys Pro Lys Tyr Val Arg Ser
755 760 765Ala Lys Leu Arg Met Val His His His His His His 770 775
780712154DNAArtificial SequenceSyntehtic oligonucleotide.
71atggacccca aaggctccct ttcctggaga atacttctgt ttctctccct ggcttttgag
60ttgtcgtacg gacaggttca gctgcggcag tctggacctg agctggtgaa gcctggggct
120tcagtgaaga tgtcctgcaa ggcttctgga tacacattta ctgactatgt
tataagttgg 180gtgaagcaga gaactggaca gggccttgag tggattggag
atatttatcc tggaagtggt 240tattctttct acaatgagaa cttcaagggc
aaggccacac tgactgcaga caaatcctcc 300accacagcct acatgcagct
cagcagcctg acatctgagg actctgcggt ctatttctgt 360gcaacctact
ataactaccc ttttgcttac tggggccaag ggactctggt cactgtctct
420gcagccaaaa caacgggccc atccgtcttc cccctggcgc cctgctccag
gagcacctcc 480gagagcacag ccgccctggg ctgcctggtc aaggactact
tccccgaacc ggtgacggtg 540tcgtggaact caggcgccct gaccagcggc
gtgcacacct tcccggctgt cctacagtcc 600tcaggactct actccctcag
cagcgtggtg accgtgccct ccagcagctt gggcacgaag 660acctacacct
gcaacgtaga tcacaagccc agcaacacca aggtggacaa gagagttgag
720tccaaatatg gtcccccatg cccaccctgc ccagcacctg agttcgaagg
gggaccatca 780gtcttcctgt tccccccaaa acccaaggac actctcatga
tctcccggac ccctgaggtc 840acgtgcgtgg tggtggacgt gagccaggaa
gaccccgagg tccagttcaa ctggtacgtg 900gatggcgtgg aggtgcataa
tgccaagaca aagccgcggg aggagcagtt caacagcacg 960taccgtgtgg
tcagcgtcct caccgtcctg caccaggact ggctgaacgg caaggagtac
1020aagtgcaagg tctccaacaa aggcctcccg tcctccatcg agaaaaccat
ctccaaagcc 1080aaagggcagc cccgagagcc acaggtgtac accctgcccc
catcccagga ggagatgacc 1140aagaaccagg tcagcctgac ctgcctggtc
aaaggcttct accccagcga catcgccgtg 1200gagtgggaga gcaatgggca
gccggagaac aactacaaga ccacgcctcc cgtgctggac 1260tccgacggct
ccttcttcct ctacagcagg ctaaccgtgg acaagagcag gtggcaggag
1320gggaatgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta
cacacagaag 1380agcctctccc tgtctctggg taaagctagc gacatggcca
agaaggagac agtctggagg 1440ctcgaggagt tcggtaggcc tatagtgcag
aacatccagg ggcaaatggt acatcaggcc 1500atatcaccta gaactttaaa
tgcatgggta aaagtagtag aagagaaggc tttcagccca 1560gaagtaatac
ccatgttttc agcattatca gaaggagcca ccccacaaga tttaaacacc
1620atgctaaaca cagtgggggg acatcaagca gccatgcaaa tgttaaaaga
gaccatcaat 1680gaggaagctg cagaatggga tagagtacat ccagtgcatg
cagggcctat tgcaccaggc 1740cagatgagag aaccaagggg aagtgacata
gcaggaacta ctagtaccct tcaggaacaa 1800ataggatgga tgacaaataa
tccacctatc ccagtaggag aaatttataa aagatggata 1860atcctgggat
taaataaaat agtaagaatg tatagcccta ccagcattct ggacataaga
1920caaggaccaa aagaaccttt tagagactat gtagaccggt tctataaaac
tctaagagcc 1980gagcaagctt cacaggaggt aaaaaattgg atgacagaaa
ccttgttggt ccaaaatgcg 2040aacccagatt gtaagactat tttaaaagca
ttgggaccag cggctacact agaagaaatg 2100atgacagcat gtcagggagt
aggaggaccc ggccataagg caagagtttt gtga 215472693PRTArtificial
SequenceSynthetic peptide. 72Gln Val Gln Leu Arg Gln Ser Gly Pro
Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30Val Ile Ser Trp Val Lys Gln
Arg Thr Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Pro Gly
Ser Gly Tyr Ser Phe Tyr Asn Glu Asn Phe 50 55 60Lys Gly Lys Ala Thr
Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Thr
Tyr Tyr Asn Tyr Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105
110Val Thr Val Ser Ala Ala Lys Thr Thr Gly Pro Ser Val Phe Pro Leu
115 120 125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu
Gly Cys 130 135 140Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser145 150 155 160Gly Ala Leu Thr Ser Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205Thr Lys Val
Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro
Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe225 230
235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
Val 245 250 255Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
Val Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly
Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345
350Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser385 390 395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val
Asp Lys Ser Arg Trp Gln Glu 405 410 415Gly Asn Val Phe Ser Cys Ser
Val Met His Glu Ala Leu His Asn His 420 425 430Tyr Thr Gln Lys Ser
Leu Ser Leu Ser Leu Gly Lys Ala Ser Asp Met 435 440 445Ala Lys Lys
Glu Thr Val Trp Arg Leu Glu Glu Phe Gly Arg Pro Ile 450 455 460Val
Gln Asn Ile Gln Gly Gln Met Val His Gln Ala Ile Ser Pro Arg465 470
475 480Thr Leu Asn Ala Trp Val Lys Val Val Glu Glu Lys Ala Phe Ser
Pro 485 490 495Glu Val Ile Pro Met Phe Ser Ala Leu Ser Glu Gly Ala
Thr Pro Gln 500 505 510Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly
His Gln Ala Ala Met 515 520 525Gln Met Leu Lys Glu Thr Ile Asn Glu
Glu Ala Ala Glu Trp Asp Arg 530 535 540Val His Pro Val His Ala Gly
Pro Ile Ala Pro Gly Gln Met Arg Glu545 550 555 560Pro Arg Gly Ser
Asp Ile Ala Gly Thr Thr Ser Thr Leu Gln Glu Gln 565 570 575Ile Gly
Trp Met Thr Asn Asn Pro Pro Ile Pro Val Gly Glu Ile Tyr 580 585
590Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg Met Tyr Ser
595 600 605Pro Thr Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu Pro
Phe Arg 610 615 620Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu Arg Ala
Glu Gln Ala Ser625 630 635 640Gln Glu Val Lys Asn Trp Met Thr Glu
Thr Leu Leu Val Gln Asn Ala 645 650 655Asn Pro Asp Cys Lys Thr Ile
Leu Lys Ala Leu Gly Pro Ala Ala Thr 660 665 670Leu Glu Glu Met Met
Thr Ala Cys Gln Gly Val Gly Gly Pro Gly His 675 680 685Lys Ala Arg
Val Leu 690732187DNAArtificial SequenceSyntehtic oligonucleotide.
73atggaatgga ggatctttct cttcatcctg tcaggaactg caggtgtcca ctcccaggtt
60cagctgcggc agtctggacc tgagctggtg aagcctgggg cttcagtgaa gatgtcctgc
120aaggcttctg gatacacatt tactgactat gttataagtt gggtgaagca
gagaactgga 180cagggccttg agtggattgg agatatttat cctggaagtg
gttattcttt ctacaatgag 240aacttcaagg gcaaggccac actgactgca
gacaaatcct ccaccacagc ctacatgcag 300ctcagcagcc tgacatctga
ggactctgcg gtctatttct gtgcaaccta ctataactac 360ccttttgctt
actggggcca agggactctg gtcactgtct ctgcagccaa aacaacgggc
420ccatccgtct tccccctggc gccctgctcc aggagcacct ccgagagcac
agccgccctg 480ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg
tgtcgtggaa ctcaggcgcc 540ctgaccagcg gcgtgcacac cttcccggct
gtcctacagt cctcaggact ctactccctc 600agcagcgtgg tgaccgtgcc
ctccagcagc ttgggcacga agacctacac ctgcaacgta 660gatcacaagc
ccagcaacac caaggtggac aagagagttg agtccaaata tggtccccca
720tgcccaccct gcccagcacc tgagttcgaa gggggaccat cagtcttcct
gttcccccca 780aaacccaagg acactctcat gatctcccgg acccctgagg
tcacgtgcgt ggtggtggac 840gtgagccagg aagaccccga ggtccagttc
aactggtacg tggatggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaac ggcaaggagt acaagtgcaa ggtctccaac
1020aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggca
gccccgagag 1080ccacaggtgt acaccctgcc cccatcccag gaggagatga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctaccccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
ggctaaccgt ggacaagagc aggtggcagg aggggaatgt cttctcatgc
1320tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc
cctgtctctg 1380ggtaaagcta gcgatacaac agaacctgca acacctacaa
cacctgtaac aacaccgaca 1440acaacacttc tagcgcccct catcctgtct
cggattgtgg gaggctggga gtgcgagaag 1500cattcccaac cctggcaggt
gcttgtggcc tctcgtggca gggcagtctg cggcggtgtt 1560ctggtgcacc
cccagtgggt cctcacagct gcccactgca tcaggaacaa aagcgtgatc
1620ttgctgggtc ggcacagcct gtttcatcct gaagacacag gccaggtatt
tcaggtcagc 1680cacagcttcc cacacccgct ctacgatatg agcctcctga
agaatcgatt cctcaggcca 1740ggtgatgact ccagccacga cctcatgctg
ctccgcctgt cagagcctgc cgagctcacg 1800gatgctgtga aggtcatgga
cctgcccacc caggagccag cactggggac cacctgctac 1860gcctcaggct
ggggcagcat tgaaccagag gagttcttga ccccaaagaa acttcagtgt
1920gtggacctcc atgttatttc caatgacgtg tgtgcgcaag ttcaccctca
gaaggtgacc 1980aagttcatgc tgtgtgctgg acgctggaca gggggcaaaa
gcacctgctc gggtgattct 2040gggggcccac ttgtctgtaa tggtgtgctt
caaggtatca cgtcatgggg cagtgaacca 2100tgtgccctgc ccgaaaggcc
ttccctgtac accaaggtgg tgcattaccg gaagtggatc 2160aaggacacca
tcgtggccaa cccctga 218774710PRTArtificial SequenceSynthetic
peptide. 74Gln Val Gln Leu Arg Gln Ser Gly Pro Glu Leu Val Lys Pro
Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asp Tyr 20 25 30Val Ile Ser Trp Val Lys Gln Arg Thr Gly Gln Gly
Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Pro Gly Ser Gly Tyr Ser Phe
Tyr Asn Glu Asn Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Thr Tyr Tyr Asn Tyr Pro
Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ala
Ala Lys Thr Thr Gly Pro Ser Val Phe Pro Leu 115 120 125Ala Pro Cys
Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140Leu
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser145 150
155 160Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp
His Lys Pro Ser Asn 195 200 205Thr Lys Val Asp Lys Arg Val Glu Ser
Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro Cys Pro Ala Pro Glu Phe
Glu Gly Gly Pro Ser Val Phe Leu Phe225 230 235 240Pro Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255Thr Cys
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265
270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly Leu Pro Ser Ser Ile
Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350Glu Glu Met Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365Phe Tyr Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380Glu
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser385 390
395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln
Glu 405 410 415Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
His Asn His 420 425 430Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
Lys Ala Ser Asp Thr 435 440 445Thr Glu Pro Ala Thr Pro Thr Thr Pro
Val Thr Thr Pro Thr Thr Thr 450 455 460Leu Leu Ala Pro Leu Ile Leu
Ser Arg Ile Val Gly Gly Trp Glu Cys465 470 475 480Glu Lys His Ser
Gln Pro Trp Gln Val Leu Val Ala Ser Arg Gly Arg 485 490 495Ala Val
Cys Gly Gly Val Leu Val His Pro Gln Trp Val Leu Thr Ala 500 505
510Ala His Cys Ile Arg Asn Lys Ser Val Ile Leu Leu Gly Arg His Ser
515 520 525Leu Phe His Pro Glu Asp Thr Gly Gln Val Phe Gln Val Ser
His Ser 530 535 540Phe Pro His Pro Leu Tyr Asp Met Ser Leu Leu Lys
Asn Arg Phe Leu545 550 555 560Arg Pro Gly Asp Asp Ser Ser His Asp
Leu Met Leu Leu Arg Leu Ser 565 570 575Glu Pro Ala Glu Leu Thr Asp
Ala Val Lys Val Met Asp Leu Pro Thr 580 585 590Gln Glu Pro Ala Leu
Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser 595 600 605Ile Glu Pro
Glu Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp 610 615 620Leu
His Val Ile Ser Asn Asp Val Cys Ala Gln Val His Pro Gln Lys625 630
635 640Val Thr Lys Phe Met Leu Cys Ala Gly Arg Trp Thr Gly Gly Lys
Ser 645 650 655Thr Cys Ser Gly Asp Ser Gly Gly Pro Leu Val Cys Asn
Gly Val Leu 660 665 670Gln Gly Ile Thr Ser Trp Gly Ser Glu Pro Cys
Ala Leu Pro Glu Arg 675 680 685Pro Ser Leu Tyr Thr Lys Val Val His
Tyr Arg Lys Trp Ile Lys Asp 690 695 700Thr Ile Val Ala Asn Pro705
710752268DNAArtificial SequenceSyntehtic oligonucleotide.
75atggaatgga ggatctttct cttcatcctg tcaggaactg caggtgtcca ctcccaggtt
60cagctgcggc agtctggacc tgagctggtg aagcctgggg cttcagtgaa gatgtcctgc
120aaggcttctg gatacacatt tactgactat gttataagtt gggtgaagca
gagaactgga 180cagggccttg agtggattgg agatatttat cctggaagtg
gttattcttt ctacaatgag 240aacttcaagg gcaaggccac actgactgca
gacaaatcct ccaccacagc ctacatgcag 300ctcagcagcc tgacatctga
ggactctgcg gtctatttct gtgcaaccta ctataactac 360ccttttgctt
actggggcca agggactctg gtcactgtct ctgcagccaa aacaacgggc
420ccatccgtct tccccctggc gccctgctcc aggagcacct ccgagagcac
agccgccctg 480ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg
tgtcgtggaa ctcaggcgcc 540ctgaccagcg gcgtgcacac cttcccggct
gtcctacagt cctcaggact ctactccctc 600agcagcgtgg tgaccgtgcc
ctccagcagc ttgggcacga agacctacac ctgcaacgta 660gatcacaagc
ccagcaacac caaggtggac aagagagttg agtccaaata tggtccccca
720tgcccaccct gcccagcacc tgagttcgaa gggggaccat cagtcttcct
gttcccccca 780aaacccaagg acactctcat gatctcccgg acccctgagg
tcacgtgcgt ggtggtggac 840gtgagccagg aagaccccga ggtccagttc
aactggtacg tggatggcgt ggaggtgcat 900aatgccaaga caaagccgcg
ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc
tgcaccagga ctggctgaac ggcaaggagt acaagtgcaa ggtctccaac
1020aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggca
gccccgagag 1080ccacaggtgt acaccctgcc cccatcccag gaggagatga
ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctaccccagc
gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa
gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca
ggctaaccgt ggacaagagc
aggtggcagg aggggaatgt cttctcatgc 1320tccgtgatgc atgaggctct
gcacaaccac tacacacaga agagcctctc cctgtctctg 1380ggtaaagcta
gtcagacccc caccaacacc atcagcgtga cccccaccaa caacagcacc
1440cccaccaaca acagcaaccc caagcccaac cccgctagtg agaagatccg
gctgcggccc 1500ggcggcaaga agaagtacaa gctgaagcac atcgtggcta
gtagcagcgt gagccccacc 1560accagcgtgc accccacccc caccagcgtg
ccccccaccc ccaccaagag cagccccgct 1620agtaaccccc ccatccccgt
gggcgagatc tacaagcggt ggatcatcct gggcctgaac 1680aagatcgtgc
ggatgtacag ccccaccagc atcctggacg ctagtcccac cagcaccccc
1740gccgacagca gcaccatcac ccccaccgcc acccccaccg ccacccccac
catcaagggc 1800gctagtcaca cccagggcta cttccccgac tggcagaact
acacccccgg ccccggcgtg 1860cggtaccccc tgaccttcgg ctggctgtac
aagctggcta gtaccgtgac ccccaccgcc 1920accgccaccc ccagcgccat
cgtgaccacc atcaccccca ccgccaccac caagcccgct 1980agtgtgggct
tccccgtgac cccccaggtg cccctgcggc ccatgaccta caaggccgcc
2040gtggacctga gccacttcct gaaggagaag ggcggcctgg ctagtaccaa
cggcagcatc 2100accgtggccg ccaccgcccc caccgtgacc cccaccgtga
acgccacccc cagcgccgcc 2160gctagtgcca tcttccagag cagcatgacc
aagatcctgg agcccttccg gaagcagaac 2220cccgacatcg tgatctacca
gtacatggac gacctgtacg ctagctga 226876737PRTArtificial
SequenceSynthetic peptide. 76Gln Val Gln Leu Arg Gln Ser Gly Pro
Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30Val Ile Ser Trp Val Lys Gln
Arg Thr Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Pro Gly
Ser Gly Tyr Ser Phe Tyr Asn Glu Asn Phe 50 55 60Lys Gly Lys Ala Thr
Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Thr
Tyr Tyr Asn Tyr Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105
110Val Thr Val Ser Ala Ala Lys Thr Thr Gly Pro Ser Val Phe Pro Leu
115 120 125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu
Gly Cys 130 135 140Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser145 150 155 160Gly Ala Leu Thr Ser Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205Thr Lys Val
Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro
Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe225 230
235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
Val 245 250 255Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
Val Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly
Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345
350Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser385 390 395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val
Asp Lys Ser Arg Trp Gln Glu 405 410 415Gly Asn Val Phe Ser Cys Ser
Val Met His Glu Ala Leu His Asn His 420 425 430Tyr Thr Gln Lys Ser
Leu Ser Leu Ser Leu Gly Lys Ala Ser Gln Thr 435 440 445Pro Thr Asn
Thr Ile Ser Val Thr Pro Thr Asn Asn Ser Thr Pro Thr 450 455 460Asn
Asn Ser Asn Pro Lys Pro Asn Pro Ala Ser Glu Lys Ile Arg Leu465 470
475 480Arg Pro Gly Gly Lys Lys Lys Tyr Lys Leu Lys His Ile Val Ala
Ser 485 490 495Ser Ser Val Ser Pro Thr Thr Ser Val His Pro Thr Pro
Thr Ser Val 500 505 510Pro Pro Thr Pro Thr Lys Ser Ser Pro Ala Ser
Asn Pro Pro Ile Pro 515 520 525Val Gly Glu Ile Tyr Lys Arg Trp Ile
Ile Leu Gly Leu Asn Lys Ile 530 535 540Val Arg Met Tyr Ser Pro Thr
Ser Ile Leu Asp Ala Ser Pro Thr Ser545 550 555 560Thr Pro Ala Asp
Ser Ser Thr Ile Thr Pro Thr Ala Thr Pro Thr Ala 565 570 575Thr Pro
Thr Ile Lys Gly Ala Ser His Thr Gln Gly Tyr Phe Pro Asp 580 585
590Trp Gln Asn Tyr Thr Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe
595 600 605Gly Trp Leu Tyr Lys Leu Ala Ser Thr Val Thr Pro Thr Ala
Thr Ala 610 615 620Thr Pro Ser Ala Ile Val Thr Thr Ile Thr Pro Thr
Ala Thr Thr Lys625 630 635 640Pro Ala Ser Val Gly Phe Pro Val Thr
Pro Gln Val Pro Leu Arg Pro 645 650 655Met Thr Tyr Lys Ala Ala Val
Asp Leu Ser His Phe Leu Lys Glu Lys 660 665 670Gly Gly Leu Ala Ser
Thr Asn Gly Ser Ile Thr Val Ala Ala Thr Ala 675 680 685Pro Thr Val
Thr Pro Thr Val Asn Ala Thr Pro Ser Ala Ala Ala Ser 690 695 700Ala
Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys705 710
715 720Gln Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Asp Asp Leu Tyr
Ala 725 730 735Ser77708DNAArtificial SequenceSynthetic
oligonucleotide. 77atggattttc aagtgcagat tttcagcttc ctgctaatca
gtgcttcagt cataatgtcc 60agaggacaaa ttgttctctc ccagtctcca gcaatcctgt
ctgcatctcc aggggagaag 120gtcacaatga cttgcagggc cagctcaagt
gtaagttaca tgcactggta ccagcggaag 180ccaggatcct cccccaaacc
ctggatttat gccacatcca acctggcttc tggagtccct 240gctcgcttca
gtggcagtgg gtctgggacc tcttattctc tcacaatcag cagagtggag
300gctgaagatg ctgccactta ttactgccag cagtggagta gtaacccgct
cacgttcggt 360gctgggacca agctggagct gaaacgggct gatgctgcac
caactgtatc catcttccca 420ccatccagtg agcagttaac atctggaggt
gcctcagtcg tgtgcttctt gaacaacttc 480taccccaaag acatcaatgt
caagtggaag attgatggca gtgaacgaca aaatggcgtc 540ctgaacagtt
ggactgatca ggacagcaaa gacagcacct acagcatgag cagcaccctc
600acgttgacca aggacgagta tgaacgacat aacagctata cctgtgaggc
cactcacaag 660acatcaactt cacccatcgt caagagcttc aacaggaatg agtgttag
70878213PRTArtificial SequenceSynthetic peptide. 78Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly1 5 10 15Glu Lys Val
Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 20 25 30His Trp
Tyr Gln Arg Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr 35 40 45Ala
Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55
60Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu65
70 75 80Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu
Thr 85 90 95Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala
Ala Pro 100 105 110Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu
Thr Ser Gly Gly 115 120 125Ala Ser Val Val Cys Phe Leu Asn Asn Phe
Tyr Pro Lys Asp Ile Asn 130 135 140Val Lys Trp Lys Ile Asp Gly Ser
Glu Arg Gln Asn Gly Val Leu Asn145 150 155 160Ser Trp Thr Asp Gln
Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser 165 170 175Thr Leu Thr
Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr 180 185 190Cys
Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe 195 200
205Asn Arg Asn Glu Cys 210791428DNAArtificial SequenceSynthetic
oligonucleotide. 79atggaatgga gctgggtctt tctcttcctc ctgtcagtaa
ttgcaggtgt ccaatcccag 60gttcagctgc agcagtctgg ggctgagctg gtgaggcctg
gggcttcagt gacgctgtcc 120tgcaaggctt cgggctacac atttattgac
catgatatgc actgggtgca gcagacacct 180gtgtatggcc tggaatggat
cggagctatt gatcctgaaa ctggtgatac tggctacaat 240cagaagttca
agggcaaggc catactgact gcagacaaat cctccaggac agcctacatg
300gaactccgca gcctgacatc tgaggactct gccgtctatt actgtacaat
ccccttctac 360tatagtaact acagcccgtt tgcttactgg ggccaagggg
ctctggtcac tgtctctgca 420gccaaaacaa cagccccatc ggtctatcca
ctggcccctg tgtgtggagg tacaactggc 480tcctcggtga ctctaggatg
cctggtcaag ggttatttcc ctgagccagt gaccttgacc 540tggaactctg
gatccctgtc cagtggtgtg cacaccttcc cagctctcct gcagtctggc
600ctctacaccc tcagcagctc agtgactgta acctcgaaca cctggcccag
ccagaccatc 660acctgcaatg tggcccaccc ggcaagcagc accaaagtgg
acaagaaaat tgagcccaga 720gtgcccataa cacagaaccc ctgtcctcca
ctcaaagagt gtcccccatg cgcagacctc 780ttgggtggac catccgtctt
catcttccct ccaaagatca aggatgtact catgatctcc 840ctgagcccca
tggtcacatg tgtggtggtg gatgtgagcg aggatgaccc agacgcccag
900atcagctggt ttgtgaacaa cgtggaagta cacacagctc agacacaaac
ccatagagag 960gattacaaca gtactctccg ggtggtcagt gccctcccca
tccagcacca ggactggatg 1020agtggcaagg agttcaaatg caaggtcaac
aacagagccc tcccatcccc catcgagaaa 1080accatctcaa aacccagagg
gccagtaaga gctccacagg tatatgtctt gcctccacca 1140gcagaagaga
tgactaagaa agagttcagt ctgacctgca tgatcacagg cttcttacct
1200gccgaaattg ctgtggactg gaccagcaat gggcgtacag agcaaaacta
caagaacacc 1260gcaacagtcc tggactctga tggttcttac ttcatgtaca
gcaagctcag agtacaaaag 1320agcacttggg aaagaggaag tcttttcgcc
tgctcagtgg tccacgaggg tctgcacaat 1380caccttacga ctaagaccat
ctcccggtct ctgggtaaag ctagctga 142880456PRTArtificial
SequenceSynthetic peptide. 80Gln Val Gln Leu Gln Gln Ser Gly Ala
Glu Leu Val Arg Pro Gly Ala1 5 10 15Ser Val Thr Leu Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Ile Asp His 20 25 30Asp Met His Trp Val Gln Gln
Thr Pro Val Tyr Gly Leu Glu Trp Ile 35 40 45Gly Ala Ile Asp Pro Glu
Thr Gly Asp Thr Gly Tyr Asn Gln Lys Phe 50 55 60Lys Gly Lys Ala Ile
Leu Thr Ala Asp Lys Ser Ser Arg Thr Ala Tyr65 70 75 80Met Glu Leu
Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95Thr Ile
Pro Phe Tyr Tyr Ser Asn Tyr Ser Pro Phe Ala Tyr Trp Gly 100 105
110Gln Gly Ala Leu Val Thr Val Ser Ala Ala Lys Thr Thr Ala Pro Ser
115 120 125Val Tyr Pro Leu Ala Pro Val Cys Gly Gly Thr Thr Gly Ser
Ser Val 130 135 140Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu
Pro Val Thr Leu145 150 155 160Thr Trp Asn Ser Gly Ser Leu Ser Ser
Gly Val His Thr Phe Pro Ala 165 170 175Leu Leu Gln Ser Gly Leu Tyr
Thr Leu Ser Ser Ser Val Thr Val Thr 180 185 190Ser Asn Thr Trp Pro
Ser Gln Thr Ile Thr Cys Asn Val Ala His Pro 195 200 205Ala Ser Ser
Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Val Pro Ile 210 215 220Thr
Gln Asn Pro Cys Pro Pro Leu Lys Glu Cys Pro Pro Cys Ala Asp225 230
235 240Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys
Asp 245 250 255Val Leu Met Ile Ser Leu Ser Pro Met Val Thr Cys Val
Val Val Asp 260 265 270Val Ser Glu Asp Asp Pro Asp Ala Gln Ile Ser
Trp Phe Val Asn Asn 275 280 285Val Glu Val His Thr Ala Gln Thr Gln
Thr His Arg Glu Asp Tyr Asn 290 295 300Ser Thr Leu Arg Val Val Ser
Ala Leu Pro Ile Gln His Gln Asp Trp305 310 315 320Met Ser Gly Lys
Glu Phe Lys Cys Lys Val Asn Asn Arg Ala Leu Pro 325 330 335Ser Pro
Ile Glu Lys Thr Ile Ser Lys Pro Arg Gly Pro Val Arg Ala 340 345
350Pro Gln Val Tyr Val Leu Pro Pro Pro Ala Glu Glu Met Thr Lys Lys
355 360 365Glu Phe Ser Leu Thr Cys Met Ile Thr Gly Phe Leu Pro Ala
Glu Ile 370 375 380Ala Val Asp Trp Thr Ser Asn Gly Arg Thr Glu Gln
Asn Tyr Lys Asn385 390 395 400Thr Ala Thr Val Leu Asp Ser Asp Gly
Ser Tyr Phe Met Tyr Ser Lys 405 410 415Leu Arg Val Gln Lys Ser Thr
Trp Glu Arg Gly Ser Leu Phe Ala Cys 420 425 430Ser Val Val His Glu
Gly Leu His Asn His Leu Thr Thr Lys Thr Ile 435 440 445Ser Arg Ser
Leu Gly Lys Ala Ser 450 455
* * * * *